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ABBREVIATIONS
Drug screening procedures and safety requirements for consumer products involve 
the use of large numbers of experimental animals. Reduction and refinement of animal 
use is one of the goals set out by Dutch health authorities a number of years ago. One 
of the ways to achieve this is basic research on model systems that mimic normal 
and diseased human tissues or organs that can be used as a validated alternative to 
experimental animals. A large part of the research efforts described in this thesis was 
funded by a grant of the ‘Platform alternatieven voor dierproeven’, which was later 
incorporated in the Dutch Health Research and Development Council (ZonMw, grant 
number 3170.0013). The studies described in chapter 7 were funded by a grant of the 
Netherlands Organisation for Scientific Research (NWO, Genomics program, grant 
number 050-10-102).
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Skin is the largest organ of man, comprising 15-20% of our body weight, and covering 
the entire body surface. Human skin consists of an outer layer, the epidermis, and 
an inner connective tissue layer, the dermis (see Figure 1). These two layers are 
physically separated by a basement membrane. Epidermis is a continuously renewing 
epithelium. The keratinocyte is the cell that makes up to 95% of the epidermis and 
undergoes a complex process of differentiation, which is characterised by a series of 
biochemical and morphological changes. The epidermis is subdivided into four layers 
or strata: the basal layer (BL) or stratum basale, the spinous layer (SL) or stratum 
spinosum, the granular layer (GL) or stratum granulosum, and the stratum corneum 
(SC). The basal layer provides the germinal cells necessary for the regeneration of the 
layers of the epidermis. After a mitotic division a newly formed cell is pushed toward 
the surface and the process of terminal differentiation begins as the cell migrates to 
the surface. The cells that divide in the basal layer soon begin to accumulate many 
desmosomes on their outer surface, which provide the characteristic ‘prickles’ of 
the spinous layer, which is often referred to as the prickle-cell layer. Cells enter the 
granular layer as they migrate upward from the spinous layer. The granular layer is 
the last layer of viable cells, characterised by the presence of all the organelles and 
activities typically associated with intact cellular metabolic function. The cytoplasm 
of cells in the upper, spinous layer and granular layer contain lamellar granules. 
These granules discharge their lipid components into the intercellular space and 
play an important role in the barrier function and the intercellular cohesion within 
the stratum corneum. This outermost layer of the epidermis consists of corneocytes, 
keratinocytes that have lost their nuclei and cytoplasmic organelles. The terminal 
stage of the transition process is desquamation involving degradation of lipids in the 
intercellular spaces and loss of residual intercellular desmosomal connections[1]. In 
order to maintain homeostasis, shedding of cells from the surface is counteracted by 
cell production in the germinative compartment formed by the basal layers.
1. HUMAN SKIN, STRUCTURE OF THE EPIDERMIS
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2.1 The cell cycle
Cell proliferation is defined as a process involving a sequential pattern of cyclic 
repeating changes in gene expression leading ultimately to the physical division of 
cells[2]. The basis of cell proliferation is the cell cycle. The cell cycle can be divided 
into four separate stages, G
1
 (and G
0
), S, G
2
, and M phase. The G
1
 (Gap 1) phase is 
characterised by gene expression and protein synthesis. This gap phase enables the 
cell to grow, to produce and gather all the necessary proteins and co-factors needed 
for the next phase and to replicate cell organelles. The cell may pause at the end of its 
G
1
 phase for some time before initiating DNA synthesis in the S phase. This time is 
known as the restriction or start point. If the cell remains at this point for a long period 
of time without replicating its DNA, it is said to be in the G
0
 phase. The S (Synthesis) 
phase is characterised by the DNA replication of the cell. After DNA replication is 
completed the cell enters the third cell cycle stage, the G
2
 (Gap 2) phase. During the 
G
2
 phase the cell prepares itself for the actual division by e.g. synthesising necessary 
proteins and condensing the chromosomal DNA. Finally, the cell enters the fourth and 
final phase of the cell cycle: the M (Mitosis) phase. During the M phase the actual 
cell division takes place. This division can be separated into two separate events, the 
division of the cells chromosomes (the actual mitosis also called karyokinesis) and the 
division of the cells cytoplasm in two daughter cells (called cytokinesis). With this the 
cell cycle is completed and the generated cells are directed either to enter the cycle 
again or to become a resting cell in G
0
 (called cell quiescence). At this stage of the 
cell cycle, the cell can also be directed to escape the cell cycle and start to terminally 
differentiate.
2.2 Epidermal growth
The epidermis of human skin is a self-renewing tissue: a single, adult skin stem cell 
has sufficient proliferative capacity to produce enough new epidermis to cover the 
body surface[3,4]. In the skin of furry mammals, slow-cycling, epithelial stem cells 
reside in a portion of the hair follicle known as the bulge (see Figure 1). These 
stem cells are multipotent and can give rise not only to epidermis, but also to hair 
follicles and sebaceous glands[5,6]. Those stem-cell progeny that exit the bulge and 
migrate upwards into the epidermis populate the innermost (basal) layer. The rate 
of proliferation and upward migration is greatly accelerated when the skin is injured 
and wound healing is induced. In human skin, which has a meagre version of the hair 
coat of most mammals, the epidermis is much thicker and the basal layer harbours 
highly proliferative self-renewing cells. This has led scientists to wonder whether 
this subset of epidermal cells is similar or identical to the multipotent stem cells in 
the bulge of the hair follicle. Most researchers accept a universal definition of a stem 
cell as one that can divide to produce both daughter stem cells and cells that go on to 
differentiate. According to these criteria, a subset of basal epidermal cells (at least in 
2. EPIDERMAL PROLIFERATION
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human skin), as well as bulge cells, qualifies as stem cells. Whether stem cells in the 
basal layer have the capacity to generate hair follicles, as bulge stem cells do, remains 
unclear and is a topic of considerable attention in the field.
Growth and differentiation are tightly linked processes in the epidermis, which need 
to be precisely balanced. Such a precise equilibrium in human skin is controlled by 
a complex interaction of signalling pathways from which many factors have been 
identified that influence the proliferation rate of keratinocytes. Most of the studies on 
these factors have been performed with in vitro model systems and the actual situation 
in skin is still not completely understood. Growth factors like epidermal growth factor 
(EGF), transforming growth factor alpha (TGF-α) (both sharing the EGF receptor) 
and insulin-like growth factor-1 (IGF-1) have shown to enhance both keratinocyte 
proliferation[7,8] and migration[9,10]. In the skin-disease psoriasis (see below) the 
IGF- and the EGF-system is altered compared to the situation in normal epidermis; 
there is an overexpression of EGF-receptors (EGFR)[11] and IGF-1 receptors (IGF-1-
Figure 1:  Mammalian skin consists of the epidermis and dermis, separated by a basement membrane. The 
epidermis is a stratified squamous epithelia that is composed of several layers. Resting on the basement 
membrane is the basal layer (BL) that stratifies to give rise to differentiated cell layers of the spinous layer 
(SL), granular layer (GL) and the stratum corneum (SC). Also shown is a cross-section of a hair follicle, 
which consists of an outer root sheath that is contiguous with the basal epidermal layer. At the bottom of the 
follicle is the hair bulb, made from proliferating matrix cells. The bulge is part of the outer root sheath and 
is where epidermal stem cells reside. The dermal component of the hair follicle is the dermal papilla, which 
consists of specialized mesemchymal cells surrounded by the hair matrix cells. (Reprinted by permission 
from Nature Reviews Genetics: Fuchs, E., and Raghavan, S. Vol.3: 199-209, March 2002; copyright (2002) 
Macmillan Magazines Ltd.)
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R)[12]. Treatment with antipsoriatic agents downregulates the number of IGF-1-R[12] 
and EGFR[11] in keratinocytes. In addition it has been shown that EGF is directly 
involved in regulating the expression of CK6 and CK16[13] in hyperproliferative 
keratinocytes, suggesting a possible role for these two signalling complexes in 
psoriatic keratinocyte phenotype. Another growth factor relevant for keratinocyte 
proliferation is keratinocyte growth factor (KGF, also known as FGF-7). KGF is 
a fibroblast-derived growth factor that is a potent epithelial cell mitogen like EGF, 
TGF-α and IGF. However, in contrast to members of the EGF family, KGF also plays 
a role in inducing normal keratinocyte differentiation[14]. Recently, it has been shown 
that interleukin-1 (IL-1), which is produced and released by basal epidermal cells, 
activates c-jun in the underlying fibroblasts. The fibroblasts respond by producing and 
secreting granulocyte macrophage colony stimulating factor (GM-CSF) and KGF. 
Both factors stimulate their respective tyrosine kinase receptors, and promote the 
proliferation and differentiation of overlying epidermal keratinocytes[15]. 
Besides IL-1[16,17] also other inflammation mediators like interleukin-4 (IL-4)[18] and 
interleukin-6 (IL-6)[19,20] display stimulatory effects on keratinocyte proliferation. 
There have also been reports on other signalling molecules that stimulate keratinocyte 
proliferation like nitric oxide (NO)[21] and Substance P[22]. In contrast to these factors 
that specifically induce or stimulate keratinocyte proliferation there are factors 
that have opposite effects and suppress or block proliferation in keratinocytes. 
The most extensively studied factor is transforming growth factor beta (TGF-β). 
Many studies have shown the repression of keratinocyte proliferation by TGF-β in 
vitro. The presumed mechanism involves the regulation of the retinoblastoma gene 
product (pRB) function by TGF-β[23,24]. This is supported by the fact that events 
that compromise the function of pRB (e.g. the presence of viral proteins with pRB 
binding domains) uncouple TGF-β regulation of proliferation[25]. There are several 
indications that other factors that have repressive effects on keratinocyte proliferation 
as well as on other cell types, like e.g. tumour necrosis factor alpha (TNF-α)[26,27]), 
and interferon gamma (IFN-γ)[26]) also mediate these effects through pRB[28-31]. The 
tumour suppressor gene product pRB seems to play a central role in the repression 
of keratinocyte proliferation and there are indications that proliferation repression 
by a number of factors through pRB could be a mechanism for the initiation of 
keratinocyte terminal differentiation[32-35]. The above-mentioned studies were 
performed using a variety of different model systems. With respect to the factors that 
influence keratinocyte proliferation, it remains indefinite what their relative roles are, 
whether the effects interact meaningfully, and whether they truly coexist.
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The epidermis and dermis of normally differentiated human skin are separated by 
a basement membrane that is composed of extracellular matrix proteins, which 
contribute to the mechanical properties of the tissue. An important mechanism by 
which keratinocyte differentiation is initiated is through loss of contact with the 
basement membrane and the extracellular matrix. Columnar basal keratinocytes 
of the stem cell population are attached to the basement membrane by integrin 
receptors and hemidesmosomes. Several studies have indicated that loss of integrin 
mediated attachment of keratinocytes to either fibronectin, or laminin in the basement 
membrane, leads to cell-cycle withdrawal and commits the cell irreversibly to 
terminal differentiation[36-40]. The basal cells express two keratin-type intermediate 
filaments, CK5 and CK14[41]. However, upon the loss of adhesiveness to the basal 
membrane, a down-regulation of this pair of cytokeratins accompanies entrance of the 
cell to the first suprabasal layer: the spinous layer. This layer is characterised by the 
presence of extensive desmosomal connections between cells, forming a stabilising 
network. Some of the early markers of keratinocyte differentiation like involucrin and 
transglutaminase are first expressed in this layer[42]. Subsequently, the cytokeratins 
CK1 and CK10 become pair-wise induced in this suprabasal layer[43].
The next upward layer is the granular layer of which the granules contain cystatin-
α[44], loricrin[45], and filaggrin[45], together with lipids that serve as building blocks 
to create the corneocyte membrane[46]. A transition zone called the stratum lucidum 
separates the dead from the living epidermal layers. Here, proteases, nucleases and 
other enzymes destroy cellular organelles and nucleic acids while simultaneously 
the final steps in assembly of the keratin intermediate filament network and the 
cornified envelope occur. The cornified envelope consists of an array of proteins 
that are covalently connected via ε-(γ-glutamyl)-lysin protein-protein cross-links[42,47] 
effected by transglutaminase[48-50]. Adjacent corneocytes are held together by modified 
desmosomes and a three-dimensional structure of ridges and grooves[42]. Programmed 
cell death followed by desquamation is the main cause of cell loss in normal human 
skin. This process is distinct from programmed cell death by the classical apoptosis 
pathway [51]. 
As stated above, growth and differentiation are tightly linked processes in the 
epidermis. Obviously, factors that repress keratinocyte proliferation could be the 
first signal for initiation of terminal differentiation whereas factors that stimulate 
proliferation indirectly prohibit the initiation of differentiation. For instance, both 
the growth factor TGF-β and the cytokine IFN-γ displayed apart from an inhibitory 
effect on keratinocyte proliferation, also induction of  differentiation[52-56]. Calcium 
has been studied extensively for its effect on keratinocyte differentiation. In the 
normal human epidermis a calcium gradient exists with relatively low concentrations 
in the basal layer and higher concentrations in the suprabasal layers[57,58]. This gradient 
suggests a role for calcium in regulating keratinocyte differentiation. Studies with 
3. EPIDERMAL DIFFERENTIATION
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cultured keratinocytes confirm this possibility since low calcium-containing medium 
(< 0.1 mM) results in low level expression of differentiation marker genes, while 
elevation of levels of extracellular calcium induced markers of differentiation (e.g. 
involucrin, loricrin)[59-61]. Other well-known small molecules that affect keratinocyte 
differentiation are vitamin A en vitamin D
3
. Their individual roles will be discussed 
elaborately below, in “Pharmacotherapy in psoriasis”.
Clearly, the process of epidermal differentiation is a complex phenomenon, in which 
many factors are involved (e.g. growth factors, cytokines, transcription factors). 
Despite increasing knowledge of individual pathways and the role of single molecules 
therein, it largely remains to be elucidated how these pathways are exactly involved 
and how they intersect. For current insight into this matter one is referred to several 
comprehensive reviews[62-64].
Figure 2:  Typical lesions of psoriasis vulgaris, the most common form of psoriasis, showing sharply 
demarcated erythematosquamous plaques.
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4.1 General aspects of psoriasis
Psoriasis is a worldwide occurring common inflammatory disease of the skin. Clinically, 
psoriasis is considered as a disease of the entire skin marked by hyperproliferation and 
well-circumscribed erythematous lesions with silvery scaling plaques that may be 
symmetrically distributed[65] (see Figure 2). The severity may range from a relatively 
minor disease consisting of pinpoint lesions to a life-threatening disease covering 
nearly the entire body-surface (erythrodermic psoriasis). The prevalence of psoriasis 
varies with race and geographical area. Approximately 2% of the Western population is 
affected. However, psoriasis is virtually absent in certain West-African communities, 
China, Eskimo and Native American populations[66,67]. Males and females seem to be 
equally affected with an earlier onset in females. Although the aetiology of psoriasis 
remains unknown, genetic and environmental factors are causative. Hereditary factors 
play an important role in the aetiology of the disease. Several reports indicate that 
there is a strong genetic background and diverse patterns of inheritance in families[68]. 
Psoriasis is supposed to be a polygenic and multifactorial disease. In addition, several 
psoriasis-susceptibility alleles at HLA and complement loci have been identified[69]. 
Inheritance does not directly imply that psoriasis will develop. There are a significant 
number of family members carrying potential psoriatic haplotypes that remain disease 
free. Additional environmental factors (i.e. stress, medication, focal infections, 
chemical and physical injuries) also play a crucial role. 
4.2 Histological properties of psoriasis
In psoriatic skin there are several histological abnormalities of acute/chronic lesions. 
These include elongated rete pegs with respect to normal skin; influx of immunocytes 
including both CD4 and CD8 positive lymphocytes and dendritic antigen presenting 
cells (APCs); endothelial cell activation, and tissue inflammation with neutrophils 
in the stratum corneum[70]. Moreover, a marked epidermal keratinocyte hyperplasia 
exists with a profile of altered differentiation. 
Keratinocyte hyperplasia in lesional psoriatic epidermis is related to a dramatically 
increased number of cycling cells[71]. The observed altered differentiation is 
characterised by the strong expression of a number of molecules that are absent in 
normal skin, like CK6, CK16, and CK17[72-74], and the epidermal proteinase inhibitor 
‘skin-derived antileukoproteinase’ (SKALP)[75-78]. Furthermore, several molecules 
have a restricted expression pattern in normal skin, but are highly upregulated 
in psoriatic skin. These include psoriasis-associated fatty acid binding protein 
(PA-FABP)[79], involucrin[80,81], transglutaminase[82,83], psoriasin[84], TGF-α[85,86], 
amphiregulin[87], EGFR[88], calgranulins A and B (reviewed in[79]), IL-1 receptor 
antagonist (IL-1ra)[89], IL-1β[90], IL-6 and IL-8[20,91,92], growth-related oncogene (GRO) 
α/β/γ[93], and fibronectin[80]. Another abnormality is the altered expression of integrins. 
In psoriasis a suprabasal expression of integrins is observed, while they normally are 
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restricted to the basal layer[94-96]. Few molecules are reported to be downregulated in 
psoriatic epidermis compared to normal epidermis (e.g. IL-1α)[97].
4.3 Aetiology of psoriasis: contributions of keratinocyte and immunocyte 
Despite the high prevalence and the accessibility of the target tissue, many puzzling 
questions about psoriasis remain unanswered. Perhaps the most obvious unresolved 
issue, reflecting the lack of an identification of the major genetic susceptibility 
determinants, is whether this disorder fundamentally reflects an abnormality in 
the epidermal keratinocyte (KC) or in the bone marrow-derived immunocyte. 
This distinction becomes blurred because of cross-talk between activated KCs and 
immunocytes that begins immediately upon lesion formation and culminates in the 
mature psoriatic plaque. This uncertainty prompts further questions: Does psoriasis 
represent a primary defect in the terminal differentiation response following an 
injurious stimulus (e.g. stress, infection) by KCs that fail to produce a normal stratum 
corneum and, therefore, do not create a protective physiological barrier? Alternatively, 
is the aberrant KC differentiation program in psoriasis a consequence of an influx of 
pathogenic immunocytes participating in a destructive autoimmune reaction? 
The dramatic increase in epidermal proliferation that occurs in psoriasis has 
led a considerable amount of research to focus on potential abnormalities in the 
keratinocyte. In the 1970s-1980s the psoriatic epidermis has been subject of intense 
investigations. Many alterations in the lesional epidermis have been demonstrated 
(regarding second messenger, polyamine, protease, cytokine, arachidonic acid 
metabolism). The expression patterns of these molecules are not psoriasis-specific and 
can be found in keratinocytes from normal individuals during pathological conditions 
(e.g. wound healing and inflammation[98,99]). In addition, some authors have claimed 
that keratinocytes from uninvolved skin of psoriatic patients also display several 
discrepancies compared to keratinocytes from normal skin. For example, in culture 
they have a 100-fold higher resistance to vitamin D
3
[100]; upon tape stripping they show 
a marked higher induction of proliferation[101]; and located at the suprabasal layer they 
express an altered differentiation pattern (e.g. presence of CK6, CK16)[102]. Moreover, 
the regulatory subunit of cyclic adenosine monophosphate (cAMP)-dependent protein 
kinase has a decreased cAMP binding ability in erythrocyte membranes of psoriatic 
patients[103]. Whether the above-mentioned  aberrations are causally involved in the 
pathogenesis of psoriasis is presently not evident. The possibility exists that they are 
mere epiphenomena not directly related to the disease process. 
During the last decade several lines of psoriasis research have postulated the 
involvement of the immune system. It was demonstrated that if one can eliminate 
the activated T lymphocyte in psoriatic plaques, keratinocyte proliferation and 
differentiation return to normal, both clinically and histologically[104,105]. Many drugs 
that selectively target activated T cells are very effective in producing remissions 
in psoriasis patients e.g. cyclosporin A[106-108]. The presence of CD4+ and CD8+ 
lymphocytes at sites of the psoriatic plaques led to the hypothesis that psoriasis is a 
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T lymphocyte-mediated disease directed against unknown (auto) antigens[109]. Other 
reports support the role for bacterial superantigens[110] and/or cross-reactivity between 
bacterial antigens and keratinocyte proteins, such as keratins[111,112].
More recently, a comprehensive view is endorsed which states that the interaction 
between APCs, T cells and endothelial cells is involved decisively in the 
pathophysiology of psoriasis[113-115]. It is hypothesised that the compensatory immune 
response mediated by Langerhans cells (LCs) and NK-T cells (lymphocytes that 
express both surface receptors typically for NK cells and for T cells) is coupled to the 
disrupted KC barrier function[114]. Briefly, following an injurious stimulus, the initial 
cutaneous innate immune response involves the activation of immature dendritic cells 
(DCs) and KCs. Activated LCs may dampen the pro-inflammatory response of KCs, 
but activate NK cells and macrophages. Initial production of cytokines such as IFN-
γ and TNF-α can influence mature DCs to facilitate an adaptive immune response 
involving NK-T cells and T cells. Evidence in accordance with the hypothesised 
model is constantly surfacing. For example, recently therapy with IL-4, a type-2 
cytokine of decisive significance in regulating the type-1/type-2 cytokine balance, 
showed to be effective in psoriasis. The observed clinical improvement was associated 
with a strong induction of Th2 differentiation in human CD4+ T cells and a concurrent 
reduction of IFN-γ/IL-4 ratio[116]. Although in the model proposed by Nickoloff, the 
innate immune system is invoked through activation of LC, recent data further stress 
the potential role of epidermal KC in this process. The discovery of functional toll-
like receptor 2 (TLR2) on epidermal KC in vivo[117] provides support to the active 
role of epidermal keratinocytes in innate immune responses. Innate recognition of 
pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors 
(PRRs), particular TLRs, is a key step for activation of adaptive immune responses[118-
123]. This finding integrates innate immunity of the epidermal KC with the adaptive 
immune system. In view of the fact that psoriasis is generally accepted to be a 
polygenic disease that responds successfully to different pharmacological approaches 
through diverse molecular targets, it can be concluded that abnormalities or defects 
both at the keratinocyte level and at the level of the immune system are important 
factors contributing to the pathogenesis of this disease. 
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Established treatments for psoriasis are supposed to act either on hyperproliferation, 
inflammation, aberrant epidermal differentiation or a combination of these aspects of 
the disease. A large number of in vitro studies have been performed, with a view to 
unravel the exact mode of action for a large number of antipsoriatic therapies. As yet, 
it remains to be determined to what extent these in vitro approaches reflect the real 
in vivo situation. The next section describes most of the currently used antipsoriatics. 
The overview is supplemented with various potentially novel therapies. These include 
some immunotherapies, as well as therapies based on peroxisome proliferator-
activated receptor-gamma (PPAR-γ) ligands, and on p38 mitogen–activated protein 
(MAP) kinase inhibitors. A number of these potentially novel therapies are still in 
clinical development.    
 
Retinoids
Retinoids (vitamin A and related ligands) operate through binding to specific nuclear 
retinoic acid receptors that exist of two major subclasses: the retinoic acid receptors 
(RAR)-α, -β, -γ and the retinoid X receptor (RXR)- α, -β, -γ[124]. The RAR-receptors 
preferentially bind all-trans retinoic acid (ATRA), while the RXR types preferentially 
bind 9-cis-retinoic acid[125-127]. The complex of the nuclear receptor and ligand binds 
to specific DNA binding domains, called hormone response elements (RARE, 
RXRE)[128]. As a result of this interaction transactivation of specific target genes 
occurs, which results in the modulation of transcription of various genes. The precise 
mechanisms of action are still incompletely understood. 
Retinoic acids utilised by the cells are either taken up from the blood circulation, 
or formed from vitamin A via the subsequent action of various retinol and retinal 
dehydrogenases under the influence of intracellular retinol and retinoic acid binding 
proteins (CRBP and CRABP, respectively)[129]. The most extensively studied effects 
of retinoids in psoriasis involve those associated with normalisation of the disturbed 
growth and differentiation of keratinocytes. Exposure of keratinocyte cultures to a 
variety of different retinoids resulted in a dose-dependent decrease in CK16 with 
a subsequent increase in CK14/CK16 ratio, and a decrease in cornified envelope 
formation. In vivo analysis revealed that the retinoid etretinate caused a reduction in 
CK16 and an increase in CK14/CK16 ratio. The magnitude of these changes and the 
correlation with the clinical improvement was variable[130]. In another study, vitamin 
A derivatives including etretinate, inhibited neonatal mouse keratinocyte proliferation 
and specific differentiation events in vitro. It is suggested that etretinate works by 
interfering with the terminal differentiation of keratinocytes[79,131,132]. When human 
keratinocytes were cultured in presence of RA a diminished expression of epidermal 
cytokeratins CK1, CK10[133]; CK6, CK16[134]; and CK5, CK14[134,135] was observed. 
In contrast, another study described the induced expression of CK6 and CK16 
upon treatment with ATRA[136]. Induction of cytokeratins by ATRA has also been 
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reported for CK4[137], CK13[134,138,139], and CK19[134,138,139]. Moreover, the expression of 
filaggrin, transglutaminase and loricrin was reduced after exposure of keratinocytes 
to ATRA[140-142]. These results suggest that ATRA works via interference with terminal 
differentiation. Treatment of cultured murine keratinocytes with etretinate, acitretin, 
ATRA or 13-cis RA, increased the IL-1 bioactivity in culture supernatants and cell 
extracts. The increased effect of the retinoids was enhanced by prolongation of 
the culture period[143]. The growth stimulatory effect of EGF on mouse epidermal 
keratinocytes was dramatically enhanced in the presence of ATRA. The same in vitro 
model showed that ATRA greatly enhanced the growth inhibitory action of TGF-β 
on EGF-induced DNA synthesis[144]. ATRA inhibited proliferation of rapidly growing 
human epidermal keratinocytes in keratinocyte growth medium (KGM; serum-free) 
(0.15 mM and 1.4 mM calcium). However, treatment of keratinocytes resulted in 
growth stimulation when cells were cultured in keratinocyte basal medium (KBM). 
Under all these conditions, keratinocyte adhesion and production of thrombospondin 
and fibronectin were inhibited[145]. To conclude, although there is at present no clarity 
with respect to the entire mode of action of retinoids, there is general consensus on 
the fact that interference with terminal differentiation and keratinisation of the human 
keratinocyte is determinative for the antipsoriatic effect of this drug.
Cyclosporin A
Cases of psoriasis that are characterised as being refractory are often successfully 
treated with cyclosporin A (CsA). This drug complexes with cyclophilin, which 
is a family of isomerases found in almost all mammalian cells. The complex 
inhibits calcineurin, the key-enzyme in calcium-dependent signalling processes. 
Since calcineurin is essential for signal transduction from the T cell receptor to the 
cytokine promoters, blockage of this pathway is believed to induce the profound 
immunosuppressive effect attributed to CsA. 
Although CsA is generally believed to act via the T lymphocyte, several groups 
have reported that CsA directly inhibits keratinocyte proliferation in vitro[146-
148]. Of the groups referred to, Dykes et al. reported in addition that CsA had no 
effect on keratinocyte differentiation in vitro. Besides, it has been described that a 
prolonged duration of exposure to CsA increases the concentration-dependent growth 
inhibition[146]. In another study, CsA specifically inhibited keratinocyte cell-cycle 
progression in the G
1
 phase without causing keratinocytes to terminally differentiate. 
CsA did not decrease the expression of epidermal growth factor receptors or TGF-α. 
These results indicate that CsA has no direct effect on autocrine growth regulation of 
keratinocytes via TGF-α production or EGF-receptor modulation[149].
Corticosteroids
Topical glucocorticosteroids (GCs) are frequently used as a treatment for psoriasis. 
Their mode of action involves suppression of the synthesis of inflammatory 
mediators, induction of anti-inflammatory mediators, inhibition of T lymphocytes 
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and neutrophils and a direct inhibition of epidermal proliferation (reviewed in[150]). 
GCs have an anti-inflammatory action because they interfere with arachidonic 
acid metabolism by blocking either prostaglandin or leukotriene production. For 
example, production of cyclooxygenase metabolic products (e.g. prostaglandin E2) 
by newborn rat keratinocytes was inhibited in vitro by dexamethasone, a synthetic 
glucocorticoid[151]. GCs interact with an intracellular GC receptor, which subsequently 
translocates to the nucleus as a ligand-activated transcriptional modulator. In turn, 
the GC receptor regulates the expression of genes such as those encoding cytokines, 
matrix metalloproteinases, and cell adhesion molecules known to be critical to both 
inflammation and the immune response[152,153]. Besides a direct “type 1” interaction 
with a palindromic GC-responsive element in GC-sensitive gene promoters[154,155], 
functions of the GC receptor also include a “type 2” interaction with chromatin-
associated cis-acting transcription factors. For example, the GC receptor can 
physically interact with the Fos and Jun components of dimeric activator protein-1 
(AP-1)[156,157], the p65 subunit of NF-κB[158,159], and the signal transducer and activator 
of transcription 5 (STAT5) family[160,161] to modulate the trans-activation of gene 
promoters that contain no GC-responsive elements. GCs also alter the nuclear 
availability of transcription factors as in the case when NF-κB activity is suppressed 
by induction of the I-κB inhibitory protein, which sequesters the regulatory element 
NF-κB as an inactive cytoplasmic complex[162,163].
Further insight in the regulatory role of glucocorticoids in the extent of specific 
promoter activation and expression of key genes involved in the inflammatory response 
was derived by Lukiw et al.[164]. Gene expression of cyclooxygenase 2 (COX-2), a key 
regulator of prostaglandin biosynthesis, induced by either platelet-activating factor 
(PAF) or IL-1β in normal human keratinocytes, was strongly suppressed in presence 
of dexamethasone. Concurrently, dexamethasone elicited strong inhibition of DNA 
binding activity of several transcription factors to their corresponding sites (AP-1 
site, gamma interferon activation site (GAS), NF-κB site), of which DNA consensus 
sequences are located in the immediate promoter region of the COX-2 gene. 
Fumarates
Fumaric acid (FA) esters have been used empirically in the treatment of psoriatic 
patients for many years. In 1989 the first controlled study was performed showing the 
efficacy of dimethylfumarate (DMF)[165]. Subsequently, several open and controlled 
studies have confirmed the efficacy of FA esters in psoriasis. The molecular basis of 
their function has only partially been resolved by in vitro studies. For example, in 
lymphocytes, DMF and its hydrolysis product, methyl hydrogen fumarate (MHF), 
modulated cytokine expression toward a Th2 cytokine profile[166,167]. Also, both 
substances inhibited keratinocyte proliferation[168] and monocyte differentiation 
into dendritic cells[169]. Recently, an important role for DMF was discovered in 
transcriptional regulation of NF-κB-driven gene expression. Loewe et al. showed 
that DMF selectively inhibited the TNF-induced nuclear entry of NF-κB proteins in 
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human endothelial cells[170]. Since a Th2 switch is also found in mice that have an 
impaired NF-κB signalling pathway[171,172], by analogy it may well be that the Th2 
switch induced by DMF is mediated by preventing nuclear entry of NF-κB. 
Vitamin D
3
Vitamin D
3
 and analogues can bind to the vitamin D
3
 receptor (VDR). This nuclear 
receptor is a member of the so-called steroid receptor superfamily, which, among 
others, includes receptors of retinoids and corticosteroids. Binding to the receptor, 
results in modulation of transcription of target genes. Furthermore, vitamin D
3
 
and analogues can act through a non-nuclear mechanism that involves trans-
membrane signalling. This leads to an increased influx of calcium into the cell[173]. 
Various vitamin D
3
 derivates (e.g. calcipotriol, tacalcitol) have the ability to inhibit 
proliferation of human keratinocytes in vitro[174-176], as well as  in vivo[177-180]. It has 
been reported that keratinocytes isolated from both involved and uninvolved psoriatic 
epidermis displayed resistance to 1,25-dihydroxyvitamin D
3
 treatment. A 100-fold 
higher concentration of 1,25-dihydroxyvitamin D
3
 was required to inhibit their DNA 
synthesis compared to normal keratinocytes[100]. However, other findings describe no 
discrepancy in sensitivity between normal and psoriatic keratinocytes[181]. Vitamin D
3
 
indisputably modulates epidermal differentiation (reviewed in[182]), although the in 
vitro response is strongly dependent on culture conditions[183-185].
Besides a direct role in growth and differentiation, vitamin D
3
 also has a profound 
effect on cutaneous inflammation mediators. For example, the production of IL-
1, IL-2[186], and IL-6[187] by lymphocytes is largely inhibited. Also, the release of 
arachidonic acid in vivo by rat polymorphonuclear leucocytes is blocked[188], thereby 
preventing the subsequent conversion into leukotrienes and other eicosanoids, which 
are well-established mediators of skin inflammation[189-191]. Summarised, although 
vitamin D
3
 is generally regarded to be a compound that targets the epidermis, an 
immunomodulatory effect cannot be excluded.
Methotrexate
One of the most effective treatments for severe psoriasis is achieved with the 
application of the folic acid antagonist methotrexate (MTX)[192]. However, because of 
the possibility of severe side effects (e.g. leukopenia, thrombocytopenia, hepatoxicity, 
liver fibrosis/cirrhosis), MTX is not a first choice in the treatment of moderate to severe 
psoriasis. It is believed that MTX exerts its antipsoriatic effect by immunomodulation, 
inhibition of epidermal proliferation and interference with cutaneous inflammation[193] 
although some contradiction exists in present data. 
Administration of methotrexate in psoriatic patients causes inhibition of DNA synthesis: 
keratinocytes are not able to pass G
1
 phase of the cell cycle and cells in S phase are 
killed[194,195]. This harmonizes with the observation that MTX inhibited proliferation of 
cultured keratinocytes, and induced several markers of differentiation[196]. In contrast, 
Jeffes et al. reported that in vitro cultures of keratinocytes that were treated with MTX 
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showed no reduction in clonal efficiency as compared to untreated controls. Also, 
at MTX concentrations that would be expected to occur in vivo after once-weekly 
therapy only 10% of proliferating keratinocytes were killed, as opposed to >95% of 
proliferating lymphoid cells[197]. Additional proof for a role of the immune system is 
the strong correlation that exists between the severity of psoriasis and the number of 
proliferating blood mononuclear cells[198]. Besides, preliminary data from the latter 
study, also demonstrate a decrease in the number of proliferating blood mononuclear 
cells with MTX therapy before clinical improvement is psoriasis was demonstrated.
Dithranol
Dithranol has been used as a successful antipsoriatic drug for over more than 100 
years. Despite a century of utilisation, the precise mode of action is incompletely 
understood. Dithranol is an anthrone derivate (1-8-dihydroxy-9-anthrone) that 
is changed by oxidation to anthraquinone dimers. The oxygen radicals that are 
extracellularly generated in this process are in part held responsible for the 
antipsoriatic potential of the compound. The growth modulating effects of the 
extracellularly generated superoxide anion radicals comprise inhibition of DNA 
replication and repair, interference with cellular respiration and inhibition of key 
enzymes of metabolic pathways[199]. Recently, dithranol was found to target 5-
ribonuclease P, an essential enzyme in tRNA biogenesis that endonucleolytically 
cleaves all tRNA precursors to produce the mature 5’ end[200]. Several in vitro effects 
of dithranol have been reported including the inhibition of calmodulin activity[201], 
and inhibition of keratinocyte oxygen metabolism resulting in a decreased adenosine 
triphosphate (ATP) content[202]. Dithranol reacts with redox components in different 
biologic membranes thereby altering the subcellular/cellular redox status and energy 
metabolism. These changes might significantly contribute to its antiproliferative 
activity[202]. In contrast to Tucker et al (1986)[201], Wollina et al (1989)[203] report results 
that argue against calmodulin inhibition of psoriatic epidermal keratinocytes as the 
primary event in the antipsoriatic action of dithranol. With respect to involvement of 
growth factor pathways, it was observed that dithranol decreased keratinocyte TGF-α 
expression and EGF-receptor binding in vitro[11]. This finding indicated that dithranol 
altered components of the EGF receptor pathway in cultured keratinocytes. 
Furthermore, co-incubation with a subcytotoxic and antiproliferative concentration 
dithranol significantly lowered the expression of IFN-γ-induced CK17 in cultured 
HaCaT cells in a study of Bonnekoh et al.[204]. Because recently an epitope within 
CK17 was proposed as a putative psoriasis autoantigen[205], Bonnekoh et al. 
hypothesise that the antipsoriatic mode of action of dithranol may be related to a direct 
down-regulation of this skin-specific autoantigen structure.
Immunotherapies
Apart from the debate concerning whether the immune cell infiltrates are 
pathogenetically relevant for psoriasis or whether keratinocyte hyperproliferation 
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is the key factor, it is evident that immunotherapy has become an established 
antipsoriatic treatment. Immunotherapy in poriasis includes approaches targeting 
the action of proinflammatory mediators and the administration of anti-inflammatory 
cytokines, T cell activation, and antigen presentation and co-stimulation. Examples of 
each of the approaches are described below. 
TNF-α has a proximal position in the effector cytokine cascade, which made it an 
interesting candidate target for the inhibition of inflammatory reactions. Treatments 
using humanized anti-TNF-α-mAb (infliximab)[206] or soluble TNF-α receptor 
(etanercept)[207] were effective.
Psoriasis can also be attenuated by cytokines that suppress T cell mediated immune 
responses such as IL-10, which induces T cell anergy[208-210], IL-11, which attenuates 
Th1 reactions[211], or IL-4, which induces Th2 differentiation in human CD4+ 
cells[116].
Although effective, the approaches mentioned above carry the risks associated with 
general immunosuppression and may enhance susceptibility to infectious agents, 
especially intracellular pathogens such as mycobacteria. 
Since the early 1990s therapies based on the use of T cell specific monoclonal antibody 
(mAb) have been tested. The mAbs target T cell surface molecules thereby preventing 
activation of the cell. Anti-CD2 and anti-CD3 mAbs, directed against all T cells, and 
anti-CD4 mAb, directed predominantly against T-helper cells, have rapidly produced 
improvement[212-216]. Although several successful studies have been published, anti-
CD treatments are by no means a standard treatment in psoriasis.
The therapeutic concepts discussed so far target mainly the effector part of the 
immune response. This most likely implies a necessity of repeated or even permanent 
treatment; since it is unlikely that targeting of effector mechanisms can cure the 
disease by reprogramming of tolerance. However, targeting the APC - T cell 
communication might lead to more persistent effects, allowing selectivity, specificity 
and tolerance of the therapy. Various experimental therapies are based on a targeted 
blockade of co-stimulation. For example, LFA3-TIP (Amevive/Alefacept) blocks the 
leukocyte functional antigen (LFA)-3-CD2 interaction, while cytotoxic T lymphocyte-
associated antigen (CTLA)-4 fusion protein blocks the interaction of CD80 and CD86 
(B7 molecules) with CD28. The humanized anti-CD11a mAb (Efalizumab) inhibits 
the interaction of CD11a with a variety of intercellular adhesion molecules (ICAMs) 
molecules. Because ICAM-1 (CD54) is expressed on activated endothelial cells and 
on APCs, the Ab inhibits both the APC – T cell interaction and the adhesion of T cells 
to endothelial cells. In the latter case, subsequent transendothelial migration is also 
prevented.
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New small molecule drugs
Peroxisome proliferator-activated receptor-gamma ligands
As described above, psoriasis is often treated with agents that activate nuclear hormone 
receptors for glucocorticoids, retinoids, and vitamin D. The peroxisome proliferator-
activated receptor-gamma (PPAR-γ) is a related nuclear hormone receptor that can 
be activated by its ligands, including the thiazolidinediones or glitazones. PPAR-γ is 
expressed in cultured human keratinocytes, and increased levels of expression were 
demonstrated after induction of keratinocyte differentiation by shifting the culture 
medium to high Ca2+ concentration[217]. In a study of Ellis et al., ligands for PPAR-γ 
inhibited the proliferation of normal and psoriatic human keratinocytes in culture. In 
addition, troglitazone treatment normalised the histological features of psoriatic skin 
in organ culture. Also, in lesional psoriatic skin transplanted onto severe combined 
immunodeficiency disease (scid) mice treated with troglitazone orally, overall skin 
thickness was reduced, a more normal pattern of epidermal differentiation occurred, 
the granular layer (which is decreased or lacking in the untreated psoriatic skin) was 
present in much of the epidermis, and the inflammatory response was reduced. The 
same study describes that troglitazone was effective in systemic psoriasis therapy, 
although only five patients with chronic, stable plaque psoriasis were included in the 
study[218]. 
P38 mitogen-activated protein inhibitors 
Mitogen-activated protein (MAP) kinases are key enzymes involved in signal 
transduction and the amplification of cellular responses to stimuli. The p38 MAP 
kinase enzyme is a specific member of the MAP kinase family associated with the 
onset and progression of inflammation. P38 MAP kinase regulates the production of 
proinflammatory cytokines such as TNF-α, IL-1β and IL-6, which are known to play 
key roles in a range of inflammatory diseases. Specific p38 MAP kinase inhibitors 
almost completely blocked the induction of SKALP expression when cultured 
human keratinocytes were incubated with either TNF-α or foetal calf serum[219,220]. 
These results suggest that in keratinocytes, p38 activity is crucial for the induction 
of SKALP gene expression. Several p38 MAP kinase inhibitors are currently being 
evaluated in phase II clinical trials.
In conclusion, although evidence suggests that the majority of the established 
antipsoriatic therapies target predominantly either immune system or epidermis, it 
cannot be excluded that the therapeutic outcome of most of the individual antipsoriatics 
results from a combinatorial effect. In general, single-target immunotherapies act in a 
specific manner, while most small molecules operate rather non-specifically. 
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In the past years a large number of models for the investigation of epidermal growth 
and differentiation have been described and used. The next paragraphs describe 
several in vivo and in vitro models that are applicable to study aspects of psoriasis, as 
they allow the analysis of normal as well as abnormal growth and differentiation of 
epidermis.
6.1 In vivo models (human)
Studies performed with human in vivo models have greatly provided relevant data 
on epidermal growth and differentiation because interactions between the different 
cell types in skin and the interaction of skin cells with the organism’s immune system 
occur in their entire natural environment.    
A well-known standardised human model for epidermal injury has been named “tape 
stripping”. The model is defined as a repeated application of adhesive tape to the skin in 
order to remove the stratum corneum. This tape stripping results in hyperproliferation 
of the affected skin accompanied by inflammation and abnormal differentiation[221-
223]. Other models are the application of detergents and other skin irritants to normal 
skin[224,225], the study of the spreading margin of a psoriatic plaque[226-228], controlled 
wounding of skin[229,230] and UV irradiation of normal human skin[231,232]. Obviously, 
application of these human models is largely limited from an ethical point of view.
6.2 In vivo models (mouse)
At present there is no naturally occurring animal disease mirroring both phenotype and 
immunopathogenesis of psoriasis. This has considerably prevented the advancement 
in psoriasis research. Nevertheless, several spontaneous mutations, transgenic 
animals, xenotransplantation models, T cell transfer models, and chemical-induced 
models have been used to study aspects of the disease. The main animal models and 
their potential value for psoriasis are described below.
Mice homozygous for the chronic proliferative dermatitis (cpd) or the flaky skin (fsn) 
mutations are characterised by skin alterations including epidermal hyperproliferation, 
a mixed inflammatory infiltrate with neutrophils accumulating in epidermal micro-
abscesses, and enlarged and dilated dermal blood vessels. The main deficit of these 
models is the lack of a T cell based immunopathogenesis[233,234], which limits their 
value for psoriasis research for those adhering to the dogma that T cells are central to 
the disease. 
Transgenic mice with targeted cytokine expression within the skin provided promising 
tools for studying possible roles of these cytokines in the pathogenic cascade of 
psoriasis. Skin specific expression has mostly been achieved utilising promoters of 
CK10, CK14, or involucrin. Unexpectedly, CK14 promoter-driven overexpression of 
IL-6[235], KGF[236], or TGF-α[237], resulted in no (in IL-6 transgenics) or minor (KGF 
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and TGF-α transgenics) changes of keratinocyte proliferation and differentiation. 
Moreover, no inflammatory infiltrates and vascular alterations were observed (with 
the exception of some severely affected TGF-α transgenics). Although the sole 
overexpression of IL-6, KGF, and TGF-α was not sufficient to evoke many psoriasis-
like features, the possibility exists that a more complex (e.g. synergistic) pattern 
of these and other cytokines may be necessary to achieve a psoriatic phenotype. 
Transgenic mice with CK14 promoter-driven overexpression of IL-1α hold dermal 
infiltrates of macrophages/monocytes within the dermis of clinically uninvolved 
skin[238]. Severely affected animals have inflammatory lesions, characterised by a 
mixed inflammatory infiltrate, and by acanthosis and parakeratosis in some cases. 
Since the effect on keratinocyte differentiation was only subtle, other mediators 
present in psoriatic skin are probably lacking in these skin lesions. However, the 
phenotype of IL-1α transgenic mice provides evidence that supports a primary role of 
IL-1α as an inducer of cutaneous inflammation. Interestingly, in a small percentage 
(5-20%) of transgenic mice with involucrin promoter-driven overexpression of IFN-γ, 
hyperproliverative changes of differentiation, induction of major histocompatibility 
complex (MHC) class II and ICAM-1, and enlarged dermal capillaries were seen[239]. 
No T cells infiltrated the epidermis, which suggests that IFN-γ is not directly involved 
in T cell-associated growth response of the epidermis. The effects observed in IFN-
γ transgenics appear to complement the effects of IL-1α transgenics in view of a 
psoriasis-like phenotype. It is therefore speculated that synergistic effects of both 
cytokines might contribute to the pathogenesis of human psoriasis.
It was recently reported that transgenic mice with epidermis-specific deletion 
of IκB kinase-2 (IKK-2) developed a severe inflammatory skin disease with a 
psoriasiform character that is caused by a TNF-mediated, αβ T cell independent 
inflammatory response. IKK2 deficiency inhibited NF-κB activation, but did not lead 
to cell-autonomous hyperproliferation or impaired differentiation of keratinocytes[240]. 
Previous in vivo and in vitro experiments showed hyperproliferation and epidermal 
hyperplasia after NF-κB inhibition and growth arrest after NF-κB activation in 
epidermal keratinocytes, and suggested a role for NF-κB in the regulation of 
keratinocyte growth[241,242]. However, in these studies NF-κB activity was modulated 
downstream of the IKK complex. This suggests that the proposed growth regulatory 
function of NF-κB in epidermal keratinocytes can be mediated through an IKK2-
independent pathway. The biological significance of NF-κB in inflammation is 
well-established, and many efforts have been undertaken to block NF-κB-induced 
gene transcription in order to reduce/inhibit the process of inflammation[243-250]. It 
is therefore seemingly paradoxical that IKK2-deficiency results in the onset of an 
inflammatory skin disease in mice. However, a tightly regulated microenvironment 
of cytokines and growth factors produced by keratinocytes, dermal fibroblasts and 
immune cells is critical for the maintenance of physiological skin homeostasis[15]. It 
is hypothesised that the IKK2-mediated NF-κB signalling pathway may be essential 
for epidermal keratinocytes to respond to such regulatory mediators and/or to produce 
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factors that are important for the maintenance of a well balanced interplay between 
the epidermis, dermis and the immune system[240]. In conclusion, the transgenic mouse 
with epidermis-specific deletion of IKK-2 is a model particularly interesting in view 
of the fact that it provides new insight into the function of NF-κB in the epidermis 
and suggests that keratinocytes can act as the initiating cell type in inflammatory skin 
disease.
A T cell-based immunopathogenesis of psoriasiform features was shown in a form 
of graft-versus-host disease in scid/scid mice reconstituted with MHC-matched, but 
minor histocompatibility mismatched CD4+/CD45RBhi T lymphocytes demonstrating 
that deregulated T cells can induce psoriasiform skin alterations without a primary 
epithelial abnormality[251]. This model appeared to be valuable for studying the array 
of local events resulting from the localization of activated T cells within the skin[252].
A very attractive in vivo animal model for psoriasis research nowadays is the 
xenotransplantation model since it directly involves the study of human tissue. In 
studies using scid/scid recipients, pathogenic links were established between T cells 
isolated from psoriatic patients and cutaneous alterations characteristic for psoriasis. 
Autologous blood-derived immunocytes were injected into dermis of full-thickness 
human skin transplants. As a result, all skin samples derived from uninvolved skin 
of patients with psoriasis converted to a full-fledged psoriatic plaque. In contrast, 
none of the skin samples derived from normal human skin injected with autologous 
immunocytes converted to psoriatic plaques[70,253]. Another study showed that skin-
infiltrating lymphocytes, but not T cells derived from peripheral blood, maintained the 
psoriatic phenotype of human skin grafted on to scid/scid mice[254]. Also, circumstantial 
evidence for a pathogenic role of bacterial superantigens in psoriasis resulted from 
this model. Repetitive intradermal injections with a bacterial superantigen and 
simultaneous intraperitoneal injections with the patients superantigen-stimulated 
peripheral mononuclear blood cells resulted in an inflammatory reaction exhibiting 
some of the hallmarks of psoriasis[255]. Despite being an appropriate tool for studying 
local events underlying the pathogenesis of psoriasis, processes involving the entire 
organism, like T cell activation (which may involve lymph nodes) and recirculation of 
leukocytes, may be difficult to assess in these ‘two-species-systems’.  
An additional murine model to study aspects of  psoriasis is the chemical induction of 
cutaneous inflammation and epidermal hyperplasia. The localised topical application 
of the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) on hairless 
mouse skin has been described to generate these psoriatic hallmarks. As yet, the 
TPA-model has been used to test the effect of staurosporine derivatives[256], matrix 
metalloproteinases inhibitors[257] and several phosphonamide-based inhibitors[258].
To date the complete pathogenesis and phenotype of psoriasis is incompletely covered 
by any single animal model. However, the currently available models clearly provide 
a handle on many specific phenotypic and pathogenic aspects of this skin disorder.
Inherent to the in vivo model are the limitation of source material and the absence of 
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exact system control. These drawbacks have been circumvented by a number of in 
vitro models for keratinocyte growth and differentiation that will be discussed next.
6.3 In vitro models (submerged / skin equivalent / explant)
Already at the closure of the 19th century it was reported that excised pieces of skin 
remained viable when cultured in ascites fluid at room temperature, and that the skin 
could subsequently be grafted onto wounds[259]. However, it was not until the mid 
1970s that a major breakthrough into modern keratinocyte culture came with the report 
that epidermal keratinocytes could be cultured at clonal density when maintained in 
the presence of a feeder layer of irradiated mouse embryo cells[260]. As to date this 
method is still widely employed, especially since it allows large numbers of cells to 
be grown from small biopsies. Much effort has been put in the development of more 
defined growth media for keratinocytes, allowing cells to be cultured in the absence 
of feeder layers or conditioned medium[261,262]. Although nowadays keratinocytes can 
be cultured in serum-free medium, in general, medium is supplemented with crude 
protein factors (e.g. bovine pituitary extract) since presence of exogenous growth 
factors is still required for growth[263,264]. 
A number of culture models based on primary keratinocytes have been developed 
at our department, in which keratinocyte differentiation can be manipulated. The 
keratinocytes differentiate either normally or follow a pathway leading to a psoriatic 
phenotype depending on the composition of the culture medium[59,265]. Induction of 
differentiation with foetal calf serum resembled the psoriatic phenotype (sustained 
hyperproliferation; high levels of CK16, SKALP, transglutaminase and involucrin; 
moderate psoriasin expression) whereas differentiation induced by growth factor 
depletion in a confluent culture resembled the normal differentiation phenotype (low 
proliferative rate; high expression levels of CK1 and CK10; moderate expression of 
involucrin and transglutaminase; low expression levels of SKALP and CK16; absence 
of psoriasin). These models allow study of the induction of normal and psoriatic 
differentiation pathways.
An alternative to the use of primary keratinocytes is the application of immortalised 
keratinocytes, like the spontaneously immortalised HaCaT cell line. This cell line has 
been extensively characterised and despite chromosomal alterations associated with 
the immortalisation, its differentiation behaviour largely resembles that of normal 
human keratinocytes[266]. 
Despite a clear number of advantages, submerged systems have limitations in some 
respects. These cell cultures are evidently only suitable to test soluble factors. 
Moreover, due to the absence of a stratum corneum many properties of skin are 
altered. This has led research to explore alternatives to complement or substitute 
submerged culture systems. In the last two decades possibilities for the application 
of artificial skin cultures, for both research and therapeutics, have been examined. 
In these so-called skin equivalent models keratinocytes are cultured on (collagen) 
matrices containing fibroblasts or on de-epidermised dermis (DED). Although both 
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skin equivalents show great similarities in morphology with native tissue, they 
exhibit some abnormalities such as different expression patterns of differentiation 
markers[267,268] lipid composition and organization[269,270], and barrier function[271,272]. 
In addition, more than a century after the first report of cultured pieces of skin 
by Ljunggren, maintenance of fresh skin biopsies in culture still finds use as skin 
explants are applied in studies with the objective to study epidermal differentiation, 
re-epidermization, cytotoxicity, epidermal permeation, and transepidermal drug 
delivery[273]. 
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A large number of leading and innovative pharmaceutical industries utilise research 
and development programs to identify new active compounds and improve existing 
therapeutics in dermatology. In the preclinical phase specific animal models are 
applied to examine a compound’s capacity to exert a defined desirable effect. These 
models can be categorised as follows: 
(1) specific models, which allow measurement of well-defined and restricted cell 
biological response. An example is the so called rat-vagina model, in which the 
inhibition of vaginal keratinisation can be used as a rapid and convenient in vivo 
model for screening retinoid candidates with antikeratinizing activity[274,275]. Other 
animal models being used to test retinoid and retinoid-mimetic effects are the vitamin 
A-deficient rat[276] and the rhino mouse[277,278].
(2) general models in which a complete process (e.g. inflammatory reaction, irritation, 
ulceration, immunological response) can be measured[279-281]. Specific examples are 
the mouse-ear test (Arthus reaction, delayed type hypersensitivity, irritative response) 
and the application of a mouse-tail model to study effects on proliferation and 
differentiation[282].
In view of the relative large number of compounds that become available for a first 
screening and the necessity to test these over a broad concentration range, it is clear 
that an urgent need exists for adequate in vitro systems that allow for large-scale 
testing. However, current literature makes hardly any mention of keratinocyte-based 
drug screening models. Most of the experimental assays comprise models that 
assess retinoid activity in keratinocyte differentiation[130,283]. The remainder of the 
assays described to date that qualify for large-scale application is used to test cell 
growth, cytotoxicity or chemoprevention efficacy. An example of these is the Human 
Epidermal Cell (HEC) assay that was developed to rapidly identify agents with the 
potential to prevent carcinogen-induced cancer[284].
7. MODELS USED IN PHARMACOLOGICAL SCREENING
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Potentially novel antipsoriatic drugs usually emerge as lead compounds by screening 
large compound libraries in cellular assays that are based upon the read-out of a small 
number of parameters. However, uncovering the specific mode of action of a drug 
is desirable since this can substantially contribute to a more tailored approach of 
therapy, thereby increasing efficacy and reducing unwanted side-effects. Microarray 
expression profiling is a powerful method that can be employed to reveal (clusters 
of) genes that are differentially expressed in drug-treated and untreated cell culture 
models. Thereby, it may reveal pathways specifically affected by the lead compound. 
The basic concept behind all microarrays is the precise positioning of DNA fragments 
(probes) at high density, typically hundreds to tens of thousands, on a solid support 
so that they can act as molecular detectors for gene activity. In practice, microarrays 
vary greatly both in physical design and in application. For a detailed insight into this 
matter the reader is referred to several comprehensive reviews[285,286]. Below, a concise 
description is given of the experimental methodology used in a typical microarray 
experiment that surveys patterns of gene expression. Firstly, RNA is isolated 
from different tissues, developmental stages or samples subjected to appropriate 
treatments (e.g. drug treated versus control cell cultures). Then, either the total RNA 
or the purified mRNA fraction (target) is labelled and hybridised to the array. After 
hybridisation, and after stringent washing, an image is taken of the array. The location 
and intensity of the label on the array surface indicates the presence or relative 
abundance of each specific target sequence in the hybridised sample, each reflecting 
specific gene activity. Clearly, the use of microarray analysis in drug research will be a 
powerful tool in future development of antipsoriatic drugs. Chapter 7 describes a pilot 
experiment to further examine the effects of retinoic acid on a larger scale, using an 
in-house developed microarray for dermatological research. 
8. DNA MICROARRAY GENE EXPRESSION PROFILING 
36  Chapter 1 General Introduction Chapter 1 General Introduction  37
Inflamed human epidermis (psoriasis, wound healing, UV-irradiated skin) harbours 
keratinocytes that are hyperproliferative and display an abnormal differentiation 
program (e.g. expression of CK6, CK16, and CK17 and the secreted anti-
inflammatory protein SKALP). Expression of these molecules can be used as a 
marker for psoriasis both in vivo and in vitro. High-throughput programs based on 
biological testing of large collections of compounds require cell culture systems that 
allow rapid identification of leads for potential drug candidates in the treatment of 
psoriasis. The application of cultured human epidermal keratinocytes for screening 
of anti-inflammatory/antipsoriatic drugs has long been of limited value, due to the 
absence of models that could faithfully mimic the normal and the pathological 
situation in an in vitro culture system for large scale use in pharmaceutical industry. 
In 1996 van Ruissen et al. developed at our department a model which allowed the 
culture of human keratinocytes with a normal phenotype (low proliferative rate, 
normal differentiation) and an inflammatory/psoriatic phenotype (high proliferative, 
disturbed differentiation)[59]. This culture system proved to be a promising model to 
obtain fundamental insights in cutaneous inflammation, and to be of practical value 
in preclinical drug screening programs. The model system described by van Ruissen 
was set up using standard culture dishes and was not suitable for medium throughput 
or high throughput screening. These considerations formed the starting-point of the 
project, which led to the following initial aims:
► Downscaling of the keratinocyte culture system
► Development of a reliable, non-radioactive, high-throughput 
proliferation assay for human keratinocytes
► Development and validation of ‘normal human keratinocyte’ cell 
culture systems, applicable as large-scale pharmacological screening 
systems to establish effects on keratinocyte differentiation
In the culture system that was used to screen modulators of differentiation we used 
induction and expression of SKALP as a paradigm for the induction and expression of 
the epidermal phenotype of regenerative maturation/differentiation. Although SKALP 
expression is a useful marker for psoriatic differentiation, its utility in high-throughput 
drug screens is limited due to the laborious, time-consuming multistep-ELISA needed 
for the quantification of the secreted protein from culture medium. Large-scale 
screening systems often utilise reporter genes that allow rapid, (semi)-automated 
analysis of the desired parameter. We therefore wanted to develop a permanent 
transfected keratinocyte cell line (HaCaT) able to monitor the activity of the SKALP 
promoter using a more convenient read-out, rephrased as the following aim:
9. AIMS OF THIS THESIS
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► Development of a fluorescence-based assay where the application 
of a fluorescent protein (GFP) under the control of an endogenous, 
“psoriasis-associated” promoter would allow for large-scale 
pharmacological screening.
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Pharmacological treatments for psoriasis are generally based on antiproliferative, anti-
inflammatory, or differentiation-modifying activity, or a combination of two or more of 
these actions. Potentially new drugs for treatment of psoriasis that act on proliferation, 
can be identified by screening large compound libraries in a cell proliferation model, 
that allows for characterisation of drug effects on in vitro growth of normal human 
keratinocytes. High-throughput programs based on biological testing of diverse 
collections of compounds can rapidly identify leads for potential drug candidates 
in the treatment of psoriasis. Here we describe non-radioactive measurement of 
keratinocyte proliferation in the exponential growth phase in a 96-well format, using 
a sensitive DNA-binding dye to analyse drugs that are pharmacologically active in 
growth inhibition. Release of lactate dehydrogenase was used to exclude cytotoxic 
effects. We examined a number of compounds in a test range of 10-7 to 10-5 M, 
including known antipsoriatic drugs, and experimental drugs that are potentially 
useful in the treatment of psoriasis. We found strong concentration-dependent growth 
inhibition by dithranol, an antipsoriatic compound that is presumed to target the 
epidermal compartment. Methotrexate, cyclosporin A and all-trans retinoic acid did 
not significantly affect proliferation at therapeutically relevant concentrations. The p38 
mitogen-activated protein (MAP) kinase inhibitor SB220025 and curcumin, a natural 
phytochemical, inhibited keratinocyte proliferation at 10-5 M. We conclude that this 
assay, in combination with previously developed assays for psoriatic differentiation, 
provides a useful tool for identification of antipsoriatic drugs.
2.1 ABSTRACT
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Psoriasis is characterised by hyperproliferation of keratinocytes associated with an 
inflammatory infiltrate in the epidermis. The aetiopathogenesis of this skin disease 
remains unclear at present; however, a combination of immunological predisposition 
(autoimmunity, superantigen stimulation) and keratinocyte abnormalities is very 
likely key to the disease mechanism. 
Biological testing of diverse collections of compounds in high-throughput programs 
can rapidly identify leads for potential drug candidates in the treatment of psoriasis. 
Previously, we described a model for high-throughput screening of drugs that 
modulate normal and psoriasis-like differentiation in confluent cultures of human 
keratinocytes[220]. The read-out of this model was based upon two differentiation 
markers for normal and psoriatic skin, respectively cytokeratin 10 (CK10) and 
skin-derived antileukoproteinase (SKALP). As hyperproliferation of epidermal 
keratinocytes is a distinct feature of psoriasis, simple, inexpensive high-throughput 
systems to measure the effect of antiproliferative compounds are clearly useful 
for the identification of new antipsoriatic drugs. Drugs that inhibit keratinocyte 
proliferation are potentially useful in the treatment of psoriasis, since a rebalanced 
homeostatic control of keratinocyte growth and differentiation is crucial for recovery 
from psoriatic to normal epidermis. Therefore, a successful antipsoriatic drug that 
targets the epidermis (rather than the immune system) is defined as a compound that 
ideally shows low toxicity and restores skin homeostasis by suppressing keratinocyte 
hyperproliferation, abnormal differentiation, or both.
High sample numbers in microtitre plate-based assays for cellular growth inevitably 
limit the available growth surface per well. As a consequence, the detection window 
for changes in cell number is set by the sensitivity of the method applied for 
quantification. To this end, radiolabeled nucleotides such as tritiated thymidine are 
widely used in a variety of cell types to measure cellular proliferation. Apart from 
the obvious disadvantage of radiochemicals, these assays typically measure a growth 
fraction in a short time frame, rather than true increases in cell mass during exponential 
growth. Metabolic pathways that utilise thymidine can cause non-linearity of this 
assay, as has been reported for keratinocytes[287].  In order to monitor increases in 
absolute cell numbers in microtitre plate formats, highly sensitive, fluorescent DNA-
specific dyes are used. Fluorescence assays based on the use of propidium iodide, a 
member of the phenantridinium class of DNA intercalating dyes, have been described 
to be applicable as an in vitro proliferation assay[288]. This fluorochrome was used to 
develop a simple and rapid test system for cell cultures of several human tumour cell 
lines. Recently, in a comparative study where Hoechst 33342, propidium iodide and 
PicoGreen were used to detect the mitotic activity of human primary cell cultures 
(endothelial cells, hepatocytes), PicoGreen was found to be the dye with the highest 
sensitivity and accuracy[289]. It was our objective to employ PicoGreen staining in 
96-well plate cultures of keratinocytes to develop a sensitive proliferation assay. We 
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subsequently aimed to apply this proliferation assay to develop a high-throughput 
screen to identify new (classes of) antipsoriatic drugs that act via the keratinocyte 
as the primary target cell. Analysis of known antipsoriatic compounds was used to 
validate the model system.
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Chemicals and Preparations
Curcumin, dithranol, methotrexate (MTX), indomethacin and all-trans retinoic acid 
(ATRA) were all purchased from Sigma-Aldrich (St. Louis, MO, USA). SB220025 
was obtained from Calbiochem (San Diego, CA, USA). Cyclosporin A (CsA) was 
obtained from Sanvertech (Heerhugowaard, the Netherlands). Stock solutions were 
prepared according to directions of the supplier, either in ethanol (curcumin 10-2 M, 
CsA 10-2 M, indomethacin 10-2 M, ATRA 5 x 10-3 M), in DMSO (SB220025 10-2 M, 
dithranol 10-2 M), or in 0.1 M NaOH (MTX 10–3 M).
Cell culture
Human epidermal keratinocytes were derived from skin biopsies of healthy 
volunteers to obtain primary cell cultures as described previously[59]. Liquid nitrogen 
stored keratinocytes from these primary cultures were seeded in 96-well flat bottom 
cell culture plates and cultured in keratinocyte growth medium (KGM). KGM was 
composed of keratinocyte basal medium (KBM) (BioWhittaker, Walkersville, MA, 
USA) supplemented with ethanolamine (0.1 mM) (Sigma, St. Louis, MO, USA), 
phosphoethanolamine (0.1 mM) (Sigma, St. Louis, MO, USA), bovine pituitary 
extract (BPE; 0.4%) (BioWhittaker, Walkersville, MA, USA), insulin (5 µg/ml) 
(Sigma, St. Louis, USA), hydrocortisone (0.5 µg/ml) (Collaborative Research Inc, 
Lexington, MA, USA), recombinant mouse epidermal growth factor (EGF; 10 ng/ml) 
(Sigma, St. Louis, MO, USA), penicillin (100 U/ml) (Gibco, Breda, the Netherlands) 
and streptomycin (100 µg/ml) (Gibco, Breda, the Netherlands). Agents to be tested for 
their potential effect on keratinocyte growth were immediately before the experiment 
diluted in KGM to create a dose range of 10–5, 10–6, 10–7 M and added to the culture 
on day 3 after seeding. 
Cytotoxicity test 
In order to assess the cytotoxic effect of the tested agents on the cultured 
keratinocytes, supernatants were collected at culture endpoints and screened by the 
Cytotoxicity Detection Kit, which uses release of lactate dehydrogenase (LDH) as a 
readout, according to directions of the supplier (Boehringer Mannheim, Mannheim, 
Germany).
PicoGreen dsDNA Quantitation Reagent vs. Propidium Iodide
The correlation between increased cell mass of a keratinocyte cell culture and the 
culture’s dsDNA dependent fluorescence was determined for two dyes: PicoGreen 
dsDNA Quantitation Reagent (Molecular Probes, Leiden, the Netherlands) and 
propidium iodide. In brief, human keratinocytes were seeded in triplicate in a two 
fold dilution series starting at 5000 cells/well in a 96-well microtitre plate. Once 
confluency was reached in the well with the highest initial cell number, medium 
2.3 MATERIALS AND METHODS
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was aspirated; cells were washed three times with PBS before fixation with acetone/
methanol (1:1) of –20°C (10 minutes, -20°C). Subsequently, plates were air-dried 
after removal of fixative. For measurements based on PicoGreen dsDNA Quantitation 
Reagent, 100 µl of a freshly prepared 2.5 mg/ml trypsin (Sigma, St. Louis, MO, 
USA) solution in PBS was added to each well. Plates were incubated for 30 min at 
37°C. Next, without removal of trypsin solution, an additional 100 µl/well of a 1:
200 dilution of PicoGreen in PBS was added. Subsequently, sample fluorescence was 
measured at excitation/emission wavelengths of 485/520 nm using a fluorescence 
microplate reader (Polarstar, B&L). For measurements based on propidium iodide, 
cells were fixed with 70% ethanol of –20°C (5 minutes, -20°C), and air-dried after 
removal of fixative. Cells were then incubated with 100 µl/well 30 µg/ml propidium 
iodide in PBS (30 minutes, R.T.). Subsequently, cells were washed three times with 
PBS, wells were filled with 100 µl/well PBS and sample fluorescence was measured 
using a fluorescence microplate reader (CytofluorII, Applied Biosystems) with an 
excitation wavelength of 530 nm (bandwidth 25 nm) and an emission wavelength of 
620 nm (bandwidth 40 nm). 
Cell number measurements: PicoGreen dsDNA Quantitation Reagent
The correlation between the amount of DNA measured by the PicoGreen assay and 
cell numbers as determined by manual counting was established. In brief, cultured 
human keratinocytes were seeded and cultured to mid-log phase. Then cells were 
trypsinised, fixated in acetone/methanol (1:1) and concentrations of several dilutions 
of single cell suspensions were determined in a Bürker hemocytometer. Subsequently, 
a series of quantitated amounts of fixated cells in PBS (100 µl) was added to a 96-well 
microtitre plate and the dsDNA dependent fluorescence was determined as described 
in the section above.
Agents to be tested for their inhibitory effects on keratinocyte cell growth were 
added to keratinocyte cell cultures at 15-20% confluence. In order to study possible 
drug effects on proliferation rate during the additional 4 days of culture, cell number 
quantitation was performed at four time points (day 1, 2, 3, and 4) using PicoGreen 
dsDNA Quantitation Reagent in an adapted protocol as described in the section 
above. 
Statistical Analysis
One-way analysis of variance (ANOVA) was employed for comparison of 
measurements of the various drug concentrations. A minimal number of 4 wells 
per drug concentration were used for all tested compounds. A value of p < 0.05 was 
considered significant.
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PicoGreen dsDNA Quantitation Reagent vs. propidium iodide in cell number 
measurements
Due to high sample numbers in high-throughput drug screening models it is advisable 
to exclude time-consuming steps in cell number quantitation assay design. Dengler 
et al. have proposed a proliferation assay that meets this criterion[288]. The propidium 
iodide fluorescence assay can easily be used for cell number determinations in 
biological and pharmacological studies in a 96-well microtitre plate format. However, 
the lower limit of cell detection varied for eight cell lines studied, ranging from 150 to 
1500 cells per well. Our initial experiments, using the propidium iodide fluorescence 
assay on a dilution series of human keratinocytes, resulted in a lower limit of detection 
of 2000 cells per well (results not shown). In search for lower cell detection limits 
we then set out to compare propidium iodide and PicoGreen dsDNA Quantitation 
Reagent. Figure 1 shows a comparison of PicoGreen and propidium iodide in a 
dilution range of cell densities cultured in 96 well plates. In the linear range of the 
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Figure 1: Comparison of the fluorescent DNA dyes PicoGreen and propidium iodide for the detection of 
small numbers of human keratinocytes in a 96-well microtitre plate format. Cells were seeded in triplicate 
in a serial twofold dilution series. When confluency was reached in the well with the highest initial cell 
number, the plates were harvested and cells were stained for DNA as a reflection of cell mass. Relative 
fluorescence (mean ± SD) is expressed as a percentage of the signal that was measured in the confluent 
well.
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assay PicoGreen has an approximate 5-fold higher sensitivity than propidium iodide, 
and was used for further experiments.
Keratinocyte growth characteristics in the presence of drugs
To evaluate the antiproliferative effects of a panel of drugs, we quantitatively 
measured dsDNA as a reflection of cell mass, during a 4-day period of growth of 
keratinocyte cell cultures. First, single cell suspensions were prepared from wells of 
a 96-well microtitre plate that contained different confluencies, in order to establish 
the correlation between cell numbers and fluorescence. Cell numbers derived by 
manual cell count in a hemocytometer correlated in a linear fashion (R2=0.991) 
with the fluorescent signal obtained from the DNA staining by PicoGreen (see 
inset Figure 2). Subsequently, we established the growth characteristic of untreated 
keratinocytes in our culture model. Figure 2 shows that keratinocyte growth was 
exponential (R2=0.994) from day 3 through day 7 after seeding. Therefore, we chose 
day 3 to be the starting point for addition of test compounds in further experiments 
(approximately 15 to 20% confluence), in a 4-day time course. A standard range 
of 10-7 to 10-5 M was used for all compounds. We examined 4 compounds that are 
commonly used in antipsoriatic therapy: ATRA, MTX, CsA and dithranol. Curcumin, 
a putative inhibitor of nuclear factor kappaB (NF-κB) and jun kinase signalling[290] 
and the p38 MAP kinase inhibitor SB220025 were tested as experimental drugs of 
potential therapeutic use. The anti-inflammatory drug indomethacin was included in 
the test panel to investigate the effects of products of the cyclooxygenase pathway on 
keratinocyte growth. Cytotoxicity (LDH-release) was only observed at the highest 
concentration of ATRA. These data were confirmed by visual inspection using phase 
contrast microscopy. The highest concentration of ATRA revealed dramatic changes 
of keratinocyte cell morphology and cell membrane rupture. Table 1 summarises 
the effects of all tested drugs on cell proliferation. None of the drugs stimulated 
proliferation of human keratinocytes. Among members of the test panel, ATRA, 
 
ANOVA Duncan's ANOVA Duncan's ANOVA Duncan's ANOVA Duncan's 
all-trans  Retinoic Acid † n.s n.s n.s n.s 
Indomethacin n.s n.s n.s n.s 
Methotrexate n.s < 0.05 10 -5 ,10 -7 n.s n.s 
Cyclosporin A < 0.05 10 -5 < 0.001 10 -5 < 0.001 10 -5 < 0.001 10 -5 
Curcumin < 0.001 10 -5 < 0.001 10 -5 < 0.001 10 -5 ,10 -6 < 0.001 10 -5 
SB220025 < 0.001 10 -5 < 0.001 10 -5 < 0.001 10 -5 ,10 -6 < 0.001 10 -5 ,10 -6 
Dithranol < 0.01 10 -5 ,10 -6 < 0.001 10 -5 ,10 -6 < 0.001 10 -5 ,10 -6 < 0.001 10 -5 ,10 -6 
day 1  day 2   day 3  day 4 
The effects of various drugs on keratinocyte cell growth were studied in a cell proliferation assay on four 
consecutive days. One-way analysis of variance (ANOVA) was applied to untreated controls and drug 
treated (10-5- 10-7 M) samples; p-values are shown for each time-point. Duncan’s multiple comparison test 
was used to determine the significant differences between group means. Values given under “Duncan’s” 
indicate drug concentrations that resulted in significant difference with respect to untreated controls. 
n.s = not significant 
† = 10-5 M omitted from data because of toxicity
Table 1:  The effects of various drugs on keratinocyte cell growth.
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indomethacin and MTX exhibited the weakest effect on cell growth. During the 4-day 
time span, both ATRA and indomethacin showed no inhibition while MTX showed 
only 20% inhibition of cell growth (day 2, 10-7 M and 10-5 M, not shown). Dithranol 
displayed a remarkably strong growth inhibition at concentrations of 10-6 M and 10-5 
M, even up to 90% for 10-5 M at day 4 (Figure 3A). Moreover, Figure 3A shows 
that dithranol remains active throughout the culture period, as the cell number per 
well, relative to the untreated control wells, further decreases in time. With respect to 
CsA and curcumin, for both compounds inhibition was observed only at the highest 
concentration applied. However, while the presence of curcumin resulted in a equally 
diminished cell growth of 50% at all time points, CsA showed a gradual increase in 
inhibitory effect over time, viz. 50% at day 1 and 80% at day 4. 
The effect of SB220025 on keratinocyte proliferation is depicted in Figure 3B. 
Initially, during the first two days of culture, SB220025 showed considerable 
reduction of growth (40 to 60%) only at a concentration of 10-5 M. However, 
prolonged incubation of these cultures with the p38 MAP kinase inhibitor, resulted in 
a significant growth reduction of 20% for 10-6 M on day 3 and day 4.
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Figure 2: Time curve of keratinocyte growth in 96-well plates as measured with PicoGreen staining. The 
inset shows the linear correlation between cell number and fluorescence for a series of manually counted 
cells that was added to a 96-well microtitre plate in order to assess fluorescence by PicoGreen staining. 
Cell numbers depicted in the inset are representative for quantities expected between day 3 and 7 in the 
time curve. An exponential increase of cell numbers (mean ± SD) was found between day 3 and 7 after 
cell seeding.
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Figure 3: Keratinocyte growth characteristics in the presence of dithranol or SB220025. Proliferating 
96-well microtitre plate cultures of normal human keratinocytes received different concentrations of test 
compounds at day 0 (corresponding to day 3 after seeding the cells). Cell growth was determined at day 
1 through day 4 using DNA quantitation. Relative cell numbers (mean ± SD) for cultures treated with 
dithranol (A) or p38 MAP kinase inhibitor SB220025 (B) are expressed as a percentage of the untreated 
controls.  * = p < 0.001, ** = p < 0.01
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The validity of an in vitro model system is dependent on the how accurately it coincides 
with the available data from the in vivo situation that it aims to mimic. We intend to 
use the culture system described here and the model for psoriatic differentiation[220], to 
make predictions on the relevance of new compounds as potential antipsoriatic drugs. 
We show that antipsoriatics that are presumed to act on the immune system (CsA) or 
on keratinocyte differentiation (ATRA) are not effective in growth suppression, at 
least not at therapeutically relevant levels. Dithranol, an effective topical antipsoriatic, 
was a potent suppressor of keratinocyte growth. Indomethacin, a pharmacologically 
active compound in a number of diseases, but not in psoriasis, did not affect 
keratinocyte growth. Two experimental drugs, curcumin and the p38 MAP kinase 
inhibitor SB220025, were found to inhibit keratinocyte proliferation, marking them 
as potentially useful compounds.
In previous studies we have described submerged culture systems of normal human 
keratinocytes that can mimic both the normal and the psoriatic phenotype of human 
epidermis. These systems were applied for screening of drugs that modulate 
keratinocyte differentiation by using expression of marker proteins for normal 
and psoriatic differentiation. In the study presented here, we describe a system 
applicable to screen drugs that are pharmacologically active in keratinocyte growth 
inhibition, using an inexpensive highly sensitive fluorescent dye to monitor cell 
growth in a 96-well format. Some of these compounds have been tested before in 
assays for keratinocyte proliferation such as [3H]-thymidine incorporation, but no 
comprehensive study using a standardised assay that actually measures cell mass, has 
been published.
Using first-passage normal human keratinocytes in KGM, we found ATRA to have 
no effect on growth. There is no consensus in the literature with respect to the effect 
of ATRA on normal human keratinocyte growth. Sorenson et al. report a slight 
stimulatory effect when second-passage normal human keratinocytes were grown in 
KGM to approximately 30% confluency before incubation with ATRA[291]. However, 
Varani et al. found ATRA to inhibit proliferation when early passage keratinocytes 
(i.e. between passages 3-8) were incubated 1 or 2 days and concomitantly treated with 
1 μg/ml (3.5 x 10-6 M)[145]. Data from our cell culture model were limited to 10-6 and 
10-7 M since a higher concentration was toxic. 
Proliferating human keratinocytes exposed to MTX experienced virtually no effect on 
cell growth. The insensitivity of normal human keratinocytes for MTX as shown from 
these data is in accordance with earlier observations where keratinocytes treated with 
similar concentrations of MTX showed no reduction in clonal efficiency compared 
to untreated controls[197]. Also, Jeffes et al. showed that at MTX concentrations that 
would be expected to occur in vivo after once-weekly therapy,  >95% of proliferating 
lymphoid cells would be killed, and only a small percentage (10%) of proliferating 
keratinocytes. In another study of Jeffes et al., it is been shown that a strong 
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correlation exists between the severity of psoriasis and the number of proliferating 
blood mononuclear cells[198]. Besides, preliminary data in this paper demonstrate a 
decrease in the number of proliferating blood mononuclear cells with MTX therapy 
before clinical improvement is psoriasis was demonstrated. With respect to the belief 
that MTX mediates its effect in psoriasis primarily on proliferating cells, the available 
data suggest that keratinocyte growth control is an unlikely target of MTX therapy.
Although CsA is generally believed to act via the T lymphocyte, several groups 
have reported that CsA can directly inhibit keratinocyte proliferation in vitro at 
concentrations of 1-10 µg/ml (10-6 - 10-5 M)[146-148]. In addition, it has been described 
that a prolonged duration of exposure to CsA increases the concentration-dependent 
growth inhibition[146]. Our data are in line with these findings as we found significant 
growth inhibition at a CsA concentration of 10-5 M, and we also observed a gradual 
increase of the inhibitory effect over time, viz. 50% at day 1 and 80% at day 4. The 
effective drug concentration in our experiments, however, was approximately 50-fold 
higher than those being considered as therapeutic blood levels[292], and 5-fold higher 
than the reported CsA levels in psoriatic skin lesions[293]. It is therefore doubtful if 
the clinical antipsoriatic effect of CsA can be attributed to inhibition of keratinocyte 
proliferation.
We found a strong growth inhibitory effect of dithranol. Similar strong effects have 
been described by Gottlieb et al, who observed a nearly complete inhibition of 
keratinocyte growth at an even lower concentration of dithranol (4.4 x 10-8 M)[11]. The 
same study showed that dithranol decreased keratinocyte transforming growth factor 
alpha (TGF-α) expression and EGF-receptor binding in vitro, which indicates that this 
drug alters components of the EGF receptor pathway in cultured keratinocytes and 
that these effects might contribute to the clinical efficacy of dithranol in the treatment 
of active psoriasis.
The rationale for the inclusion of curcumin in the panel of drugs was based on 
the accumulating evidence that curcumin is involved in the suppression of NF-κB 
activation dependent pathways associated with cell proliferation[294,295]. Moreover, 
both in human multiple myeloma cells and prostate cancer lines curcumin caused 
downregulation of NF-κB, which resulted in the induction of apoptosis[295,296]. In 
this study we found that curcumin exhibited a profound growth inhibitory effect on 
cultured human keratinocytes at a concentration of 10-5 M without apparent cellular 
toxicity. Recently, a phase 1 curcumin study has been performed, reporting the 
absence of toxicity up to 8,000 mg per day, corresponding to a serum level of 0.5 x 
10-6 M[297]. The putative involvement of tumour necrosis factor alpha (TNF-α)/NF-κB 
signalling in the psoriatic phenotype and the reported clinical efficacy of anti-TNF-α 
on psoriasis[206] lend further support to investigate the effect of drugs that modulate 
cellular stress response pathways, such as curcumin.
Indomethacin belongs to the family of non-steroidal anti-inflammatory drugs. Although 
inflammation of the skin is a hallmark of psoriasis, application of indomethacin in 
psoriasis has been reported to be associated with exacerbation of the disease[298]. We 
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would therefore predict that indomethacin is not effective in keratinocyte growth 
inhibition in our assay, which was indeed the case. Two studies, however, describe 
that indomethacin reduces keratinocyte proliferation rates, as measured by either 
[3H]-thymidine incorporation or 5-bromodeoxyuridine labelling[299,300]. This apparent 
discrepancy might be caused by different methodologies used to measure cell 
proliferation. Since human keratinocytes are able to catabolise [3H]-thymidine and 
nucleoside analogues of thymidine, such as 5-bromodeoxyuridine, this may lead to 
underestimations of true proliferation rates[287]. Application of a dsDNA-binding dye, 
like PicoGreen, circumvents this drawback and may therefore reflect cell proliferation 
more accurately. 
Inhibitors of p38 MAP kinase are known to downregulate the expression of pro-
inflammatory cytokines[301]. We previously reported that the p38 MAP kinase inhibitor 
SB220025 is a potent suppressor of differentiation-associated gene expression in 
human keratinocytes[219,220]. Here we investigated the potential effect of SB220025 on 
proliferating keratinocyte cell cultures, and found reduced cell growth at 10-5 M (day 
1 through 4) and 10-6 M (only day 3 and 4). Therefore, this experimental drug might 
have potential therapeutic use in psoriasis not only by modulation of pathways directly 
involved in inflammation but also by affecting keratinocyte proliferation rate. 
We conclude that the described model is a simple, inexpensive and rapid system 
for screening of drugs that modulate keratinocyte proliferation. Validation of such 
model systems remains problematic, as even for most established antipsoriatic drugs 
there is no strong experimental evidence or consensus on how they might act in the 
patient. Nevertheless, the system used here confirms a number of observations from 
other studies and allows discrimination of antiproliferative and cytotoxic effects 
of experimental compounds. Moreover, a combined application of our previously 
described differentiation model and the proliferation model presented here, will allow 
identification of candidate antipsoriatic drugs in high-throughput formats.
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SKALP/elafin is an epithelial proteinase inhibitor with antimicrobial properties that 
is not normally expressed in human epidermis, but is induced under inflammatory 
conditions and in some types of skin cancer. SKALP is a member of the recently 
described trappin gene family, which encodes a new class of proteins, characterised 
by a four-disulphide core and a transglutaminase substrate domain. Polyclonal 
antisera against SKALP were shown to be useful for monitoring disease activity 
in psoriasis and tumour differentiation in squamous cell carcinoma. We developed 
ten different mouse monoclonal antibodies against synthetic peptides corresponding 
to a hexapeptide epitope in the transglutaminase substrate domain and three mAbs 
recognising an epitope in the proteinase-inhibiting domain. The antibodies could 
be used with high specificity in affinity chromatography, Western blotting, and 
enzyme-linked immunosorbent assay (ELISA) for the detection of SKALP/elafin. 
These antibodies have several advantages over existing polyclonal antisera, such as a 
defined epitope, the detection of full length SKALP/elafin and unlimited supply. The 
monoclonal antibodies will serve as important new tools to measure SKALP/elafin 
and trappin family members in research and diagnostics.
3.1 ABSTRACT
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Skin-derived antileukoproteinase (SKALP)[75], otherwise known as elafin[76] or 
ESI (elastase-specific inhibitor)[302], is a  proteinase inhibitor with specificity for 
polymorphonuclear leukocyte (PMN)-derived elastase and proteinase-3[303]. SKALP 
is structurally related to secretory leukocyte proteinase inhibitor (SLPI)[304] also 
known as antileukoproteinase (ALP)[305] and both these proteins were recently shown 
to possess antimicrobial activity[306-308]. SKALP is absent in normal skin whereas 
SLPI is only expressed in the stratum granulosum; however, both are expressed 
at high levels in psoriatic epidermis and several other inflammatory skin diseases 
[76,306,309,310]. SKALP protein is found in psoriatic epidermis as a short polypeptide of 6 
kD originally described as elafin[76]. The full-length protein, as expressed in cultured 
epidermal keratinocytes, is translated as a 12.3 kD protein of 117 amino acids termed 
pre-elafin or trappin-2[77]. Cleavage of the signal peptide yields a mature protein of 
95 amino acids with a calculated molecular mass of 9.9 kD. In addition to the known 
proteinase inhibitor domain, the mature protein contains a domain with 4 repeats, 
which are homologous to putative transglutaminase substrate motifs[311]. Recently, 
several other proteins have been found with a transglutaminase substrate domain and 
a four-disulphide core and these are now known as the trappin gene family[312,313]. The 
9.9 kD secreted protein is the major form found in cultured cells[77]. Once secreted in 
the epidermis, full length SKALP is presumably cross-linked by transglutaminase to 
other proteins, and subsequently the 6 kD form is clipped and reaches the circulation 
where it is cleared via the kidney[314]. SKALP is constitutively expressed by a 
number of epithelia[315] but is induced in skin upon inflammation. Therefore, SKALP 
is considered to be a clinically relevant and useful marker for psoriasis and other 
inflammatory diseases[316]. Expression of this protein by keratinocytes in vitro was 
shown to be inducible by tumour necrosis factor alpha (TNF-α) and serum, thereby 
transforming keratinocytes into a ‘psoriasis-like’ state[219]. The selection of drugs that 
attenuate or modulate this ‘psoriasis-like’ transformation may be critical in psoriasis 
pharmacological research[317]. Therefore, antibodies to quantify SKALP in culture 
supernatants or in sera of psoriasis patients are useful tools to evaluate the potency of 
new antipsoriatic drugs. In addition to its use in psoriasis research, SKALP was shown 
to be a useful marker in the histological grading of squamous cell carcinoma[318,319]. So 
far, only polyclonal antibodies against the recombinant C-terminal 57 amino acids of 
SKALP, or synthetic peptides have been generated. We now describe the generation 
of monoclonal antibodies (mAbs) against different epitopes that will serve as an 
unlimited supply for research and diagnostics.
3.2 INTRODUCTION
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Chemicals
All reagents for sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) were obtained from Novex (Invitrogen, Groningen, The Netherlands). Rabbit-
anti-mouse Ig conjugated with horseradish peroxidase was obtained from DakoPatts 
(Glostrup, Denmark). Columns and materials for chromatographic purification 
of anti-SKALP monoclonal antibodies were obtained from Pharmacia (Uppsala, 
Sweden). Purified TRAB-2O monoclonal antibody was biotinylated according to the 
instructions of the manufacturer (Roche Diagnostics, Belgium). Synthetic peptides 
were obtained from Ansynth (Roosendaal, The Netherlands).
 
Polyclonal antisera
The antisera were raised against the 6 kD form of SKALP/elafin, which lacks the 
transglutaminase substrate domain. We used both recombinant elafin (a kind gift 
of Dr. N. Russell, ICI, United Kingdom) or SKALP purified from psoriatic scales. 
Protein (50 µg) was cross-linked with glutaraldehyde, dialysed against distilled 
water and emulsified with Freund’s complete adjuvant. Rabbits were immunised 
intracutaneously in the back, followed by two subcutaneous boosters at week 2 and 
4. Preimmune serum was drawn before the experiments and immune serum was 
collected after 6 weeks.
Generation of monoclonal antibodies
Balb/c mice were primed with two different peptides in complete Freund’s adjuvant. 
The first synthetic peptide comprised amino acids 66 to 82: AQEPVKGPVSTKPGSC 
(SKALP peptide-1) corresponding to the first amino acids of mature elafin. The second 
peptide for immunisation contained a GQDPVK-motif, which is common to all 
known trappin family members: GQDPVKGQDPVKGQDPVK (SKALP peptide-2). 
The peptides were prepared by coupling the peptides via a COOH-terminal cysteine 
residue to Keyhole Limpet Hemocyanin (KLH), using the Sulfosuccinimidyl 4-[N-
maleimidomethyl]-cyclohexane-1-carboxylate (sulfo-SMCC) procedure according to 
the manufacturer’s instructions (Pierce, Rockford, IL).
Mice were boosted every three weeks with peptides in Incomplete Freund’s adjuvant. 
On days 4 and 3 before fusion, mice were boosted intraperitoneally with 100 μg 
of SKALP peptides in saline. Mouse spleen cells were fused with SP2/0 cells by a 
modified procedure of Kohler and colleagues[320]. The hybridomas were seeded in 25 
x 96-well plates and screened after 10 days in a direct ELISA on KLH-free SKALP-
peptides 1 and 2. Positive cells were immediately subcloned and frozen in liquid 
nitrogen.
All hybridomas were grown in Dulbecco’s modified Eagle’s medium supplemented 
with 20% foetal calf serum, sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin 
3.3 MATERIALS AND METHODS
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(100 U/ml) and Streptomycin (50 μg/ml). All products were purchased from Life-
Technologies (Paisley, U.K.). Cells were incubated in a humidified 8% CO
2
 air 
incubator.
Antibody characterisation
The screening ELISA used for the detection of anti-SKALP peptide-1 antibodies was 
a direct ELISA with 3 µg/ml SKALP peptide-1 coated overnight at 4ºC in NUNC 
(Life Technologies) U-bottom high-binding 96-well microtitre plates in 50 µl/well 
coating buffer (10 mM Tris, 10 mM NaCl, and 10 mM NaN
3
, pH 8.5). The next day, 
the plates were coated with 75 µl/well of 0.1% casein in PBS for 1 h at 37ºC to reduce 
non-specific binding. Next, 50 µl hybridoma-supernatant was added and incubated 
for 1 h at 37ºC. After washing, the bound monoclonal antibodies were detected with 
50 µl/well of Rabbit-anti-mouse Ig conjugated with horseradish peroxidase for 1 h at 
37ºC. Both reagents were diluted in 0.1% Casein/PBS. The plates were washed and 50 
μl of a solution of 0.42 mM 3,5,3’,5’-tetramethyl-benzidine, 0.003% (vol/vol) H
2
O
2
 
in 100 mM citric acid and 100 mM disodium hydrogen phosphate (pH 4.3) was added 
as the substrate. The reaction was allowed to proceed for maximum 15 min on a plate 
shaker at room temperature (RT), after which the colour development was stopped 
with 50 µl/well 2N H
2
SO
4
. Subsequently, the plates were read on a Thermomax 
(Molecular Devices, Sunnyvale, CA) microtitre plate reader at 450 nm. The cross-
reactivity of the selected monoclonal antibodies with recombinant SKALP was tested 
in a direct ELISA, identical to the screening assay, except that recombinant SKALP 
was used instead of peptide-1 SKALP. In a second step, the selected positive cultures 
were confirmed on Western blotting with recombinant SKALP and psoriatic scale 
extracts.
The screening ELISA used for the detection of anti-SKALP peptide-2 antibodies 
was a sandwich ELISA system with the anti-SKALP peptide-1 monoclonal antibody 
TRAB-2F in the coating phase. This IgG
2b
 mAb showed a high binding affinity for 
recombinant and native human SKALP in keratinocyte culture supernatant. TRAB-
2F was coated overnight at 5 µg/ml, identical to the ELISA for the detection of 
antibodies against peptide-1 SKALP. After coating with casein to reduce non-specific 
binding, 50 µl of native full-length SKALP was incubated for 2 h at 37ºC.  Next, 50 µl 
hybridoma-supernatant was added and incubated for 1 h at 37ºC. After washing, the 
bound monoclonal antibodies were detected with a mixture of biotinylated goat anti-
mouse IgG
1
 and biotinylated goat anti-mouse IgG
2a
 antibodies for 1 h at 37ºC.  The 
plates were than washed 5 times and incubated for 30 min at 37ºC with streptavidin 
conjugated with horseradish peroxidase. Plates were further processed exactly as in 
the screening assay for SKALP peptide-1.
Sandwich ELISA with two monoclonal antibodies for SKALP detection
The ELISA for the measurement of SKALP levels in culture supernatant of 
keratinocyte monolayers, sera of psoriasis patients or control sera was performed as 
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follows:  Briefly, TRAB-2F antibody was coated at 5 µg/ml overnight at 4ºC in NUNC 
flat-bottom high-binding 96-well microtitre plates in 100 µl/well coating buffer. The 
next day, plates were overcoated and incubated with 100 μl/well of samples for 2 
h at 37ºC.  The plates were washed, followed by incubation with 100 μl/well of 
biotinylated detecting antibody TRAB-2O at 2 µg/ml for 1 h at 37ºC. The plates 
were washed 5 times and incubated for 30 min at 37ºC with horseradish peroxidase 
conjugated Streptavidin.  Plates were further processed exactly as in the screening 
assay for SKALP peptide-1.
Extraction of SKALP from psoriatic scales
Scales from psoriatic patients were homogenised in a glass-glass grinder in distilled 
water. After centrifugation (15 min at 12,000 x g) the supernatant was boiled and 
again centrifuged. The supernatant was concentrated by vacuum evaporation and 
subjected to SDS-PAGE and immunoblotting as described below.
Preparation of affinity purified full-length human SKALP
Five milligrams of TRAB-2F anti-SKALP monoclonal antibody purified from serum 
free culture supernatant on protein G (Pharmacia, Uppsala, Sweden), was coupled to 
1 g of cyanogen bromide-activated Sepharose (Pharmacia, Uppsala, Sweden) using 
the method proposed by the manufacturer. Culture supernatant of normal human 
keratinocytes, stimulated for 48 h with 5% foetal calf serum, was diluted 1:2 in 0.1M 
phosphate buffer (pH 8.5) and applied to the column. The column was washed with 
0.1 M phosphate, and SKALP was eluted with 0.1 M glycine (pH 2.5) and neutralised 
immediately with concentrated Tris-buffer. This yielded highly purified SKALP as 
shown by SDS-PAGE on 20% gels.
SDS-PAGE and Western blotting
Psoriatic scale extract, affinity purified normal human native SKALP and purified 
recombinant SKALP were boiled in reducing SDS sample buffer containing 
dithiotreitol (DTT). Psoriatic scale extract (10 µg/lane), purified recombinant SKALP 
(5 ng/lane) and affinity purified normal human native SKALP (5 ng/lane) were run on 
precast 10-20% gradient gels (NOVEX, Invitrogen, Groningen, The Netherlands) and 
semi-dry blotted to 0.22 µm PVDF sheets for 30 min at 1 mA per cm2. The blotting 
buffer composition was 1.3 mM SDS, 39 mM glycine, 48 mM Tris pH 9.2, and 
20% (v/v) methanol. A biotinylated low molecular weight protein ladder was used 
as molecular weight standard. The membranes were blocked with 5% (w/v) non-fat 
dry milk (BioRad) in PBS for 1 hour. They were then incubated with the appropriate 
monoclonal antibody at 1 µg/ml overnight at 4°C. Subsequently, the membranes were 
washed in PBS-0.1% Tween20 for 5 min with five changes of buffer, incubated for 1 
h with an hP-conjugated goat anti-mouse antibody (New England Biolabs, Beverly, 
MA) 1:2000 dilution for 1 h at RT. After washing, the bands of interest were visualised 
by chemiluminescence detection according to instructions of the manufacturer. Scans 
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were taken with a Lumi-Imager (Roche, Boehringer Mannheim, Germany). Aurodye 
staining was performed according to the AuroDye-forte kit (RPN 490) of Amersham 
Life Science (Buckinghamshire, England).
Patients
Sera examined were from patients that participated in a clinical trial previously 
described[321], in which a correlation was found between PASI score and serum SKALP 
levels using a sandwich-type ELISA with polyclonal sera. Sera were collected from 
psoriasis patients before and after therapy with the retinoic acid analogue etretinate (2 
patients) or with liarozole, an inhibitor of endogenous retinoid metabolism (1 patient). 
A clinical score, the psoriasis area and severity index (PASI) was taken at the start and 
the end of treatment.
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Monoclonal antibody production
SKALP-specific peptide-1 antibodies
A panel of six mice was immunised with 100 μg of KLH coupled SKALP-peptide-1. 
One mouse with a serum IC50 titre of 1/10,000 was selected for fusion with SP2/0 
myeloma cells. Ten days after fusion, more than 6,000 different hybridoma clones 
were screened in a SKALP peptide-1 solid phase ELISA. Out of these hybridomas, 
73 culture wells initially showed a clear positive signal in a SKALP peptide-1 ELISA. 
These 73 cultures were tested on an IgG specific recombinant SKALP ELISA and 
21 cultures remained positive. Positive supernatants were checked in Western blot 
on recombinant SKALP. Eleven wells with a clear positive signal in Western blot 
were immediately cloned and recloned once. Finally 11 stable hybridoma clones were 
selected, frozen in liquid nitrogen and named TRAB-2A to TRAB-2K (TRAB being 
an acronym for trappin antibody). The IgG
2b
 mAb TRAB-2F, showed the highest 
affinity for both recombinant and full-length SKALP (not shown) and this antibody 
was selected for further studies.
GQDPVK-motif peptide-2 antibodies
Another six mice were immunised with 100 μg of KLH coupled SKALP-peptide-2. 
This peptide is a trimer of the hexapeptide GQDPVK, a motif from the transglutaminase 
substrate domain that is common to all known trappin family members[311,312]. Spleens 
of two mice, who showed high sera titres in a sandwich ELISA with native human 
full-length SKALP, were selected and pooled for fusion with SP2/0 myeloma cells. 
Ten days after fusion, more than 12,000 different hybridoma clones were screened 
in a sandwich ELISA for the detection of human native full-length SKALP. After 
screening, 12 out of 40 hybridomas, which reacted clearly positive in the sandwich 
ELISA, were selected. Of these antibodies, the IgG
1
 mAb TRAB-2O showed the 
highest affinity for native human full-length SKALP, and was selected for further 
studies.
Characterisation and application of the monoclonal antibodies
Western blotting
Purified TRAB mAbs (TRAB-2O and TRAB-2F) were probed in a Western blot 
on psoriatic scale extracts, on recombinant SKALP and human native full-length 
SKALP as shown in Figure 1. Psoriatic scale extracts are known to contain 
predominantly the truncated forms (6 kD and smaller) of SKALP in the soluble 
fraction, presumably leaving the cross-linked portion in the insoluble fraction. 
Native SKALP purified from cultured keratinocytes contains predominantly the 9.9 
kD form[77], whereas recombinant SKALP contains the C-terminal 6 kD portion that 
3.4 RESULTS
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lacks the transglutaminase substrate domain[322]. TRAB-2F showed a clear signal 
with recombinant SKALP and a moderate signal with psoriatic scale extracts at the 
expected molecular weight. This antibody did also recognise human native full-length 
SKALP. In contrast, TRAB-2O mAb reacted strongly with full-length SKALP, but 
did not recognise the low molecular weight species present in scale extract. TRAB-
2O however did show a minor reaction with recombinant SKALP, which is probably 
caused by a weak crossreaction of this monoclonal antibody with the degenerate motif 
in the N-terminus of recombinant SKALP.
Sandwich ELISA with two monoclonal antibodies
Previous studies have used a competitive type ELISA[323] or a sandwich ELISA[321] with 
two polyclonal antisera to detect SKALP in biological samples such as serum, urine 
and culture supernatant. Here we used two of our monoclonal antibodies (TRAB-2O 
and TRAB-2F) to perform an ELISA on serum samples of psoriasis patients before 
and after therapy. Figure 2 shows the calibration curve of the ELISA using purified 
full length SKALP as a standard in the range of 100-6000 pg/ml. 
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Figure 1: Immunoblots of SKALP preparations and scale extracts probed with monoclonal antibodies (A) 
TRAB/2F and (B) TRAB/2O. The immunoblot comprises a low molecular weight-biotinylated marker 
(LMW), 10 µg/lane psoriatic scale extracts, containing multiple forms of SKALP/elafin (scale), 5 ng/lane 
purified human native full-length SKALP (native) and 5 ng/lane recombinant SKALP (recombinant). (C) 
The negative control of a duplicate blot of A or B was probed only with a Goat anti-mouse-HRP labelled 
secondary antibody. (D) Aurodye staining of a duplicate blot.
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Using this ELISA, SKALP concentrations in serum and culture supernatant can 
be read with sufficient sensitivity of more than 1 ng/ml and greater accuracy than 
previous assays. The correlation between SKALP levels in the old and new ELISA 
was good (R2=0.9 and p<0.002). Figure 3 confirms our previous finding[321] that serum 
SKALP levels strongly correlate with the clinical status of a patient (PASI-score), and 
can be used as an objective measure for disease activity.
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Figure 2: Calibration curve 
of the sandwich ELISA using 
purified full-length SKALP, 
diluted in casein, as a standard. 
The SKALP levels are given as 
pg/ml. Values represent mean ± 
SD (n=3).
Figure 3: Three severely affected psoriasis patients were treated as indicated in the Materials and Methods 
section. Serum was collected before the start of treatment and after 20-24 weeks. (A) Clinical improvement 
of the patients was scored with the PASI. (B) Measurement of serum SKALP levels by ELISA showed a 
decrease concomitantly with clinical improvement. Identical symbols refer to the same patient.
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The importance of SKALP/elafin as an epithelial protein implicated in host protection 
and defence is increasingly recognised[308,323]. Therefore, antisera that can be used in 
research and diagnostics are important tools for further study of SKALP and other 
trappin family members. We have previously described polyclonal antisera that could 
be used for qualitative and quantitative assays[314,316]. However, these sera have obvious 
disadvantages as (a) the epitopes were unknown, (b) they did not react with full length 
SKALP, (c) availability was limited and (d) use in other species than humans was 
limited. Therefore, a strategy was developed to start the production of an unlimited 
supply of monoclonal antibodies against SKALP/elafin and other trappin family 
members. Initial attempts to raise monoclonal antibodies against recombinant protein 
failed, perhaps as a consequence of the low immunogenicity of the small 6 kD protein. 
We therefore decided to use synthetic peptides coupled to KLH as an immunogen[311]. 
Because the nuclear magnetic resonance (NMR) solution structure of recombinant 
SKALP/elafin (the 57 C-terminal amino acids comprising the whey acidic protein 
(WAP) domain) was published[324], we first focused for the immunisation strategy on 
the most N-terminal sequence of the 57 amino acid form. This N-terminal part has 
a random conformation, probably because it is already part of the transglutaminase 
domain of SKALP. An N-terminal peptide (called peptide-1) was designed and 
applied as immunogen for fusion. Monoclonal antibodies that were isolated out 
of this fusion were superior to existing polyclonal sera with respect to specificity, 
affinity and detection of full length SKALP/elafin both in Western blot (reducing and 
non-reducing conditions), and ELISA (lower background). However, quantification 
of SKALP protein in ELISA was impossible with a combination of mAbs selected 
from the peptide-1 fusion. This sandwich ELISA failed probably because of steric 
hindrance of the antibodies for a random coil peptide that only comprises 16 amino 
acids that sticks out of the WAP domain. Therefore, a second peptide was chosen 
for an additional hybridoma fusion. This second peptide for immunisation contained 
a trimer of the GQDPVK sequences, a motif common to all known trappin family 
members. The screening strategy for the isolation of monoclonal antibodies was 
specifically designed to pick up mAbs that could recognise human native SKALP 
and its precursors in solution, i.e. as “presented” by a capturing monoclonal antibody. 
Whereas antibody pairs from the pool of peptide-1 mAbs did not work in a sandwich 
ELISA, this screening with peptide-2 hybridomas yielded clones, which worked in 
combination with TRAB-2F (peptide-1 mAb) as capturing antibody. One of these 
mAbs, called TRAB-2O, was selected to develop a sandwich ELISA, based on the 
use of two mAbs. This ELISA was found to have several advantages over the existing 
assay based on polyclonal sera, such as reduced assay time, better reproducibility 
and detection of full length SKALP. As such, this ELISA is a tool for drug screening 
with SKALP being a marker for psoriasis, as shown before for retinoids[317] in 
3.5 DISCUSSION
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psoriasis. Finally, the development of monoclonal antibodies against peptide-2 (the 
common GQDPVK motif) can be useful for detection of other members of the trappin 
gene family that was shown to be extensively diversified in several mammalian 
species[312,313]. In addition to their use in research and diagnostics in humans, these 
antibodies provide tools for further characterisation of the new trappin gene family.
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Established treatments for psoriasis act either on hyperproliferation, inflammation, 
aberrant epidermal differentiation or a combination of these aspects of the disease. 
Potentially new drugs for treatment of psoriasis or other disorders with abnormalities 
in epidermal differentiation, can be identified by high-throughput screening of large 
compound libraries using disease markers. Here we describe a screening model to 
detect pharmacologically active drugs in two keratinocyte-based, 96-well culture 
models that use expression of cytokeratin 10 (CK10) and SKALP/elafin as markers 
for respectively normal and psoriatic differentiation and allow multiple parameters to 
be determined from a single well. In this model we tested a number of compounds in 
a pharmacological range of 10-7 to 10-5 M, including known antipsoriatic drugs, and 
experimental drugs that are potentially useful in the treatment of psoriasis. All-trans 
retinoic acid, dithranol, and the p38 MAP kinase inhibitor SB220025 displayed a 
strong inhibitory effect on SKALP expression while cyclosporin A, dexamethasone, 
the vitamin D
3
 derivative calcipotriol and the p38 MAP kinase inhibitor SB203580 
showed only moderate inhibition. Methotrexate and dimethylfumarate did not affect 
the expression of SKALP. With respect to CK10 expression, all-trans retinoic acid, 
calcipotriol, SB203580 and SB220025 exhibited strong inhibition while dithranol 
showed only moderate suppression of this normal differentiation marker. Expression 
levels of CK10 were not significantly affected by dexamethasone, methotrexate, 
cyclosporin A or dimethylfumarate. This model system parallels most, but not all, 
findings on the in vitro effect of known antipsoriatic drugs on keratinocytes. In 
addition the model identifies p38 MAP kinase inhibitors as potent suppressors of 
differentiation-associated gene expression. Although further delineation and validation 
of this model is required, we conclude that the system is amenable to downscaling and 
application as a high-throughput screen for differentiation-modifying compounds.
4.1 ABSTRACT
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Psoriasis is a common skin disease in which the cutaneous lesions are characterised by 
benign epidermal hyperplasia, abnormal differentiation, inflammation, and changes 
in the dermal vasculature. It is very likely that a combination of immunological 
predisposition (autoimmunity, superantigen stimulation) and keratinocyte 
abnormalities is key to the disease mechanism[85,325]. Pharmacological treatments for 
psoriasis are generally based on anti-proliferative, anti-inflammatory, or differentiation-
modifying activity, or a combination of two or more of these actions. It has been 
postulated that epidermal keratinocytes are actively involved in the pathogenesis of 
psoriasis[326]. These cells form a signalling interface between the external and internal 
milieu by secreting cytokines and growth factors that act on endothelium and on 
inflammatory cells, and alter keratinocyte growth in a paracrine-autocrine manner. 
Keratinocytes of the psoriatic lesion are hyperproliferative and display an abnormal 
differentiation program characterised by the induction of genes that are not expressed 
by keratinocytes in normal skin such as the cytokeratins CK6, CK16, CK17[327] and 
the proteinase inhibitor SKALP otherwise known as elafin[75,76]. Expression of these 
genes can be used as a marker for psoriasis in in vitro drug screening procedures[317]. 
High-throughput programs based on biological testing of diverse collections of 
compounds can rapidly identify leads for potential drug candidates in the treatment of 
psoriasis. Ideally, a successful drug is defined as a compound that shows low toxicity 
in the usual in vitro test range for xenobiotics (typically 10-7 to 10-5 M), affects the 
expression of the marker and does not affect the normal metabolic pathways of the 
target cells. We have previously described submerged keratinocyte culture systems 
that can mimic both the normal and the psoriatic phenotype of human epidermis[59]. 
In these systems expression of cytokeratin 10 (CK10) and SKALP was identified as 
useful marker for respectively normal and psoriatic differentiation.
The aim of the current study was to scale down the existing culture format to develop 
a 96-well cell culture system that enables determination of drug effects on normal and 
abnormal keratinocyte differentiation. Thus, the presented model can be used as a 
high-throughput screening model to identify new (classes of) antipsoriatic drugs that 
act via the keratinocyte as a primary target cell.
4.2 INTRODUCTION
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Chemicals and Preparations
Dexamethasone, dithranol, methotrexate (MTX), all-trans retinoic acid (ATRA) were 
all purchased from Sigma (St. Louis, MO, USA). SB203580 was a kind gift from 
Dr. D. Griswold from SmithKline Beecham (PA, USA). SB220025 and SB202474 
were obtained from Calbiochem (San Diego, CA, USA). Dr. L. Binderup from 
Leo Pharmaceutical Products (Ballerup, Denmark) kindly provided the vitamin 
D
3
 derivative calcipotriol. Cyclosporin A (CsA) was obtained from Sanvertech 
(Heerhugowaard, the Netherlands). Dimethylfumarate (DMF) was purchased from 
BDH Chemicals Ltd. (Poole, England). 
Stock solutions were prepared according to suppliers directions either in ethanol (CsA 
10-2 M, ATRA 5 x 10-3 M, in isopropanol (calcipotriol 4 x 10–3 M), in DMSO (DMF 
10–3 M, dithranol 10-2 M), in 0.1 M NaOH (MTX 10–3 M) or in tissue culture grade 
water (dexamethasone 10–3 M). 
Cell culture
Keratinocytes were seeded in 96 well flat bottom cell culture plates and cultured 
until confluence in keratinocyte growth medium (KGM). KGM was composed 
of keratinocyte basal medium (KBM) (BioWhittaker, Walkersville, MA, USA) 
supplemented with ethanolamine (0.1 mM) (Sigma, St. Louis, MO, USA), 
phosphoethanolamine (0.1 mM) (Sigma, St. Louis, MO, USA), bovine pituitary extract 
(BPE; 0.4%) (BioWhittaker, Walkersville, MA, USA), insulin (5 µg/ml) (Sigma, St. 
Louis, USA), hydrocortisone (0.5 µg/ml) (Collaborative Research Inc, Lexington, 
MA, USA), recombinant mouse epidermal growth factor (EGF; 10 ng/ml) (Sigma, 
St. Louis, MO, USA), penicillin (100 U/ml) (Gibco, Breda, the Netherlands) and 
streptomycin (100 µg/ml) (Gibco, Breda, the Netherlands). Induction of keratinocyte 
differentiation was established by switching the cells at confluence for 48, 72 and 96 
h either to KGM supplemented with 5% FCS (KGM/FCS) (Seralab, Nistelrode, the 
Netherlands) or to KGM depleted of hydrocortisone and growth factors (BPE, insulin, 
and EGF) (KGM/-gf). Agents to be tested for their potential effect on keratinocyte 
differentiation were immediately before the experiment diluted in KGM/FCS and 
KGM/-gf to create a dose range of 10–5, 10–6, 10–7 M and added upon switching the 
culture medium. 
SKALP ELISA of culture supernatants
A sandwich-type ELISA was developed to determine SKALP levels in supernatants 
of cultured keratinocytes. Briefly, 96 wells flat bottom microtitre plates (Greiner, 
Frickenhausen, Germany) were coated overnight with mouse monoclonal antibody 
(mAb) TRAB-2F that we have recently developed[328]. Plates were blocked with 1% 
BSA and probed with the test sample for 2 h at 37 °C. Subsequently, biotinylated 
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mAb TRAB-2O[328] was added and the plates were incubated for 1 h at 37°C. Finally, 
the plates were incubated with Avidin Biotin Complex (Vector Laboratories Inc., 
Burlingame, CA, USA) which was followed by 30 min incubation at RT. Between all 
steps the plates were washed with PBS/0.05% Tween-20.
o-Phenylene diamine dihydrochloride (Pierce, Rockford, IL, USA) was added as 
chromogenic substrate for a 15-min incubation at RT. The enzyme reaction was 
stopped by addition of 4M H
2
SO
4
 . Absorbance was measured at 492 nm. A SKALP 
calibration curve (0.5 – 12.5 ng/ml) was prepared from a stock of full-length 
SKALP obtained by purification from cell culture supernatants[328]. Concentrations 
of SKALP were read from this curve and expressed as ng secreted SKALP per ml 
culture medium. Levels of SKALP of keratinocytes treated with test compounds are 
presented as a percentage of the level in untreated control cultures.  
CK10 ELISA of fixed keratinocytes
A solid phase ELISA was used for semi-quantitative determination of CK10 levels 
in cultured keratinocytes. In brief, cells were fixed with acetone:methanol (1:1) for 
20 minutes. Plates were then blocked with 1% normal horse serum/1% BSA/0.05% 
Tween-20 in PBS for 30 min at 37°C. Subsequently, an anti-CK10 mouse mAb 
(DE-K10) (Eurodiagnostica, Arnhem, the Netherlands) was added and plates were 
incubated for 2 h at 37°C. Then biotinylated anti-mouse IgG was added and plates 
were incubated for 1.5 h at 37°C. Subsequently, plates were incubated with Avidin 
Biotin Complex (Vector Laboratories Inc., Burlingame, CA, USA) during 1 h at 37°C. 
Plates were washed between all steps with PBS/0.05& Tween-20. Finally, o-phenylene 
diamine dihydrochloride (Pierce, Rockford, IL, USA) was added as chromogenic 
substrate for a 15 min incubation at RT. Addition of 4M H
2
SO
4
 to stop the enzyme 
reaction was omitted to allow subsequent cell number measurements as described 
below. Absorbance was measured at 492 nm. Absorbance of cultures stained without 
primary antiserum was used as a blank. Levels of CK10 in keratinocytes treated with 
test agents are expressed as a percentage of levels in untreated controls. 
Cytotoxicity test 
In order to assess the cytotoxic effect of the tested agents on the cultured keratinocytes, 
supernatants were collected and screened by the Cytotoxicity Detection Kit, which 
uses release of lactate dehydrogenase (LDH) as a readout, according to directions of 
the supplier (Boehringer Mannheim, Mannheim, Germany).
Cell number measurements using PicoGreen dsDNA Quantitation 
Reagent
Agents to be tested for their potential effect on keratinocyte differentiation were added 
to post-confluent keratinocyte cell cultures with low proliferative activity. However, 
in order to study possible drug effects on cell number during the additional 72 h of 
culture, cell number quantitation was performed using PicoGreen dsDNA Quantitation 
72  Chapter 4 A simple technique for high-throughput screening of drugs Chapter 4 A simple technique for high-throughput screening of drugs  73
Reagent (Molecular Probes, Leiden, the Netherlands) in an adapted protocol. In brief, 
directly following CK10 ELISA, cells were washed with PBS and 100 µl/well of a 
freshly prepared 2.5 mg/ml trypsin (Sigma, St. Louis, MO, USA) solution in PBS was 
added. Plates were incubated for 30 min at 37°C. Next, without removal of trypsin 
solution an additional 100 µl/well of a 1:200 dilution of PicoGreen in PBS was added. 
Subsequently, sample fluorescence was measured using a fluorescence microplate 
reader (excitation/emission 485/520nm). The amount of DNA measured by the 
PicoGreen assay correlated well with cell numbers as determined by manual counting 
(data not shown). Cell numbers per well after 72 h were within the linear range of the 
DNA standard curve.
Statistical Analysis
A one-way ANOVA was employed for comparison of end point measurements of the 
various drug concentrations. A minimal number of 4 wells per drug concentration was 
used for all tested compounds, except for calcipotriol and DMF (n=2). A value of p < 
0.05 was considered significant.
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Optimisation of culture conditions and determination of CK10 and 
SKALP expression in 96-well cultures
In previous studies we have qualitatively characterised CK10 and SKALP expression 
by Northern blotting and immunocytochemistry in two different culture systems, 
using standard culture dishes[59,219]. In these studies it was suggested that CK10 and 
SKALP could be useful as markers for screening of drugs that affect keratinocyte 
differentiation. In order to apply such models, downscaling of the culture format 
to 96 or 384 well systems, and (semi-) quantitative determination of SKALP and 
CK10 levels is required. Therefore, keratinocytes were plated in 96 well plates at 
approximately 3 x 103 cells per well in KGM, and it was found that constant growth 
rates could be maintained in all wells except for the outer wells of the plate. In the 
final culture protocol cells were only plated in the inner 60 wells of a 96-well plate, 
and the outer wells were filled with sterile saline. All wells reached confluence in 
approximately 7 days, and no major differences in cell content were found across the 
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Figure 1. Expression levels of CK10 
(mean ± SEM) in a time course experiment 
where confluent cultures of normal human 
keratinocytes were maintained in KGM, 
KGM/-gf or KGM/FCS for 48, 72 and 
96 h. 
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Figure 2. Calibration curve of full-length 
SKALP, showing a linear correlation 
between SKALP concentrations (0.5 - 12.5 
ng/ml) and absorbance.
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plate, as determined by quantitation of cell density by DNA measurement (not shown). 
At confluence, the cultures were switched to growth factor depleted medium (KGM/-
gf) which allows induction of normal differentiation, or switched to KGM with 5% 
FCS (KGM/FCS) which induces psoriasis-like differentiation[59]. Here we used a 
soluble substrate to quantify immunostaining of CK10 in keratinocytes that were fixed 
in situ in the wells. Figure 1 shows a time course experiment where confluent cultures 
of keratinocytes were maintained in KGM, KGM/-gf or KGM/FCS for 48, 72 and 96 
h. As previously found at the mRNA level and with immunocytochemistry, only in 
the growth factor depleted medium significant induction of CK10 expression is found. 
SKALP expression was measured in culture supernatants after switching the cells to 
either KGM/FCS or KGM/-gf, using a new ELISA that we have developed, based on 
a set of monoclonal antibodies that were recently generated[328]. The calibration curve 
used in this ELISA is presented in Figure 2 and shows a strong linear correlation 
between SKALP concentration and absorbance. SKALP levels in 96-well plate 
cultures were similar to those known from other culture formats. The peak of SKALP 
expression was found at 72 h (not shown). Therefore the 72 h time point was chosen 
for further drug studies, on one hand as a suitable endpoint for expression of CK10 
and SKALP, and on the other hand for practical reasons to minimise drug metabolism 
and avoid the need for medium change.
Drug effects on CK10 expression
Using the culture models and assays described above, levels of CK10 were measured 
after addition of test agents to confluent cell cultures. A standard range of 10-7 to 10-5 
M was used. No cytotoxic effect was observed at any concentration of the substances 
tested and final cell numbers were not altered by presence of the drugs (not shown). 
Also, visual inspection using phase contrast microscopy did not reveal changes of cell 
size or cell morphology. Figure 3 visualises data of an example of an experimental 
drug, the p38 MAP kinase inhibitor SB220025, which induces a dose-dependent 
suppression of CK10 expression. In comparison, Figure 3 also shows typical 
data of the antipsoriatic drug MTX, which does not affect CK10 expression at the 
concentrations tested. Table 1 summarises the effects of all tested drugs on CK10 
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Figure 3. The effect of different 
concentrations of methotrexate (MTX) and 
the p38 MAP kinase inhibitor SB220025 
on the expression of CK10 in human 
keratinocytes. Levels of CK10 (mean ± 
SEM) in keratinocytes treated with test 
agents are expressed as a percentage of 
levels in the untreated controls (UC). * p 
≤0.001
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expression. None of the drugs increased CK10 expression, whereas several drugs 
showed a profound inhibitory effect. ATRA, calcipotriol, SB203580 and SB220025 
exhibited strong inhibition while dithranol showed only moderate suppression of 
this normal differentiation marker. Expression levels of CK10 were not significantly 
affected by dexamethasone, MTX, CsA, DMF or SB202474, a compound structurally 
related to SB220025/SB203580 but lacking p38 inhibiting activity.
Drug effects on SKALP expression
An example of a compound with a strong inhibitory effect on SKALP expression 
throughout the complete concentration range tested is the established antipsoriatic 
drug ATRA (Figure 4). In contrast, the experimental drug DMF displayed no 
 compound p-value 
10-7 M 10-6 M 10-5 M 
CyclosporinA 109 121 115 n.s. 
Dexamethason 77 71 52 n.s. 
Dimethylfumarate 109 95 100 n.s. 
Dithranol 114 84 67 ≤ 0.01 
Calcipotriol 43 18 17 ≤ 0.001 
Methotrexate 81 81 70 n.s. 
all-trans Retinoic Acid 27 20 30 ≤ 0.001 
SB202474 117 104 91 n.s. 
SB203580 89 80 6 ≤ 0.001 
SB220025 53 29 10 ≤ 0.001 
The effects of 3 concentrations of various drugs on CK10 expression were determined by ELISA. 
Data are given as a percentage of CK10 levels in untreated control cultures. One-way analysis of 
variance; n.s = not significant. 
concentration 
he effects f 3 concentrations of various drugs on CK10 expression were determined by ELISA.
Data given as a percentage of CK10 levels in untreated control cultures. 
One-way analysis of variance; n.s. = not significant. 
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Figure 4. The effect of different 
concentrations of dimethylfumarate 
(DMF) and all-trans retinoic acid (ATRA) 
on the secretion of SKALP by human 
keratinocytes. Levels of SKALP (mean 
± SEM) in supernatants derived from 
cultured keratinocyts that were treated with 
test agents are expressed as a percentage of 
levels in the untreated controls (UC). * p 
≤ 0.001
Table 1.  Effects of various drugs on CK10 expression.
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inhibition at any of the concentrations tested (Figure 4). The inhibitory effects on 
SKALP expression of all drugs tested are summarised in Table 2. ATRA, dithranol, 
and SB220025 displayed a strong effect on SKALP levels while CsA, dexamethasone, 
calcipotriol, SB203580, and SB202474 showed only moderate inhibition. Both MTX 
and DMF did not affect the expression of SKALP. Cytotoxicity (LDH-release) and 
cell numbers at the end of the culture were evaluated for all agents, and no significant 
effects were noted (results not shown). In addition, microscopic analysis revealed no 
irregularities for cell size and morphology. 
 compound p-value 
10-7 M 10-6 M 10-5 M 
CyclosporinA 95 78 59 ≤ 0.001 
Dexamethason 85 77 61 ≤ 0.05 
Dimethylfumarate 95 107 97 n.s. 
Dithranol 113 93 10 ≤ 0.001 
Calcipotriol 99 91 61 ≤ 0.05 
Methotrexate 111 101 101 n.s. 
all-trans Retinoic Acid 39 33 30 ≤ 0.001 
SB202474 122 103 78 ≤ 0.001 
SB203580 98 71 53 ≤ 0.001 
SB220025 75 48 34 ≤ 0.001 
The effects of 3 concentrations of various drugs on SKALP expression were determined by ELISA. 
Data are given as a percentage of SKALP levels in supernatants of untreated control cultures. One-
way analysis of variance; n.s = not significant. 
concentration 
The eff ts f  concentrations of various drugs on SKALP expression wer  determined by ELISA.
Data given as a percentage of SKALP levels in supernatants of  untreated control cultures.
One-way analysis of variance; n.s. = not significant. 
Table 2. Effects of various drugs on SKALP expression.
78  Chapter 4 A simple technique for high-throughput screening of drugs Chapter 4 A simple technique for high-throughput screening of drugs  79
Rapid, inexpensive microplate-based assays are required to develop high-throughput 
screens for new antipsoriatic agents. Since abnormalities in epidermal differentiation 
form a key aspect of psoriasis, potential drugs for treatment of this skin disease can 
be identified by monitoring their effect on markers of epidermal differentiation. The 
model system proposed here combines a number of findings described in previous 
studies into a 96-well format for large-scale culture and assaying of markers. Levels 
of CK10 are assessed by a solid-phase ELISA while SKALP levels are determined 
by an ELISA, that is sufficiently sensitive to detect 0.5 ng SKALP per ml (Figure 2), 
requiring only 1 to 5 µl of culture supernatant. This opens the possibility to measure 
additional parameters in the supernatant e.g. secreted cytokines. In this model levels 
of markers for psoriatic differentiation, normal differentiation and cytotoxicity 
(expression of SKALP, expression of CK10 and release of lactate dehydrogenase) 
can all be determined from a single well, allowing many compounds to be tested per 
single culture plate. Based on these three parameters, a successful drug is defined 
as a compound that shows low toxicity in a useful pharmacological range (typically 
10-7 to 10-5 M), suppresses the expression of the psoriasis-associated marker SKALP, 
and ideally does not affect the normal differentiation pathway as assessed by CK10 
expression.
Several established antipsoriatics and experimental antipsoriatic drugs were tested in 
order to validate these models. Compounds that are known to act via the keratinocyte 
were expected to be identified positively, while others were anticipated to be without 
effect because they presumably act via the immune system. In the following, most 
prominent data will be discussed. 
Our observations fully confirm earlier reports in which ATRA is well recognised 
for its reduction of early and late markers of normal differentiation (e.g. K1/K10[329] 
and loricrin[141]) and for the negative regulation of SKALP in skin raft cultures[317]. 
An example of a tested agent with relatively specific immunosuppressive features 
is CsA, which inhibits T cell activation. Also, CsA has been shown not to interfere 
with normal differentiation of human keratinocytes in vitro[148]. This is confirmed 
by our data since CK10 levels were not changed throughout the tested range of 
concentrations. Interestingly, the concomitant reduction of SKALP apparently labels 
CsA as an antipsoriatic drug that acts via the keratinocyte without affecting normal 
differentiation. However, reduced expression of SKALP was only observed at drug 
concentrations that were approximately 10- to 100-fold higher than those being 
evaluated as therapeutic range of whole blood CsA concentration in the treatment of 
psoriasis[292]. Therefore, at physiological concentration CsA did not have any effect on 
markers of both normal and psoriasis-like differentiation.
1,25-Dihydroxyvitamin D
3
 and its derivatives are known to stimulate keratinocyte 
differentiation in a concentration-dependent manner as evidenced by enhanced 
4.5 DISCUSSION
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formation of cornified envelopes and activation of the marker gene involucrin[330,331]. 
Here we noticed a reduction of both SKALP and CK10 expression. Reduction of 
SKALP was expected as calcipotriol is assumed to normalise aberrant differentiation. 
A possible explanation for decreased levels of CK10 was raised by Gniadecki who 
showed that clonogenic keratinocytes when cultured in the presence of relative high 
concentrations of 1,25-dihydroxyvitamin D
3
 (e.g. 10-6, 10-5 M) were pushed towards 
terminal differentiation. As a result these cultures contained mainly involucrin-
positive cells, at the expense of the early differentiation marker CK10[331]. Further 
study on the effects of vitamin D
3
 derivatives on involucrin expression and cornified 
envelope formation in the model system presented here is required to resolve this 
issue. 
Recently a number of studies have shown p38 involvement in IFN-γ signalling at 
the level of STAT1 phosphorylation[332-334]. The transcription factor STAT1 has been 
implicated in regulation of CK17 gene expression in activated keratinocytes[335,336]. 
Since CK17 gene expression is a well-known marker for psoriasis-like differentiation 
of keratinocytes[327,336] we tested the possible involvement of p38 in the transition 
from normal to abnormal epidermal phenotype as mimicked in our in vitro models. 
Two specific inhibitors of p38 MAP kinase (SB220025, SB203580) were found to 
be potent suppressors of differentiation-associated gene expression. In addition, 
p38 inhibitors are known to downregulate the expression of pro-inflammatory 
cytokines[301]. Together with the observed effect on keratinocyte differentiation this 
makes these compounds excellent leads for antipsoriatic drugs. However, in view 
of the suppression of normal differentiation (CK10), side effects similar to those of 
retinoids e.g. suppression of cornification, should be considered.
Both MTX and DMF were found to leave levels of CK10 and SKALP unaffected. 
Our data on DMF confirm the proposed therapeutic mode of action of fumaric acid 
derivatives, that points to an immunomodulatory role[167,168]. With respect to MTX, it 
was earlier described that this anti-folate drug increased both the proportion of cells 
expressing involucrin and the amount of cornified envelope protein in subconfluent 
cultures of human keratinocytes[196]. However, we used fully confluent cultures that 
are low proliferative and are already differentiated to a certain extent. Therefore, the 
possibility exists that MTX exhibits its effect mainly through early onset of genes 
associated with normal differentiation. 
None of the drugs that we tested was able to fully reverse the psoriatic phenotype 
in our models, i.e. decrease of SKALP levels and simultaneous increase of CK10 
expression. At present we do not know whether our model allows detection of such 
activity, because there is no compound or biological stimulus known to us that could 
serve as a positive control in this respect. On the other hand, the potential side effect of 
a psoriatic drug such as suppression of normal differentiation could easily be detected, 
as ATRA strongly suppresses CK10 expression, a phenomenon previously found by 
others in vitro and in vivo.
Although further refining and validation of the model is required, we reach the 
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conclusion that the system is suited for further downscaling and application as a high-
throughput screen for differentiation-modifying compounds.
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Inflamed epidermis (psoriasis, wound healing, UV-irradiated skin) harbours 
keratinocytes that are hyperproliferative and display an abnormal differentiation 
program. A distinct feature of this so-called regenerative maturation pathway is the 
expression of proteins such as the cytokeratins CK 6/16/17 and the anti-inflammatory 
protein SKALP/elafin. These proteins are absent in normal skin but highly induced in 
lesional psoriatic skin. Expression of these genes can be used as a marker for psoriasis 
in drug screening procedures of large compound libraries. The aim of this study was 
to develop a keratinocyte cell line that contained a reporter gene under the control of a 
psoriasis-associated endogenous promoter and demonstrate its use in an assay suitable 
for screening. We generated a stably transfected keratinocyte cell line (HaCaT) that 
expresses Enhanced Green Fluorescent Protein (EGFP), under the control of a 0.8 
kb fragment derived from the promoter of the SKALP/elafin gene, which confers 
high levels of tissue-specific expression at the mRNA-level. Induction of the SKALP 
promoter by TNF-α resulted in increased expression levels of the secreted SKALP-
EGFP fusion protein as assessed by direct read-out of fluorescence and fluorescence 
polarisation in 96-well cell culture plates. The fold stimulation of the reporter gene 
was comparable to that of the endogenous SKALP gene as assessed by ELISA. 
Although the dynamic range of the screening system is limited, the small standard 
deviation yields a Z-factor of 0.49. This indicates that the assay is suitable as a high 
throughput screen, and provides proof of concept that a secreted EGFP fusion protein 
under the control of a physiologically relevant endogenous promoter can be used as 
a fluorescence-based high-throughput screen for differentiation-modifying or anti-
inflammatory compounds that act via the keratinocyte.
5.1 ABSTRACT
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In normal skin the epidermis follows a highly co-ordinated pathway of proliferation 
and differentiation leading to the formation of a horny layer that consists of mature 
corneocytes. In several skin conditions however (psoriasis, wound healing, UV-
irradiation) homeostasis is disturbed, leading to epidermal hyperplasia, abnormal 
differentiation and inflammation. During this so-called regenerative maturation 
pathway, keratinocytes of the psoriatic lesion become hyperproliferative and 
synthesise a set of proteins that are absent in normal epidermis. To this group belong 
structural proteins like cytokeratins CK6, CK16, and CK 17[327] and the secreted anti-
inflammatory protein SKALP/elafin[75,76]. Expression of these molecules can be used 
as a marker for psoriatic differentiation both in vivo[74,310,327] and in vitro[78].
High-throughput programs based on biological testing of large collections of 
compounds in cell culture systems can rapidly identify leads for potential drug 
candidates in the treatment of psoriasis. These large-scale screening systems often 
utilise reporter genes that allow rapid, (semi)-automated analysis of the desired 
parameter. Although SKALP expression is a useful marker for psoriatic differentiation, 
its utility in high-throughput drug screens is limited due to the laborious, time-
consuming multistep-ELISA needed for the quantification of the secreted protein from 
culture medium. We therefore wanted to develop a method to monitor the activity of 
the SKALP promoter using a more convenient read-out. As a reporter we chose the 
Green Fluorescent Protein gene (GFP) because constructs and cell lines expressing 
this protein could be useful both for screening purposes and for studying cell 
biological features of this protein. The gene encoding GFP, originally cloned from the 
jellyfish Aequorea victoria[337], has been used in numerous applications within living 
cells such as reporter for gene expression, protein fusion and tracers of cell lineage. 
The protein is almost unique with respect to its intrinsically fluorescent properties i.e. 
requiring neither substrate nor cofactor to fluoresce. Moreover, other properties of 
GFP, as low toxicity in living cells, easy imaging and quantitation, have accounted 
for the fact that it has become one of the most widely studied and exploited reporter 
proteins in biochemistry and cell biology. A number of studies have used expression 
of GFP to measure activation of relevant signalling pathways in mammalian cells[338-
340]. Most studies that use reporter genes in the context of pharmacological screening 
systems utilise artificial promoters in which either a number of transcription factor 
binding sites or cis-acting regulatory elements have been cloned to drive reporter 
gene expression[341,342].  Here we aimed to use the natural, endogenous promoter of 
SKALP to drive expression of a SKALP-EGFP fusion protein. The objective was 
to create a reporter gene that was subjected to similar transcriptional control as the 
endogenous SKALP gene and to create a protein of which routing and localization 
was identical to that of the endogenous SKALP. The SKALP promoter has previously 
been characterised in a few studies using breast or airway epithelial cells[343,344]. These 
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studies showed that depending on the cell type several different sites were relevant 
for promoter activity in vitro. From our own studies using deletion mutants of the 
SKALP/elafin promoter region in transient transfection studies of normal human 
keratinocytes we found that the approximately 800 bp upstream of the transcription 
start site retained full promoter activity[345]. We also found evidence that regulation of 
the SKALP promoter was dependent on chromatin structure, as there was a difference 
between endogenous SKALP and reporter gene expression following transient 
transfections[345]. In this study we used an 800-bp fragment of the SKALP promoter to 
drive EGFP expression in a stably transfected keratinocyte cell line. We provide proof 
of concept that an endogenous promoter can be used to construct an EGFP-reporter 
cell line that can be used in a 96-well format.
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Generation of SKALP-EGFP constructs
First, the CMV promoter was removed from the original commercially available 
plasmids pEGFP-N1 and pEGFP-N2 (BD Biosciences Benelux N.V, Alphen a/d Rijn, 
the Netherlands) by consecutive AsnI and SmaI digestion. Then, a 1.9 kb HhaI/RcaI 
fragment containing the human SKALP gene was generated from a 9.1 kb HindIII 
fragment of a human genomic DNA library[346] and subcloned into the AsnI-site and 
SmaI-site of pEGFP-N1. The resulting plasmid was linearised by AflII for random 
insertion into HaCaT by lipofection.
As a control construct we used a 6 kb HhaI fragment containing the human SKALP 
gene, generated from the 9.1 kb HindIII fragment described above, that was 
subsequently subcloned into the AsnI-site and SmaI-site of pEGFP-N2. The mRNA 
transcribed from this construct does not result in formation of a SKALP-EGFP fusion 
protein because of the shift in the reading frame. This control construct was linearised 
by HindIII digestion for random insertion into HaCaT by lipofection.
Cell culture, SKALP induction and transfection
HaCaT cells were a kind gift from Dr. N.E Fusenig (German Research Center, 
Heidelberg, Germany). To establish SKALP induction potential of the HaCaT 
cell line, cells were seeded either directly onto plastic or onto irradiated mouse 
3T3 fibroblast feeder layers in 24-well tissue culture plates (Corning Costar, 
Badhoevedorp, the Netherlands). Cultures were grown in Dulbecco’s Modified Eagle 
Media with 4.5 g/L Glucose with L-Glutamine (DMEM, BioWhitakker Europe, 
Verviers, Belgium) supplemented with 10% foetal calf serum (FCS, Harlan Seralab, 
Nistelrode, the Netherlands) and penicillin (100 U/ml) / streptomycin (100 µg/ml) 
(PS, Life Technologies B.V., Breda, the Netherlands). Upon confluence, cultures 
were stimulated with 0, 1, 5 or 25 ng/ml TNF-α (Boehringer Mannheim, Mannheim, 
Germany) during a 72-hour period. Culture supernatants were then collected and 
stored at –20°C for later analysis of SKALP concentrations in ELISA.
Also, HaCaT cells were used to create stable transfectants by random insertion. In 
brief, cells were seeded onto a 10 cm tissue-quality petri dish (Greiner Bio-One B.V., 
Alphen a/d Rijn, the Netherlands) and grown till confluence in DMEM supplemented 
with 5% FCS. Then cells were transfected with 50 µg of linearised construct using 
LipofectAmine Plus (Life Technologies B.V., Breda, the Netherlands) according to 
the manufacturers protocol. Following transfection, cells were cultured in DMEM 
supplemented with 10% FCS, and PS. Three days later, Geneticin (G418, Sigma-
Aldrich Chemie B.V., Zwijndrecht, the Netherlands) was added for selection of G418 
resistant cells. The medium was changed every third day. After 10 days of selection, 
drug-resistant colonies were isolated with cloning rings and split in 96-well plates and 
24-well plates. Upon reaching confluence, cells of 24-well plates were trypsinised 
5.3 MATERIALS AND METHODS
86  Chapter 5 Development of a keratinocyte-based screening model Chapter 5 Development of a keratinocyte-based screening model  87
and transferred to 25 cm2 culture flasks. Finally, these cells were harvested at 80% 
confluence and cryo-preserved. Confluent cultures of 96-well plates were stimulated 
with 25 ng/ml TNF-α for 72 h to assess induction of SKALP-EGFP fusion protein. 
Culture medium was harvested and stored at –20°C for a maximum of 1 month.
Fluorescence analysis 
Cells of the SKALP-EGFP stably transfected cell line that showed highest expression 
of fusion protein in ELISA were seeded on feeder layers in 24-well tissue culture 
grade plates. HaCaT cells stably transfected with the control construct were cultured 
in parallel to asses non-specific effects. At confluence, the medium was switched to 
Ham’s F12 (BioWhitakker Europe, Verviers, Belgium) supplemented with 10% FCS 
and PS, with or without addition of TNF-α (25 ng/ml). Cells were cultured for an 
additional period of 72 h. Culture supernatants were then transferred to black 96-well 
tissue culture plates (Corning Costar, Badhoevedorp, the Netherlands). Subsequently, 
both fluorescence polarisation and fluorescence were read in a microtitre plate reader 
(Polarstar, B&L, the Netherlands) at excitation and emission wavelengths of 480 and 
520 nm.
Northern blot analysis
Total RNA was isolated from G418-resistant SKALP-EGFP transfected HaCaTs and 
from G418-resistant control transfected HaCaTs, 72 h after confluent cell cultures were 
switched to Ham’s F12/10%FCS/PS with or without TNF-α (25 ng/ml). Cells were 
lysed in 1.2 ml TRIzol® reagent (Life Technologies B.V., Breda, the Netherlands). After 
lysis, 240 µl chloroform was added for phase separation. Samples were centrifuged 
for 15 minutes (13,000 rpm, 4°C). The aqueous phase was precipitated with 0.6 ml 
isopropylalcohol. Subsequently, after 15 minutes of centrifugation (13,000 rpm, 4°C), 
the resulting pellet was washed and briefly dried. This RNA pellet was resuspended in 
150 µl NSE (50 mM NaAc, 0.2% SDS, and 2 mM EDTA) and 562.5 µl 100% ethanol 
was added. Samples were spectrophotometrically quantitated and equal amounts of 10 
µg were separated on an agarose gel. The samples were blotted on positively charged 
nylon and subsequently used in hybridisation experiments. The SKALP probe was 
obtained by generation of a 0.42 kb PvuII/EcoRI fragment of the SKALP cDNA clone 
pGESKA[77]. The EGFP probe consisted of a 0.76 kb NotI/PstI fragment of pEGFP-
N1. Probes were 32P-labelled using an oligo labelling kit (Amersham Pharmacia 
Biotech Benelux, Roosendaal, the Netherlands). Autoradiography was performed 
using Kodak X-Omat TM X-ray films.    
Analysis of secreted endogenous SKALP 
A sandwich-type ELISA was developed to determine SKALP levels in supernatants 
of cultured keratinocytes. Briefly, 96 wells flat bottom microtitre plates (Greiner 
Bio-One B.V., Alphen a/d Rijn, the Netherlands) were coated overnight with 
mouse monoclonal antibody (mAb) TRAB-2F that we have recently developed[328]. 
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Plates were blocked with 1% BSA and probed with the test sample for 2 h at 37 
°C. Subsequently, biotinylated mAb TRAB-2O[328] was added and the plates were 
incubated for 1 h at 37°C. Finally, the plates were incubated with Avidin Biotin 
Complex (Vector Laboratories Inc., Burlingame, CA, USA) which was followed by 
30 min incubation at RT. Between all steps the plates were washed with PBS/0.05% 
Tween-20.
o-Phenylene diamine dihydrochloride (Pierce, Rockford, IL, USA) was added as 
chromogenic substrate for a 15-min incubation at RT. The enzyme reaction was 
stopped by addition of 4M H
2
SO
4
 . Absorbance was measured at 492 nm. A SKALP 
calibration curve (0.5 – 12.5 ng/ml) was prepared from a stock of full-length SKALP 
obtained by purification from cell culture supernatants[328]. Concentrations of SKALP 
were read from this curve and expressed as ng secreted SKALP per ml culture 
medium.
Analysis of secreted SKALP-EGFP fusion protein 
SKALP-EGFP fusion protein concentrations were measured in culture supernatants 
of G418-resistant cells after stimulation with TNF-α using a sandwich-type ELISA. 
Briefly, 96 wells flat bottom microtitre plates (Greiner Bio-One B.V., Alphen a/d Rijn, 
the Netherlands) were coated overnight with the rabbit polyclonal antibody RαEBFP-
GST, originally raised against the Enhanced Blue Fluorescent Protein (EBFP), that 
shows cross-reactivity with EGFP[347]. Plates were blocked with 1% BSA and probed 
with the test sample for 2 h at 37 °C. Subsequently, a biotinylated mouse monoclonal 
antibody directed against SKALP (TRAB-2O)[328] was added and the plates were 
incubated for 1 h at 37°C. Finally, the plates were incubated with Avidin Biotin 
Complex (Vector Laboratories Inc., Burlingame, CA, USA) which was followed by 
30 min incubation at RT. Between all steps the plates were washed with PBS/0.05% 
Tween-20.
o-Phenylene diamine dihydrochloride (Pierce, Rockford, IL, USA) was added as 
chromogenic substrate for a 15-min incubation at RT. The enzyme reaction was 
stopped by addition of 4M H
2
SO
4
. Absorbance was measured at 492 nm. Absorbance 
values for untransfected HaCaTs served as background level. Quantitative analysis 
of SKALP-EGFP levels was obtained by expression of absorbance levels as fold 
background levels.
Statistical Analysis
The two-tailed Student t-test was employed for comparison of measurements 
performed for stimulated and unstimulated cell cultures. Mean values for fluorescence, 
absorbance in the SKALP-EGFP ELISA, and fluorescence polarisation were derived 
from 12 wells. A value of p < 0.05 was considered significant.
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Rapid, inexpensive microplate-based assays are required to develop high-throughput 
screens for new antipsoriatic agents. Since abnormalities in epidermal differentiation 
form a key aspect of psoriasis, potential drugs for treatment of this skin disease can be 
identified by monitoring their effect on markers of abnormal epidermal differentiation. 
In previous studies we have described submerged culture systems of normal human 
keratinocytes that can mimic both the normal and the psoriatic phenotype of human 
epidermis[59]. In these systems expression of the anti-inflammatory protein SKALP 
was identified as a useful marker for psoriatic differentiation and it was suggested 
that SKALP could serve as a marker for screening of drugs that affect keratinocyte 
differentiation[220]. 
It was therefore our aim to develop a stably transfected immortalized keratinocyte 
cell line (HaCaT) harbouring the natural, endogenous promoter of SKALP to drive 
expression of a SKALP-EGFP fusion protein. In this way SKALP promoter activity 
would be reflected by the degree of fluorescence, thus yielding a convenient read-
out. A prerequisite for such a system is a validated HaCaT cell culture model with 
inducible SKALP promoter activity.
Optimisation of culture conditions and determination of SKALP 
expression 
Since TNF-α is a known inducer of SKALP expression in normal human 
keratinocytes[219] we investigated the capability of this cytokine to induce SKALP in 
the HaCaT cell line. Confluent cultures of untransfected HaCaT cells that were grown 
either on plastic or on irradiated mouse fibroblast feeder layers were stimulated with 
increasing concentrations of TNF-α. Cell culture supernatants, that were harvested 72 
h later, showed a profound increase of secreted SKALP that paralleled the increasing 
levels of TNF-α (Figure 1). This observation is in accordance with earlier reports 
5.4 RESULTS AND DISCUSSION
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Figure 1: TNF-α  causes dose dependent 
increase of endogenous SKALP in HaCaT 
cells. Cells were seeded either directly 
on plastic or on irradiated mouse 3T3 
fibroblasts (feeder). Levels of SKALP in 
culture medium were determined 72 h after 
the addition of TNF-α  to confluent cell 
layers. Values represent mean ± SD (n=4).
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on HaCaT cells where TNF-α was described to be an inducer of the urokinase type 
plasminogen activator (uPA). This uPA is, like SKALP, confined to those keratinocytes 
that participate in the process of wound healing rather than to keratinocytes of the 
normal epidermis. Interestingly, supernatants of cells cultured on feeder layers 
contained considerable higher amounts of SKALP than supernatants of cells that were 
grown on plastic. In the presence of feeder layers TNF-α-stimulated cultures exhibited 
SKALP levels that were five-fold higher than levels of cultures where feeder was 
omitted. This observation can be attributed to yet unknown factors released by 
(irradiated) 3T3 fibroblasts that are known to induce keratinocyte proliferation and 
differentiation in vitro[348,349].
Stable transfectants, SKALP-EGFP at RNA and protein level
We then investigated whether a SKALP-EGFP reporter gene would be subject to 
similar transcriptional control as the endogenous SKALP gene. A DNA construct 
coding for a SKALP-EGFP fusion protein, under control of a 0.8-kb fragment of the 
natural SKALP promoter was stably integrated by random insertion into the HaCaT 
genome (Figure 2). Our rationale for using this length of SKALP/elafin promoter 
region was based on transient transfection studies in normal human keratinocytes 
where we found approximately 800 bp upstream of the transcription start site to retain 
full promoter activity[345]. After 10 days of G418-selection there remained about 40 
colonies of various size in the 10 cm petri dish. Phase contrast microscopy revealed 
irregularities of cell size and morphology for the outer edge of the 8 smaller sized 
colonies, which was interpreted as an indication of decreased viability and dividing 
0.8 kb SKALP promoter
CMV-less pEGFP-N1
(4078 bp) 
ATGRca I Hha I
1.0 kb SKALP gene
Figure 2: Outline of the fusion 
construct that was used to generate 
stably transfected HaCaT cells 
expressing the SKALP-EGFP 
fusion protein under control of a 
0.8 kb fragment of the endogenous 
SKALP promoter.   
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potential. As a consequence only the 32 bigger sized colonies that showed normal 
cell size and morphology were transferred by ring cloning procedures to multi-well 
cell culture plates. Upon reaching confluence these cultures were either stimulated or 
not with TNF-α and cultured for an additional 72 h. The culture supernatants were 
screened for presence of fusion protein by an ELISA. This quantitative analysis 
could only give relative expression levels because SKALP-EGFP fusion protein 
was not available for calibration purposes. The clone giving rise to the highest 
relative expression level was selected for further study and was labelled “clone 21”. 
Remarkably, several of the selected stable transfectants exhibited little or no induction 
of fusion protein. This variation in level of expression between clones presumably 
reflects local environmental influences of differing genomic insertion sites.
Northern blot analysis using a probe directed against SKALP confirmed the induction 
of both the endogenous SKALP and the SKALP-EGFP specific mRNA with an 
expected 1.3 kb length in TNF-α stimulated clone 21 (Figure 3). The latter transcript 
was not detected in the unstimulated clone 21 cells. Moreover, as expected, the 
SKALP-EGFP mRNA was also absent in control samples of untransfected HaCaT 
cells (Figure 3). In addition, when using a probe specific for EGFP we confirmed both 
the TNF-α dependent induction of the SKALP-EGFP mRNA in the stably transfected 
clone and its absence in untransfected HaCaT (results not shown). Note that the signal 
of the SKALP-EGFP mRNA is relatively weak compared to the signal obtained for 
the endogenous SKALP mRNA. In part this can be explained by the fact that a four-
fold reduction of the signal was to be expected because only a part of the SKALP 
coding region is present in the mRNA coding for the fusion protein. Furthermore, the 
discrepancy of the local environment at the genomic insertion site as compared to the 
environment of the endogenous SKALP gene is most likely an additional explanation 
for the reduced induction of SKALP-EGFP mRNA (see also below). 
0.8 kb  >
SKALP-EGFP
HaCaT
( - )
HaCaT
( clone 21 )
SKALP
1.3 kb  >
TNF-� (ng/ml) 
0           25 0            25
Figure 3: Northern blot analysis showing 
TNF-α-dependent induction of a 1.3 
kb SKALP-EGFP mRNA in the stably 
transfected HaCaT cell line clone 21 (right 
panel). This particular mRNA is absent in 
control samples of untransfected HaCaT 
cells (left panel). Equal loading of samples 
was confirmed by methylene blue staining 
of total RNA (not shown).  
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Detection of EGFP fluorescence in culture medium
Initially we used DMEM as basal medium to culture the HaCaT cells. However, 
we found that DMEM has relatively high background fluorescence at the emission 
wavelength of EGFP, thereby reducing the sensitivity of the assay. Riboflavin is a 
constituent of DMEM that, depending on its state of oxidation, can typically make 
up a large proportion of the fluorescence in the EGFP emission range (Beat Ludin, 
personal communication). We tested a range of culture media for low basal intrinsic 
fluorescence in the EGFP emission range and we selected Ham’s F12, a readily 
available medium that contains only 10% of the riboflavin that is present in DMEM. 
Figure 4 shows a dilution curve of recombinant EGFP in Ham’s F12 medium 
supplemented with 10% FCS, giving a linear relationship between fluorescence and 
EGFP concentration. In spite of the relatively high background, levels of EGFP as 
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Figure 6: Levels of fusion protein are elevated in 
TNF-α-stimulated cultures of clone 21 as measured 
in a SKALP-EGFP-specific ELISA. Culture 
medium of cells stably transfected with a control 
construct gave only rise to background levels. 
Values represent mean levels of fold background 
(±SD) derived from 12 wells in duplicate 
experiments. The asterisk indicates a significant 
difference as determined by Student’s t test (p < 
0.05).
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Figure 5: Increased levels of fluorescence in culture 
medium of TNF-α-stimulated clone 21. Culture 
medium of cells stably transfected with a control 
construct showed no increase of fluorescence upon 
stimulation with TNF-α. Values represent mean 
levels of fluorescence ( ±SD) derived from 12 wells 
in duplicate experiments. The asterisk indicates a 
significant difference as determined by Student’s t 
test (p < 0.05). 
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Figure 4: Calibration curve of 
fluorescence versus recombinant EGFP 
in Ham’s F12 medium supplemented 
with 10% FCS. Values represent mean 
± SD (n=6).
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low as 0.5 nM can already be conveniently measured. In Figure 4 the fluorescence 
values have been corrected for background; a concentration of EGFP of 2.5 nM 
yielded a 100% increase of fluorescence over the background. Ham’s F12 was used 
as a culture medium to test TNF-α induced secretion of SKALP-EGFP by clone 21. 
Figure 5 shows that incubation with 25 ng/ml TNF-α resulted in a 2-fold increase in 
fluorescence compared to the basal medium, indicating a moderate secretion of EGFP 
fusion protein equivalent to about 2.5 nM. Although the induction of fluorescence 
over background was only two-fold, it was statistically significant, and was repeatedly 
found (3 experiments, each n=12). Because the observed increase in fluorescence was 
relatively low compared to background, we also measured the increase of SKALP-
EGFP by ELISA. Figure 6 shows that TNF-α stimulated cultures of clone 21 secrete 
elevated levels of fusion protein as verified by a SKALP-EGFP specific ELISA. In 
fact, we found a 15-fold increase compared to unstimulated cultures, similar to the 
fold-induction of the endogenous SKALP gene in this particular experiment (not 
shown). The observation that the fold-induction as measured by ELISA is much higher 
than by fluorescence measurement can be attributed to the intrinsic fluorescence of the 
medium used. In addition, the absolute amount of EGFP-SKALP fusion protein that 
is produced is far less (about 2.5 nM) than that of the endogenous SKALP (about 480 
nM), which also precludes a higher signal to background ratio.
It could be argued that the observed increase in fluorescence was not due to production 
of SKALP-EGFP but that is was rather caused by increased noise from low molecular 
weight fluorescent metabolites during culture. To investigate this we performed 
fluorescence polarisation measurement on the supernatants. Fluorescence polarisation 
is a technique that is usually applied to study macromolecular interactions, because 
binding of a fluorescent small molecule (in this case a small protein) to a sufficiently 
large molecule will decrease its rotational relaxation time. Here we have used 
fluorescence polarisation to detect the presence of EGFP in a complex solution 
(tissue culture medium) that has an intrinsic basal fluorescence due to low molecular 
weight compounds. Using Ham’s F12 medium supplemented with 10% FCS, a basal 
polarisation value of 90 millipolarisation units (mPu) was found (see Figure 7). 
When increasing concentrations of recombinant EGFP are added to culture medium 
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Figure 7: Calibration curve of 
fluorescence polarisation versus 
recombinant EGFP in Ham’s F12 
medium supplemented with 10% FCS. 
Values represent mean ± SD (n=6).
94  Chapter 5 Development of a keratinocyte-based screening model Chapter 5 Development of a keratinocyte-based screening model  95
a dose-dependent increase of the polarisation value was found due to the contribution 
of EGFP, which has less rotational freedom than the other fluorescent compounds 
in the medium. When fluorescence polarisation measurement was applied to culture 
supernatants of the TNF-α stimulated clone 21 we found the polarisation value to be 
significantly increased by approximately 80 mPu, as shown in Figure 8. Note that an 
equal increase of polarisation value for the calibration curve is achieved upon addition 
of 2.2 nM recombinant EGFP to unconditioned culture medium. These data indicate 
that increased fluorescence as found in Figure 5 is derived from a high molecular 
weight compound secreted by the cells. 
Application of reporter constructs using an endogenous promoter
Our results indicate that in principle an endogenous, physiologically relevant 
promoter can be used to construct screening procedures based on fluorescence. The 
small dynamic range, however, appears to impose a limit on its practical use. In our 
case both the intrinsic fluorescence of the basal medium and the low expression level 
of the transgene compared to the endogenous gene precluded sensitive measurement 
of SKALP-EGFP fusion protein. Recently, the Z-factor has been proposed as a simple 
statistical parameter for evaluation of high throughput screens[349] where 
   Z = 1 -
As a rule of thumb, when Z = 1 the assay is ideal, for 1 > Z > 0.5 an excellent assay is 
obtained, for 0.5 > Z > 0 the separation band is small, for Z = 0 a yes/no type of assay 
is obtained, and for Z-values < 0 screening is essentially impossible. When we use the 
data depicted in Figure 5 a Z-factor of 0.49 is obtained, indicating a reasonable assay. 
Note that the favourable Z-factor is caused by the small SD of the sample values, 
whereas the dynamic range is very small. Obviously, the development of culture media 
with less background fluorescence will allow more sensitive EGFP measurement. The 
low expression of the transgene could be caused by several factors. Random insertion 
will put the gene of interest out of its natural genomic context. We have tested about 
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Figure 8: TNF-α-stimulated cultures 
of clone 21 show increased levels of 
fluorescence polarisation. Culture medium 
of cells stably transfected with a control 
construct showed no increase. Values 
represent mean levels of fold background 
(±SD) derived from 12 wells in duplicate 
experiments. The asterisk indicates a 
significant difference as determined by 
Student’s t test (p < 0.05 ).
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32 clones and the highest producer was selected for further study. This particular clone 
(clone 21) still gave only 0.5% of the expression level of the endogenous gene. Even 
allowing for the fact that there are 2 or more copies of the endogenous gene (HaCaT 
cells are aneuploid), the transgene is still expressed at low levels. In addition to the 
effect of the insertion locus this could be due to insufficient information contained in 
the promoter fragment used. In future experiments we will aim to construct cell lines 
harbouring a EGFP reporter gene via homologous recombination which will place the 
reporter gene in the correct genomic environment and its expression will be driven by 
the correct promoter and flanking sequences.
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Elafin (also known as SKALP/trappin-2) is an epithelial host-defense protein that 
is absent in normal skin but highly induced in keratinocytes of inflamed skin (e.g. 
psoriasis), in epidermal skin tumours and after wounding. Previously, it was shown 
that in cultured keratinocytes, elafin expression is induced by serum or tumour 
necrosis factor alpha (TNF-α), and that expression is suppressed by retinoids, 
dithranol and p38 mitogen activated protein kinase inhibitors. Here we have studied 
the regulation of elafin gene expression in epidermal keratinocytes at the molecular 
level. First we determined the transcription start site of the elafin gene and found that 
the elafin mRNA possesses an unusually short 5’-untranslated region. Using transient 
transfection of luciferase reporter constructs of the elafin promoter, we mapped a 440 
bp region upstream of the translation start site that conferred high level expression in 
keratinocytes, but not in A431 cells or cells of mesenchymal origin. We observed that 
the promoter constructs were not subjected to the same regulation as the endogenous 
elafin gene since these constructs were highly active independent of keratinocyte 
stimulation. When elafin promoter constructs were stably transfected in the HaCaT 
keratinocyte cell line, TNF-α inducible expression of both the endogenous elafin gene 
and the transgene was observed, suggesting that regulation of the elafin gene is also 
dependent on chromatin structure. We found, however, that a stably transfected 4 kb 
elafin-promoter fragment did not confer retinoid sensitivity indicating that additional 
sequences are required for proper regulation. Our study reveals the complex regulation 
of a gene that can be used as a paradigm for the specific differentiation program of 
activated epidermal keratinocytes.
6.1 ABSTRACT
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Human epidermis is mainly composed of keratinocytes, which follow a 
highly coordinated process of terminal differentiation. This normal epidermal 
differentiation pathway ultimately leads to the formation of a protective layer of dead 
corneocytes[350,351]. There are, however, conditions like wounding and inflammation, 
in which the epidermis follows an alternative pathway. This pathway, which is 
characterised by hyperproliferation and distinct differentiation, is a functional 
physiological response to conditions that require rapid epidermal regeneration and 
protective gene expression. Yet a number of skin conditions exist where this pathway 
seems inappropriate and is part of a pathological skin condition, like psoriasis[352]. 
There is not much known about the molecular changes that are at the basis of this 
change in epidermal differentiation pathways. Insight into these earliest changes at the 
molecular level could provide us with knowledge about the regulation of epidermal 
differentiation routes and could ultimately lead to the identification of novel targets 
for the therapy of skin diseases.
A number of genes have been described previously, whose expression is induced or 
highly upregulated under the conditions mentioned above. Well-known examples are 
the hyperproliferation-associated cytokeratins CK 6, 16 and 17[327]. Similar to the 
expression of CK6, CK16, and CK17[353], the expression of the gene encoding elafin 
(also known as skin-derived antileukoproteinase, SKALP) is tightly correlated with 
abnormal epithelial differentiation in a context of hyperproliferation. Elafin is highly 
expressed in keratinocytes of psoriatic epidermis[76,310] and is inducible in vivo by UV-
B irradiation[354], and by tape stripping (a standardised model for epidermal injury and 
trans-epidermal water loss)[221,223].
By extrapolation, we hypothesise that knowledge on the molecular regulation of elafin 
expression could provide information on the molecular regulation of the phenotype 
associated with activated epidermis and its characteristic program of gene expression. 
In previous studies we have shown that elafin gene expression can be induced in 
vitro by stimulation of cultured undifferentiated primary keratinocytes with either 
FCS or TNF-α[59,219,315]. This in vitro induction of elafin was shown to be dependent 
on the activity of the mitogen activated protein (MAP) kinase family member p38. 
In addition we showed that elafin expression in vivo is induced by UV-B irradiation 
of normal human skin, is also correlated with p38 activation[354]. This led to the 
hypothesis that the expression of elafin is part of an epidermal stress response that 
is possibly deregulated in pathological skin conditions like psoriasis. Interestingly, 
elafin expression was found to be downregulated by retinoids and by dithranol, which 
are known potent antipsoriatics[220,317].We therefore regard elafin expression as a 
surrogate marker for psoriasis.
So far, regulation of elafin gene expression at the molecular level has only been studied 
in non-keratinocyte cells such as breast epithelial and lung epithelial cell lines[343,344]. 
6.2 INTRODUCTION
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These studies, using transient transfections, have revealed that transcription factor 
binding sites for AP-1 and NF-κB in the elafin promoter are important. Elafin 
expression and function in keratinocytes has been studied in detail at the cellular 
level in vivo, but knowledge on its molecular regulation is lacking. We have studied 
regulation of the elafin gene in primary epidermal keratinocytes and in the HaCaT 
keratinocyte cell line. An important observation from our studies is that, at least 
in keratinocytes, elafin promoter activity cannot be simply inferred from transient 
transfection studies, suggesting that other crucial regulatory mechanisms exist. 
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Chemicals 
All chemicals were obtained from Merck (Darmstadt, Germany) with the exception 
of TNF-α (Boehringer, Mannheim, Germany) and all-trans retinoic acid (RA) 
(Sigma, St. Louis, MO, USA). A 5 mM stock solution of RA was prepared in ethanol. 
Restriction enzymes were from Boehringer. Primers were from Isogen (Amsterdam, 
the Netherlands). 
Cloning of the human elafin gene promoter region and reporter gene 
constructs
We have previously reported the cloning of a 9 kb HindIII genomic fragment 
in pBluescript (Stratagene, La Jolla, CA, USA), which was shown to contain 
the human elafin gene[346]. This clone was designated pSKAG. From this clone 
an EcoRI/XbaI fragment containing approximately 1 kb promoter region in 
addition to a small part of the first exon was cloned in pBluescript KS+ resulting 
in clone pSPRO29. Construct pSPRO29 was used as template in a PCR reaction 
synthesising the 1 kb promoter fragment (pos. -1012/+13; all nucleotide positions 
in this paper are given relative to the start site of translation (see Figure 1)). Two 
primers (forward: 5’-GAATTCCCGGGTTCATATAT-3’ (pos.-1012/-993, (mutated 
nucleotide is underlined)), reverse: 5’-TGCTGGCCCCCATGGTGTCA (pos. -7/
+13)) were used to introduce a SmaI site and a NcoI at the 5’ and the 3’ site of the 
PCR product respectively. The PCR-product was cloned in the pGEM-4 T-vector 
(Promega, Madison, WI, USA) and sequenced for verification. From this clone a 
1 kb SmaI/NcoI fragment (pos. -1004/+3) was directionally subcloned in frame 
with the firefly luciferase gene in pSla4, a modified pSla3 vector[355], directly fused 
to the ATG of the luciferase gene through the NcoI site. The resulting clone was 
designated pSPL1000. From this clone deletion mutants were derived, designated 
pSPL440, pSPL290, pSPL170 and pSPL130. All these constructs were prepared 
according to standard cloning techniques using available restriction sites, except 
clone pSPL130. To generate this clone we used a mutagenic forward primer (5’-
GTGGATATCTCCCAATAC-3’ (pos. -132/-115)) in a PCR reaction with the 
previously mentioned reverse primer to introduce an EcoRV site at position -126. 
From the resulting PCR product an EcoRV/NcoI fragment was cloned in a SmaI/NcoI 
digested pSLA4 vector. The largest transfection construct pSPL4500 was constructed 
via directional cloning of an approximately 4 kb HindIII/BglII promoter fragment 
(pos. -4500/-435) in a SmaI/BglII digested pSPL1000 construct. The two promoter 
constructs pSPL1000int+ and pSPL1000int- contain the entire genomic sequence of 
the elafin gene in the correct and reverse orientation respectively. Both constructs 
containing the genomic elafin sequence were constructed by directional cloning of 
a PCR product containing the entire gene sequence (pos. +3/+1631) in the KpnI site 
6.3 MATERIALS AND METHODS
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of construct pSPL1000 between the stop codon and the first polyadenylation signal 
of the luciferase gene. Finally a construct containing the insert from clone pSPL1000 
in the reverse orientation, designated pSPL1000rev was generated. To obtain this 
clone, the previously mentioned 1 kb SmaI/NcoI fragment was used. A blunt end was 
generated at the NcoI site, and the complete fragment was subcloned in the SmaI site 
from pSla4, thus maintaining the original translation start codon from the luciferase 
gene. Figure 2A gives a schematic representation of these 9 constructs.
Determination of elafin mRNA transcription start-site using S1-nuclease 
mapping
S1 nuclease mapping using a single stranded DNA probe was used to determine 
the start site of transcription of the elafin gene. To obtain a suitable DNA probe 
we cloned a BglII/XbaI fragment (pos. -435 to +62) in pBluescript KS+. Single 
stranded DNA was obtained by transforming the plasmid in E.coli XL1-Blue cells 
and infecting the transformed cells with M13K07 helper phage (as described[356]). To 
prepare the radiolabeled probe, T7 primer (Promega) was annealed to 250 ng single 
stranded DNA, and primer extension was performed with 5 U of T7 DNA polymerase 
(Pharmacia, Upsala, Sweden) in the presence of 0.5 μM [α-32P]-dCTP (3,000 Ci/mmol, 
(Amersham, Buckinghamshire, England)), 0.4 mM dATP, 0.4 mM dTTP, 0.4 mM 
dGTP and 1.3 μM dCTP (Amersham Biosciences, Upsala, Sweden). The radiolabeled 
fragment was separated from the template on a 4% polyacrylamide gel and isolated. 
Total RNA isolated from keratinocytes grown in the presence of 5% FCS was used 
as a source for elafin mRNA. Fifty μg of this total RNA was mixed with 8x105 cpm 
           pSPL1000�                                               NF�B
-1012 GAATTCCCTG GTTCATATAT ATCACCTTTT CCAGAAGAAG GAACCCCCGT TTTCCCCTTT
-952 CATTACTCAT TCAAATAAAA TATGTTAATA GACCAGACCA AGTCTCACAC ACAACACACA
-892 CACACACACT CACACACACA CACACACACA CACACCCCTA CCTGTGGTCA GGGGTCAGGC
-832 TTTCATGATT AGCAGTCCCC ATTAGACTCA CAAGTTGATG GTTCAAAGAG ACAACAATTC
-772 TTCACAAGAA ACAGGGTGCT GTTCAAAGAA GTGGGGAGGC ATGCTGGACA CACACACTGT
-712 AGATGTCCAA TGTATACATG ATACATGTTT TCTACTACTT TCTGATTATT TTCTCCCTAC
-652 CACTGTGATT TCAAGGGCAT CATCCCTCTT CAGACCTAGA ATTCCACCTT CCAATTACTT
                                                           AP-1 
-592 TCTTGATGCA TCTGAAAGGC CGTCTCTGAA ACAGCAAAGT GCAATAATTA GTCATTATGT
-532 ATTCAAGGCA AATTTGTCTT ACAGAGTTTT TTGCAGGACC AGGGAAGAAG GAAGGAAATG
pSPL440�
-472 CCCAGTTTGA TGCTGGGAGT GGTAAAATGA TAAAGTAGAT CTGGGTGGGG TTTGTAGCAC
                                    NF-IL6                         NF-IL6 
-412 CAGAGCATAA TGGAGAAACA CCTTGGTTTT GTAATCAAGA CTGGATCTAC CAGTGACTTG
     NF-IL6/AP-1                                          NF-IL6 
-352 CTGAATAACC TTCGGTGATT CCTTTCTCTT CTTGGGTCTC ACTGTATTTC AAAACATGAA
SPL290�
-292 GAATTTCATT GTAATGTTAC CTAATAAGTG AGCCAGCACT TCTACTCTGT GAGAAAGTAG
                                      NF-IL6 pSPL170� AP-1 
-232 GAAAACTCTT GGGACAATCA GAGATGATGT GATGTAATGT CCATTAGTTC TTCCTGTGAA
      AP-1         NF�B pSPL130�    NF-IL6 
-172 TAATCCTGAG GGAAAGCCCC CAGGTCCCTC CCAGAATGGG GTGGATATTT CCCAATACAG
                                          SP1 
 -112 CTAAGGAATT ATCCCTTGTA AATACCACAG ACCCGCCCCT GGAGCCAGGC CAAGCTGGAC
-52 TGCATAAAGA TTGGTATGGC CTTAGCTCTT AGCCAAACAC CTTCCTGACA CCATG
+1
Figure 1: Nucleotide sequence 
of the human elafin gene 
promotor region.
Numbering is relative to the 
first base of the ATG translation 
codon (printed in bold). The 
borders of the fragments used 
for the luciferase transfection 
constructs are indicated with 
arrows (⇓). The putative 
“CCAAT” and “TATA” boxes 
are double underlined. The 
region of multiple transcription 
start sites is underlined with 
a dotted line, the preferential 
transcription start sites are 
printed in italics and bold. 
Consensus binding sequences 
for known transcription factors 
are indicated by name and 
underlined.
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single stranded probe DNA. As a negative control yeast tRNA (Boehringer) was used. 
The pellets were dissolved in 30 μl hybridisation buffer (40 mM PIPES (piperazine-
N, N, -bis [2-ethanesulfonic acid]) pH8.0, 0.5 M NaCl, and 80% formamide) and 
incubated for 10 minutes at 85ºC followed by an incubation for 16 h at 50ºC. After 
this probe hybridisation, 300 μl nuclease S1 reaction mix (280 mM NaCl, 5 mM NaAc 
pH4.5, 4.5 mM ZnSO
4
, 20 μg/ml herring sperm DNA (Boehringer) and 1000 U/ml 
Nuclease S1 (Amersham Biosciences) was added and the reaction was incubated at 
37ºC for 60 minutes. As a control reaction to check for sufficient nuclease S1 activity, 
free radiolabeled probe was subjected to nuclease S1 digestion.  The samples were 
separated on an 8% polyacrylamide gel, and autoradiography was performed using 
Kodak X-Omat 100 X-ray film.
Determination of elafin mRNA transcription start site using 5’-RACE
Rapid amplification of cDNA ends (RACE) was used to reconfirm transcription start 
sites of endogenous elafin found with S1-nuclease mapping in human keratinocytes. 
Using the 5’/3’-RACE kit (Boehringer) we performed 5’ RACE on 10 μg of total RNA 
isolated from keratinocytes grown in KGM/FCS, as suggested by the manufacturer. In 
the RACE reaction the elafin specific primers (SP) used were the primers SP1 (+1013/
+1037), SP2 (+942/+966) and SP3 (+30/+48). The produced RACE fragment was 
purified on an agarose gel and cloned into the pGEM-T vector (Promega). The RACE 
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elafin promoter.
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luciferase constructs containing 
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primary human keratinocytes cultured 
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clones obtained were sequenced by means of the dideoxy chain termination method. 
Cell culture
Normal human keratinocytes were seeded in 6 well culture dishes and cultured 
until confluence in keratinocyte growth medium (KGM) as described before[265]. At 
confluence the cells were either transfected or switched to one of the test media. 
Subsequently, the growth factors or cytokines that were to be tested were added in 
different concentrations. Induction of keratinocyte differentiation was established 
by switching the cells at confluence either to KGM supplemented with 5% v/v FCS 
(KGM/FCS) (FCS from Seralab, Nistelrode, the Netherlands) or to KGM depleted 
of growth factors (BPE, insulin and EGF) and hydrocortisone (KGM/-gf). Human 
skin fibroblasts derived from healthy volunteers, glioblastoma cells and A431 cells 
were seeded and cultured in 6 well culture dishes in A1 medium (DMEM/F12) 
(Flow Laboratories, Irvine, Scotland) in a ratio of 3:1 supplemented with 100 U/ml 
penicillin, 100 μg/ml streptomycin and 10% v/v FCS).
Transient Transfections
Keratinocytes were transfected at confluence. Prior to transfection the cells were 
washed twice with 1 ml KBM and 900 μl KBM was added. Transfection mixes were 
made containing 0.75 pmol transfection construct 0.5 pmol EF2-βGAL normalisation 
construct (a kind gift from Dr. G. Swart, department of Biochemistry, University of 
Nijmegen) and 25 μl lipidfection reagent (lipidfection reagent consisted of 0.8 mM 
DDAB (di-methyldioctadecylammonium bromide (Sigma), and 1.7 mM PtdEtn 
(dioleoyl-L-α-phosphatidylethanolamine (Sigma), prepared according to a method 
described elsewhere[357], in a final volume of 100 μl KBM. These mixes were 
incubated for 20 minutes at room temperature and the cells were transfected during 
6 h. Twenty-four h after transfection the medium was aspirated and the cells were 
switched either to KGM/FCS or to KGM/-gf, and incubated for another 24 h after 
which the cells were harvested.
The human fibroblasts, glioblastoma cells and A431 cells were transfected at 50-70% 
confluence. Prior to transfection the cells were washed twice with 1 ml DMEM/
F12 (ratio 3:1) and 900 μl DMEM/F12 was added. Transfection mixes were made 
containing 1.3 pmol transfection construct, 0.5 pmol EF2-βGAL and 25 μl DOSPER 
(Boehringer) in a final volume of 100 μl DMEM/F12. These mixes were incubated 
for 20 minutes at room temperature and added drop wise to the cells. After 6 h of 
incubation 1 ml A1 medium was added to the cells. Twenty-four h after transfection 
the medium was aspirated and two ml A1 was added. After a final incubation of 24 h 
the cells were harvested.
Cell harvesting and reporter assays
Transfected cells were washed twice with PBS (NPBI, Emmer-Compascuum, the 
Netherlands) and lysed in 150 μl reporter lysis buffer (Promega). Luciferase enzyme 
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assay was performed with the Luciferase Assay System (Promega) as suggested by 
the manufacturer using 10 μl cell lysate and 50 μl assay reagent. Beta-galactosidase 
enzyme assay was performed with the “Galacto-Light Plus” chemiluminescent 
reporter assay for the detection of β-galactosidase (Tropix Inc., Bedford, MA, USA) 
as suggested by the manufacturer using 20 μl cell lysate. Promoter activities were 
measured as the ratio between the luciferase activity and β-galactosidase activity per 
sample.
Cell cultures of stably transfected HaCaT keratinocytes
Previously, we have generated two stably transfected keratinocyte cell lines (HaCaT) 
in which respectively a 4 kb and a 0.8 kb fragment, derived from the promoter of the 
elafin gene, drive the transcription of a gene fusion of elafin and Enhanced Green 
Fluorescent Protein (EGFP)[358]. The original clones designated ‘clone VI B3’ and 
‘clone 21’ will hereinafter be referred to as 4kb-elafinprom and 0.8kb-elafinprom. 
Cells of these stable transfectants were seeded onto irradiated mouse 3T3 fibroblast 
feeder layers in 24-well tissue culture plates (Corning Costar, Badhoevedorp, the 
Netherlands). Cultures were grown in Dulbecco’s Modified Eagle Media with 4.5 
g/L Glucose with L-Glutamine (DMEM) (BioWhitakker Europe, Verviers, Belgium) 
supplemented with 10% foetal calf serum (FCS) (Harlan Seralab, Nistelrode, the 
Netherlands) and penicillin (100 U/ml) / streptomycin (100 µg/ml) (PS) (Life 
Technologies B.V., Breda, the Netherlands). Upon confluence, cultures were switched 
to medium with or without 25 ng/ml TNF-α. Simultaneously, RA was added to the 
medium to create a dose range of 10–6, 10–7, 10–8 M and cultures were maintained for 
another 72 h. Culture supernatants were then collected and stored at –20°C for later 
analysis in ELISA. Total RNA was isolated and stored at –80°C for Northern blot 
analysis.
Northern blot analysis
Total RNA was isolated from RA-treated cultures of HaCaT clones 4kb-elafinprom 
and 0.8kb-elafinprom, 72 h after confluent cultures were switched to medium with 
or without TNF-α. For isolation of total RNA we used TRIzol reagent according 
to directions of the manufacturer (Life Technologies B.V., Breda, the Netherlands). 
Samples were spectrophotometrically quantitated and equal amounts of 10 µg were 
separated on an agarose gel. The samples were blotted on positively charged nylon 
and subsequently used in hybridisation experiments. The elafin probe was obtained 
by generation of a 0.42 kb PvuII/EcoRI fragment of the elafin cDNA clone pGESKA. 
The EGFP probe consisted of a 0.76 kb NotI/PstI fragment of pEGFP-N1. Probes were 
32P-labelled using an oligo labelling kit (Amersham Biosciences). Autoradiography 
was performed using Kodak X-Omat X-ray films.
Analysis of secreted endogenous elafin 
Elafin levels were determined in medium derived from HaCaT cultures by means 
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of a sandwich-type ELISA which is described elsewhere[328]. An elafin calibration 
curve (0.5 – 12.5 ng/ml) was prepared from a stock of full-length elafin obtained by 
purification from cell culture supernatants. Concentrations of elafin were read from 
this curve and expressed as ng secreted elafin per ml culture medium.
Analysis of secreted elafin-EGFP fusion protein 
Elafin-EGFP fusion protein concentrations were measured in medium derived from 
HaCaT cultures using a sandwich-type ELISA as previously described[358]. Absorbance 
values for untransfected HaCaTs served as background level. Levels of elafin-EGFP 
were expressed semi-quantitatively as fold background.
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The human elafin gene contains multiple transcription start sites and 
the mRNA has an unusually short 5’-UTR
The cloning and partial structural characterisation of the elafin gene and cDNA has 
been described previously[77,346,359]. Based upon the presence of consensus sequences 
for a TATA and CCAAT box, the region directly 5’ of the translation start site was 
assigned as the putative promoter in previous studies by others, although this has not 
been verified experimentally. We initially used the S1-nuclease mapping technique to 
determine the transcription start site of the elafin gene. Using this technique, multiple 
transcription start sites were found from 9 to 24 basepairs upstream of the translation 
start site of the elafin gene (not shown). Since these positions would result in an 
unusually short 5’ untranslated region (5’UTR), an independent method was used to 
confirm this region as being the region where elafin transcription can start. Application 
of the 5’ RACE technique also yielded short 5’-fragments and confirmed the presence 
of multiple transcription start sites. However, less size variation was found, since 60% 
of all RACE clones were located around base residues -16/ -17/-18 (Figure 3). 
Deletion mapping of the elafin promoter 
In order to scan the elafin promoter for sequences relevant for transcriptional activity 
in human keratinocytes, a set of 9 reporter constructs (see Figure 2A) was designed 
covering approximately 4500 basepairs of upstream and approximately 1600 basepairs 
of downstream gene sequences. These constructs were transiently transfected in 
human keratinocytes that were stimulated with FCS (see Figure 2B). Stepwise 
deletion of the region between -4500 and -440 did not affect elafin promoter activity, 
as can be seen by the relative luciferase activity of the transfection clones pSPL4500, 
pSPL1000, and pSPL440. Based on the relative luciferase activity of the transfection 
clones pSPL1000int+ and pSPL1000int-, containing the intron sequences of the elafin 
gene in both orientations, it appears that the intron sequences do not have any effect 
on promoter activity in either orientation. Subsequent deletion, however, of the region 
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Figure 3: Determination of region 
where transcription of the elafin gene 
initiates.
Relative distribution of transcription 
start sites in the elafin gene promotor 
determined by 5’-RACE. Nucleotide 
positions (relative to the translation 
start site) are indicated on the X-axis. 
The graph summarises the results of 15 
analyzed RACE clones.
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-440 and -290 (clone pSPL290) resulted in a significant decrease of elafin promoter 
activity in human keratinocytes of about 75%. Further deletion of promoter sequences 
down to 170 basepairs 5’ of the translation start site (pSPL170) resulted in a decrease 
of promoter activity down to 10%. Transfection clone pSPL130, containing only 
minimal promoter consensus binding sequences showed almost no promoter activity 
in keratinocytes. Clone pSPL1000rev, in which the upstream sequence of the elafin 
gene is cloned in reverse orientation, resulted in a luciferase activity comparable to the 
empty luciferase gene vector pSLA4. Figure 2B depicts the activity of the promoter 
constructs transfected in keratinocytes that were subsequently stimulated with foetal 
calf serum (KGM/FCS) which is known to induce expression of the endogenous elafin 
gene[59]. When the transfected cells were induced to differentiate by growth factor 
depletion (KGM/-gf), under which condition the endogenous elafin gene is virtually 
silent compared to FCS-stimulation, the promoter constructs were still highly active 
(Figure 2B). This discrepancy between the activity of the naked plasmid DNA and the 
activity of the chromatin-embedded endogenous gene suggest additional regulatory 
mechanisms for expression of the endogenous gene, as will be discussed below.
The elafin promoter confers keratinocyte-specific gene expression
To investigate whether the promoter region that was investigated here could confer 
cell-type specific expression, reporter constructs were transfected in the epithelial 
A431 cell line, primary human skin fibroblasts and  the U138-MG glioblastoma cell 
line. Figure 4 shows the relative activity of the transfection clone pSPL1000 in the 
different cell types, compared to the relative activity of the empty luciferase gene 
vector pSLA4. As can be seen in Figure 4, the elafin promoter was highly active in 
keratinocytes, whereas in fibroblasts, glioblastoma cells, and A431 cells hardly any 
transcriptional activity was found. This effect was also observed with other promoter 
constructs (data not shown). 
0
50
100
150
Keratinocytes Glioblastoma Fibroblast A431
Cell Type
Fo
ld
 In
cr
ea
se
 P
ro
m
ot
er
 A
ct
iv
ity
 
Figure 4: Elafin promotor activity in 
different cell types.
Primary human keratinocytes, U138-MG 
glioblastoma cells, primary human skin 
fibroblasts, and epithelial A431 cells 
were cotransfected with either empty 
reporter construct pSLA4 and EF2-βGAL 
or with transfection clone pSPL1000 and 
EF2-βGAL. Twenty-four hours after 
transfection cell cultures received fresh 
medium containing either 10% FCS 
(glioblastoma, fibroblast, epithelial 
A431) or 5% FCS (keratinocyte). After 
final incubation of 24 h, cells were harvested and assayed for luciferase enzyme activity. Values represent 
the promotor activity of pSPL1000 compared to that of pSLA4 (assigned value of 1).
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Regulation of stably transfected elafin promoter constructs in HaCaT 
cells
As described above, we observed a discrepancy between the transcriptional regulation 
by the endogenous elafin promoter and the regulation by promoter gene sequences 
that were plasmid encoded. In order to gain insight in the regulatory mechanism 
underlying this divergence, we performed experiments using two different stably 
transfected HaCaT cell lines harbouring either a 0.8 kb or a 4 kb elafin promoter 
region, which drives the transcription of an elafin-EGFP gene fusion. The reason that 
in these constructs we used EGFP as a reporter gene instead of luciferase is because 
these clones were generated in a separate study to be used in a fluorescence-based 
high-throughput screening system[358]. Northern blot analysis using a probe directed 
against elafin demonstrated a TNF-α dependent induction of both the endogenous 
elafin mRNA and the elafin-EGFP specific mRNA in either of the clones (Figure 5). 
Note that discrepancies between basal transcription levels of elafin among different 
clones derived from the HaCaT cell line are a commonly observed phenomenon 
(as discussed below). The elafin-EGFP transcript was not detected in unstimulated 
cultures of these clones. In addition, by using an EGFP specific probe we confirmed 
that the elafin-EGFP mRNA is only present in the TNF-α stimulated cultures (results 
not shown). These results indicate that the transgene is subjected to similar regulation 
as the endogenous gene, following cell stimulation with TNF-α. To investigate 
if the promoter construct contained all the necessary information to respond to a 
pharmacological modulator of elafin expression, we used RA, a known inhibitor of 
elafin gene expression[317,360] Addition of RA in the dose range of 10–6, 10–7, 10–8 M 
caused a dose dependent decrease of endogenous elafin mRNA in both unstimulated 
and TNF-α stimulated cultures. We found that RA had no effect on transcriptional 
regulation of elafin-EGFP as witnessed by the mRNA levels, which remained 
Figure 5: Effects of TNF-α and RA on the mRNA expression of elafin and elafin-EGFP in cell cultures of 
stably transfected HaCaT cell lines. Both unstimulated and TNF-α-stimulated (25 ng/ml) cultures of the 
0.8 kb- and the 4 kb-elafinprom clone were treated with indicated amounts of RA for 72 h. Northern blot 
analysis was performed on total RNA isolated from these cultures. Samples were hybridised using a probe 
directed against elafin.
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unchanged for all RA concentrations tested (see Figure 5). These observations were 
confirmed at the protein level by data from two different ELISAs, one specific for 
endogenous elafin protein and the other one specific for the fusion protein transcribed 
from the transgene. Figure 6A and 6B show respectively the concentrations of 
endogenous elafin and the relative levels of elafin-EGFP fusion protein in culture 
medium of TNF-α stimulated cultures of the 0.8kb-elafinprom clone. It was found 
that levels of elafin decreased in a dose dependent way by increasing levels of RA 
whereas no effect of RA was observed on the level of elafin-EGFP fusion protein in 
culture medium.
Figure 6: RA counteracts the TNF-α- 
dependent induction of endogenous elafin 
but not the TNF-α-dependent induction of 
elafin-EGFP fusion protein.
(A) Both unstimulated and TNF-α-stimulated 
cultures of the 0.8 kb-elafinprom clone, were 
treated with indicated amounts of RA for 
72 hours. Levels of endogenous elafin were 
determined from cell culture medium using 
a sandwich-type ELISA specific for elafin. 
Values represent mean ± SD (n=4). *p<0.005 
versus control values of unstimulated 
samples, and **p<0.005 versus control 
values of TNF-α-stimulated samples, by 
one-way analysis of variance with Duncan’s 
multiple comparison test.
(B) Both unstimulated and TNF-α-stimulated 
cultures of the 0.8 kb-elafinprom clone 
and untransfected HaCaT were treated 
with indicated amounts of RA for 72 h. A 
sandwich-type ELISA specific for elafin-
EGFP was used to determine levels of fusion 
protein from cell culture medium. Assay 
background values were obtained from 
culture supernatant of either unstimulated 
or TNF-α-stimulated untransfected HaCaT. 
Levels of elafin-EGFP from samples of the 
0.8 kb-elafinprom clone were expressed 
relative to the background values. Values 
represent the mean ± SD (n=4). An effect 
of RA on levels of elafin-EFGP could not 
be demonstrated (one-way analysis of 
variance).
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Previous studies on the elafin promoter in other cell types have provisionally assigned 
the transcription start site on the basis of the location of a putative TATA box at position 
-94/-89 (all positions mentioned here are relative to the translation start site). Here we 
have experimentally determined the transcription start site of the elafin gene using 
two independent methods. We found that transcription starts at a point different than 
was expected, resulting in a messenger RNA with an unusually short 5’-untranslated 
region (5’-UTR). This would imply that the presumed TATA box is located further 
away from the transcription start site than the canonical 25 basepairs. In view of these 
results we suggest that the TATA-box sequence at position –94/-89 could be non-
functional. Alternatively, at position –48/-42 we found a sequence TAAAGAT, that is, 
with respect to spacing, more likely to serve as the actual TATA box. The fact that this 
proposed TATA-box deviates from the consensus sequence for TATA boxes (TATA[A/
T]A[A/T]) might explain the existence of multiple transcription start points[361]
A previous study by others, using elafin promoter constructs in a mammary epithelial 
cell line, has suggested the importance of an AP-1 site at -545/-539[343]. This was, 
however, not evident in our study as we found no decrease of promoter activity upon 
deletion of a sequence region from -1021 to -440. We found a significant decrease 
of promoter activity upon deletion of the sequence from -440 to -290. This region 
contains three NF-IL6 consensus binding sequences, however, the importance of 
this region has not been demonstrated in promoter constructs described by others 
using epithelial cell lines from other organs. This indicates that expression regulation 
of plasmid-encoded reporter constructs can vary between cell types from different 
tissues, or between primary cells (used by us) and cell lines. Further reduction of 
the elafin promoter region between -170 to –130 virtually abolished all residual 
promoter activity. In this region of the elafin promoter a consensus sequence for the 
transcription factor NF-κB is present at -163 to -154. The importance of this site has 
been established before in transient transfection assays in a lung epithelial cell line[344]. 
We have not further investigated the functional significance of the NF-κB site by 
internal mutation of this site in a larger fragment. 
Our transfection experiments with elafin promoter constructs in keratinocytes 
showed a discrepancy between the expression of these clones and the endogenous 
gene. Whereas the endogenous elafin gene is induced in cultured keratinocytes by 
the addition of 5% FCS, the reporter gene constructs are active under all culture 
conditions. We therefore surmised that the reporter constructs consisting of naked 
plasmid DNA were not suitable to study elafin gene regulation in further detail. 
Using stably transfected reporter constructs in the HaCaT keratinocyte cell line we 
could indeed demonstrate that both a 0.8 and a 4 kb promoter fragment contained 
enough information for TNF-α induction of the transgene. The discrepancy between 
transcription of naked DNA from promoter constructs and the nuclear DNA wrapped 
6.5 DISCUSSION
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in highly organised chromatin structure has been observed frequently[362,362,363,363] 
Therefore, also other processes like silencing elements not present in the transfection 
clones, mRNA stability or higher order chromatin structure might be involved in 
transcription regulation of the endogenous elafin gene. In that respect p38 kinase 
activity, which is crucial for elafin expression in vitro, could play a role. Recently it 
has been described in a number of papers that mRNA can be stabilised through a MAP 
kinase mediated processes including p38[364,365,365], upon cellular stress. With respect to 
mRNA stability the unusual length of the 5’-untranslated region of the elafin mRNA 
could be of some significance, although it has been described that the 3’-UTR rather 
than the 5’-UTR is important for mRNA stability[366,366,367]. 
With respect to basal transcription levels of endogenous elafin (Figure 3), it should be 
noted that these levels are not identical between stably transfected clones tested. This 
can be explained by the fact that the parental HaCaT cell line is indeed a line and not a 
clone. Originally, this line was karyotyped as being aneuploid[266]. We have confirmed 
this aneuploidity and have also found the HaCaT cell line to be heterogeneous with 
respect to chromosome number. It is from this cell line that we obtained single cells 
of which clones were derived. These now can have distinct transcription levels of 
endogenous elafin because they originate from different cells.
The rationale to study regulation of elafin expression was based on the assumption 
that elafin is a model gene for the activated keratinocyte pathway. We reasoned that 
elucidation of elafin induction, regulation of its expression and pharmacological 
manipulation could lead to further insight into the various epidermal differentiation 
pathways or could even shed light on keratinocyte abnormalities e.g. as observed in 
psoriasis. Having established that chromosomal integration of the elafin promoter/
reporter construct was necessary for proper regulation, we asked if these cell lines 
could be used to study the effect of pharmacological manipulation of elafin expression. 
Unfortunately, we found that the expression of the stably transfected reporter 
constructs carrying a 0.8 kb or a 4 kb elafin promoter fragment are not subjected to RA 
induced suppression, as is the case for the endogenous gene. This strongly suggests 
that additional cis-acting sequences or a correct genomic environment is required. 
In conclusion, the results presented in this study show the complex regulation of the 
elafin gene and provide the basis for further studies needed to unravel this gene’s 
molecular regulation mechanism. 
Acknowledgement
Part of this work was supported by a grant from Health Research and Development 
Council (ZonMw 3170.0013), the Netherlands
114  Chapter 6 Transcriptional regulation of the elafi n gene
C
hapter
114  Chapter 6 Transcriptional regulation of the elafi n gene
C
hapter
Gene expression profiling using 
the SKINarray
effects of all-trans retinoic acid on gene 
expression of cultured human keratinocytes
Arno Pol
Gys de Jongh
Rolph Pfundt
Joost Schalkwijk
7
116  Chapter 7 Gene expression profi ling using SKINarray Chapter 7 Gene expression profi ling using SKINarray  117
116  Chapter 7 Gene expression profi ling using SKINarray Chapter 7 Gene expression profi ling using SKINarray  117
Gene expression micro-array technology can be applied to in vitro dermatological 
drug screening, where data may reveal pathways specifically affected by known 
antipsoriatics or lead compounds derived from initial drug screening procedures. 
Here, we used a customised micro-array system (SKINarray) containing 750 cDNAs 
with a relevance for skin biology and inflammation, to analyse the effect of all-trans 
retinoic acid (ATRA) on the gene expression profiles of submerged keratinocyte 
culture systems that can mimic the normal or the psoriatic phenotype of human 
epidermis. The results presented here confirm most of the known effects of ATRA on 
human epidermis and cultured keratinocytes, but also uncover regulation of genes not 
previously known to be retinoid-sensitive. We anticipate the SKINarray to be a highly 
predictive tool, applicable for evaluation of compound specific expression profiles, 
which ultimately may lead to improved pharmaco-therapy for psoriasis.
7.1 ABSTRACT
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The gene expression profile of a cell determines its phenotype, function, and response 
to the environment. The complement of genes expressed by a cell is very dynamic and 
will respond rapidly to external stimuli. Therefore, measurement of gene expression 
can potentially provide clues about regulatory mechanisms, biochemical pathways, and 
broader cellular function. Gene expression can be assessed by measuring the quantity 
of the final product, i.e. the protein, or its intermediate, the mRNA template. The 
efficiency with which one can currently obtain global and quantitative information of 
gene expression by measuring mRNA surpasses the available proteomic technologies, 
which are generally lower throughput, more technologically challenging, and less 
readily compatible with routine material from clinical studies. Nevertheless, the ideal 
scenario would obviously be one where global mRNA expression is measured along 
with global protein expression within the same experiment. Various gene expression 
profiling technologies exist, which are based on systems that are labelled as ‘open’ 
or ‘closed’[368]. Technologies as differential display[369], subtractive hybridisation 
approaches, serial analysis of gene expression[370], or massively parallel signature 
sequencing[371] are categorised under open systems and are generally better suited 
to identify uncharacterised genes within biological systems. Closed systems such as 
gene arrays rely on the availability of gridded clones, cDNAs, or expressed sequence 
tags (ESTs) and are well suited to high throughput screening of multiple samples. 
Gene array applications include comparative genomic hybridisation[372], chromatin 
immunoprecipitation[373,374], mutation detection[375], genotyping[376,377], and microarray-
mediated localised cell transfection[378]. The dominant application of microarrays, 
however, has been in measuring gene expression in different situations, including 
analysis of diseased versus normal tissue[379], profiling tumours and predicting 
outcomes[380-388], studying gene regulation during development[389], and following 
the stimulation of cells in vitro[390]. With respect to the latter, microarray expression 
profiling can be applied to predictive in vitro drug screening, where data may uncover 
pathways specifically affected by compounds analysed. We have previously described 
the development of drug screening models to detect pharmacologically active drugs 
modifying growth and/or differentiation in submerged keratinocyte culture systems 
that can mimic both the normal and psoriatic phenotype of human epidermis[220,391]. 
We aim to extend the initial drug screening procedure by use of a customised skin-
specific cDNA microarray, further referred to as SKINarray, designed to disclose 
the transcriptional effect of known antipsoriatics and lead compounds. We reasoned 
that validation of the SKINarray was best performed with a drug already extensively 
studied in keratinocyte cell culture models with respect to characterisation of effects 
on epidermal differentiation and growth. Based on this criterion, the retinoid all-trans 
retinoic acid (ATRA) was selected. Retinoids (vitamin A and related ligands) are used 
widely in topical and systemic treatment of psoriasis and other hyperkeratotic and 
7.2 INTRODUCTION
118  Chapter 7 Gene expression profi ling using SKINarray Chapter 7 Gene expression profi ling using SKINarray  119
parakeratotic skin disorders, keratotic genodermatoses, severe acne and acne-related 
dermatoses, and also for therapy and/or chemoprevention of skin cancer and other 
neoplasia[392-394]. Retinoids operate through binding to specific nuclear retinoic acid 
receptors, that exist of two major subclasses: the retinoic acid receptors (RAR)-α, -β, 
-γ and the retinoid X receptor (RXR)- α, -β, -γ[124]. The RAR-receptors preferentially 
bind ATRA, while the RXR types preferentially bind 9-cis-retinoic acid[125-127]. 
These receptors are ligand-dependent transcription factors, which bind to specific 
hormone response elements (RARE, RXRE)[128] leading to transactivation of specific 
target genes.  Retinoic acids utilised by the cells are either taken up from the blood 
circulation, or formed from vitamin A via the subsequent action of various retinol 
and retinal dehydrogenases under the influence of intracellular retinol and retinoic 
acid binding proteins (CRBP and CRABP, respectively)[129]. The most extensively 
studied effects of retinoids in psoriasis involve those associated with normalisation 
of the disturbed growth and differentiation of keratinocytes. With respect to epithelial 
differentiation: retinoids enhance morphological features characteristic of simple 
epithelia and inhibit terminal differentiation in epidermis[395,396]. For example, 
in normal human keratinocytes (NHK) ATRA inhibits the in vitro expression of 
differentiation-specific keratins CK1 and CK10[133] and CK6 and CK16[397], and to a 
lesser extent the basal keratins CK5 and CK14[134,135]. The many in vivo and in vitro 
effects of retinoids have been the topic of several comprehensive reviews[398-401]. 
The aggregate of data derived from the numerous individual experiments performed 
with retinoids is a readily available source that can serve to a certain extent to predict 
and validate the outcome of a microarray expression profile. Here, we describe 
the use of ATRA in an investigation aimed to validate the SKINarray as a tool 
for gene expression profiling, and to detect new retinoid sensitive target genes in 
keratinocytes.
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Cell culture
Human epidermal keratinocytes were derived from skin biopsies of healthy 
volunteers to obtain primary cell cultures as described previously[59]. Liquid nitrogen 
stored keratinocytes from these primary cultures were seeded in 75 cm2 cell culture 
flasks (Corning, Schiphol-Rijk, the Netherlands) and cultured in keratinocyte growth 
medium (KGM). KGM was composed of keratinocyte basal medium (KBM) 
(BioWhittaker, Walkersville, MA, USA) supplemented with ethanolamine (0.1 mM) 
(Sigma, St. Louis, MO, USA), phosphoethanolamine (0.1 mM) (Sigma, St. Louis, 
MO, USA), bovine pituitary extract (BPE; 0.4%) (BioWhittaker, Walkersville, 
MA, USA), insulin (5 µg/ml) (Sigma, St. Louis, USA), hydrocortisone (0.5 µg/ml) 
(Collaborative Research Inc, Lexington, MA, USA), recombinant mouse epidermal 
growth factor (EGF; 10 ng/ml) (Sigma, St. Louis, MO, USA), penicillin (100 U/ml) 
(Gibco, Breda, the Netherlands) and streptomycin (100 µg/ml) (Gibco, Breda, the 
Netherlands). Induction of keratinocyte differentiation was established by switching 
the cells at confluence for 48 h either to KGM supplemented with 5% FCS (KGM/
FCS) (Seralab, Nistelrode, the Netherlands) or to KGM depleted of hydrocortisone 
and growth factors (BPE, insulin, and EGF) (KGM/-gf). Immediately before the 
experiment, all-trans retinoic acid (ATRA, Sigma, St. Louis, MO, USA) was diluted 
from stock (1 x 10-2 M in ethanol) to a concentration of 10–6 M in either KGM/FCS 
or KGM/-gf medium and added to the confluent cultures upon switching the culture 
medium. ‘Solvent control’ cultures were included to serve as reference.
Design and manufacturing of the SKINarray
The SKINarray is a cDNA microarray especially designed to study gene expression 
profiles in skin biology. The array contains 750 unique cDNAs, obtained from various 
sources, which are printed in triplicate. The selected cDNAs were chosen on the 
basis of their relevance for skin biology and inflammation. From the Leiden Genome 
Technology Center (LGTC) we purchased around 600 cDNAs derived from the 40K 
cDNA library that was originally constructed by Research Genetics. Approximately 
80 cDNAs were obtained through the Resource Center and Primary Database (RZPD, 
Berlin, Germany; http://www.rzpd.de/). Finally, another 70 to 80 cDNAs were selected 
from an in-house collection of cDNAs that were either cloned at our department or 
obtained through various collaborations. The cDNA inserts were amplified by PCR 
using so-called “universal primers” (forward: 5’-CTA CTA CTA CTA CTG CAA 
GGC GAT TAA GTT GGG TAA-3’, reverse: 5’-ATC ATC ATC ATC GTG AGC GGA 
TAA CAA TTT CAC ACA GGA AAC AGC-3’). Subsequently, inserts were analysed 
and quantified by agarose gel-electrophoresis. The PCR products were purified by 
filtration using Multiscreen purification 96-well plates (Millipore, Billerica, MA, 
USA). The purified inserts were dried by means of a speedvac concentrator and 
7.3 MATERIALS AND METHODS
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dissolved in spotting buffer (150 mM Na
3
PO
4
, 25% DMSO, 1% N-laurylsarcosine) 
at a concentration of approximately 500 ng/µl. The amplified inserts were printed on 
silinated slides (Corning, Schiphol-Rijk, the Netherlands) with a GMS417 pin/ring 
arrayer (Affymetrix, Santa Clara, CA, USA). After printing, the slides were dried 
overnight in the arrayer. Subsequently, slides were cross-linked onto the glass surface 
by UV irradiation (90 mJ/cm2), followed by a two-hour incubation at 80°C after which 
the slides were stored in a vacuum desiccator until further use.
RNA isolation
Total RNA was isolated from cultured keratinocytes using Trizol Reagent according 
to the protocol of the manufacturer (Invitrogen Life Technologies B.V., Breda, the 
Netherlands). Subsequently, the extracted total RNA was further purified using 
RNeasy columns (Qiagen, Valencia, CA, USA), following the “RNA cleanup” 
protocol as provided by the manufacturer. This double purified total RNA was 
dissolved in RNAse free water (NPBI, Emmer-Compascuum, the Netherlands) 
and after the addition of RNAse inhibitor (Amersham Pharmacia biotech, Uppsala, 
Sweden) stored at –80°C until further use. Directly before labelling of cDNA, mRNA 
was isolated from 15 µg of total RNA using OligoTEX columns (Qiagen). The 
obtained mRNA solution was dried in a speedvac concentrator and dissolved in 9 µl 
of RNAse free water.   
Labelling of cDNA
The processing of the purified mRNA to labelled cDNA was performed using the 
CyScribe direct labelling system (Amersham Pharmacia Biotech) in the following 
way. First, 1 µl anchored oligo-dT and 1 µl random nonamers were added to the 
purified mRNA. This mixture was placed for 5 minutes at 70°C. The primers were 
annealed to the RNA by placing the mixture at room temperature for 10 minutes. To 
this primer-RNA mixture the dNTPs, the CyScript RT-enzyme and the Cy3-dUTP or 
Cy5-dUTP were added and the samples were incubated for 120 minutes at 42°C. After 
generation of the cDNA, the reaction was stopped by adding 5 µl 500 mM EDTA. The 
RNA was hydrolysed by adding 1.5 µl 1 M NaOH and incubating the sample for 10 
minutes at 70°C. The sample was neutralised by the addition of 25 µl 1 M Tris/HCl 
(pH 7) and 200 µl water for injection was added. The newly formed cDNA was purified 
by filtration though a Microcon YM30 column. The eluate was checked for purity and 
labelling efficiencies by spectrophotometric analysis. After this analysis the Cy3 and 
Cy5 sample was mixed and 3 µg poly-dA (Amersham Pharmacia Biotech) and 4 µg 
Cot-1 DNA (Roche, Basel, Switzerland) was added. This mix was dried down in a 
speedvac concentrator in the dark. The dried-down labelling mix was dissolved in 55 
µl water for injection and denatured by heating the sample for 3 minutes at 100°C. 
After denaturation 55 µl 2x hybridisation buffer (50% formamide, 10x SSC, 2% SDS) 
was added and the sample was placed at 42°C. Finally, the samples were applied to the 
(pre)treated SKINarrays (see below). 
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(Pre)treatment and hybridisation of slides
All solutions needed for the pre-treatment of arrayed slides were freshly prepared. 
Slides were taken from the vacuum desiccator and dunked into preheated blocking 
solution (100 mM Tris (pH 9), 0.1% SDS, 50 mM ethanol-amine) and incubated for 
45 minutes at 50°C. The slides were subsequently transferred to preheated block-
wash solution (4x SSC, 0.1% SDS) and incubated for 45 minutes at 50°C. After this 
incubation the slides were washed multiple times with water and transferred to a 
beaker with boiling water in order to denature the cDNA probes spotted on the glass 
surface. Finally, the slides were incubated for 45 minutes in pre-hybridisation solution 
(5x SSC, 0.1% SDS, 1% BSA) at 42°C. After pre-hybridisation the slides were 
extensively washed with water and dried by means of centrifugation. Hybridisation 
with target mixture (described above) was carried out under a lifterslip (24x60, Erie 
Scientific Company, Portsmouth, NH, USA) in a volume of 120 µl hybridisation 
buffer (25% formamide, 5x SSC, 0.1% SDS). The slides were transferred to a 
hybridisation chamber (Genemachines, San Carlos, CA, USA) and incubated for 
40 h submerged in a water bath of 42°C. After hybridisation the slides were placed 
in a conical flask containing pre-warmed wash buffer 1 (1x SSC, 0.2% SDS) and 
incubated for 5 minutes at 42°C with occasional shaking. During this initial wash the 
lifterslip slides off by means of gravity. Subsequently, the slides were transferred to 
a slide rack and placed in a beaker containing pre-warmed wash buffer 2 (0.1x SSC, 
0.2% SDS) and incubated for 5 minutes at 42°C. The slide holder with slides was then 
transferred to pre-warmed wash buffer 3 (0.1x SSC) and incubated for 5 minutes at 
room temperature. Finally, slides were briefly dipped in wash buffer 4 (0.01x SSC) 
and immediately centrifuged to dryness (10 minutes, 1000 rpm). Slides were kept in 
the dark until start of the scanning procedure.
Scanning and data analysis
Slides were scanned in an Axon 4100A scanner (Axon Instruments, Union City, CA, 
USA) separately for Cy3 (532 nm) and Cy5 (635 nm) signals. Digitised data was 
analysed using GenePix Pro 4.0 software (Axon Instruments). 
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To study the effect of ATRA on cultured NHK, gene expression profiling was 
performed using a cDNA microarray especially designed to study a selected repertoire 
of genes relevant for skin biology, the SKINarray. NHK were grown to confluence 
in KGM before switching the cultures for 48 h to medium that induces the normal 
phenotype of human epidermis (KGM/-gf) or the psoriatic phenotype of human 
epidermis (KGM/FCS), and to which ATRA was added to a final concentration of 10-6 
M. Under the defined conditions this dosage of ATRA generates no cytotoxic effect 
on NHK[220]. 
The result of a microarray experiment of the keratinocyte culture system mimicking 
the psoriatic phenotype, which was treated with ATRA, is represented in a log
2
/
log
2
 scatter plot (Figure 1). Locally weighted linear regression (lowess)[402] of 
Y=log
2
(signal) and X=log
2
(reference) was used to calculate the log
2
(reference) value 
for each probe. Several reports indicate that the variance of log
2
(ratio) values are 
related to the log
2
(mean) intensity[403,404]. Here we use a simple exponential model to 
7.4 RESULTS AND DISCUSSION
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Figure 1: Scatter plot displaying log
2
(signal) and log
2
(reference) for a SKINarray expression profile of 
normal human keratinocytes, 48 h after addition of 10-6 M all-trans retinoic acid to confluent cultures upon 
a medium switch from KGM to KGM/FCS. The grey line represents the locally weighted linear regression 
(lowess) normalisation curve. Gene codes are indicated of the transcripts with the six highest and six lowest 
RnRel values. (see text for further explanation)
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fit the log
2
(ratio) variance for all triplos to the log
2
(mean) intensity. This estimated 
variance is then used to calculate RnRel, a measure of up- and down regulation 
corrected for the local variance:
  RnRel   = 
 where        R
n
  =    log
2
(signal) - log
2
(reference)
R
n
(Estimated Variance)1/2
RnRel Factor GenBank Gene Class Gene Name
9.52 5.7 NM_002963 S100A7 K S100 calcium binding protein A7 (psoriasin 1)
6.03 2.6 NM_000576 IL1B S Interleukin 1, beta
5.60 3.5 NM_000892 KLKB1 P Kallikrein B, plasma (Fletcher factor) 1
5.46 2.3 NM_000213 ITGB4 A Integrin, beta 4
4.77 2.5 NM_001085 SERPINA3 P Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
4.02 1.9 NM_000610 CD44 A CD44 antigen (homing function and Indian blood group system)
-4.05 -4.2 NM_000596 IGFBP1 G Insulin-like growth factor binding protein 1
-4.18 -2.1 NM_002185 IL7R S Interleukin 7 receptor
-4.19 -2.0 NM_001444 FABP5 M Fatty acid binding protein 5 (psoriasis-associated)
-4.25 -2.0 NM_005348 HSPCA S Heat shock 90kDa protein 1, alpha
-4.25 -2.3 NM_000393 COL5A2 A Collagen, type V, alpha 2
-4.33 -2.5 NM_002750 MAPK8 S Mitogen-activated protein kinase 8
-4.53 -3.6 NM_001799 CDK7 G Cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk-activating kinase)
-4.57 -2.3 NM_003064 SLPI P Secretory leukocyte protease inhibitor (antileukoproteinase)
-4.79 -3.2 NM_006919 SERPINB3 P Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3
-4.99 -2.4 NM_005729 PPIF M Peptidylprolyl isomerase F (cyclophilin F)
-5.31 -5.5 NM_004950 DSPG3 A Dermatan sulfate proteoglycan 3
-6.01 -3.6 NM_173343 IL1R2 S Interleukin 1 receptor, type II
-7.28 -3.6 NM_001185 AZGP1 P Alpha-2-glycoprotein 1, zinc
-7.73 -3.4 NM_002638 PI3 P Protease inhibitor 3, skin-derived (SKALP)
-8.07 -3.7 NM_000359 TGM1 K Transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase)
-8.44 -5.1 NM_002133 HMOX1 S Heme oxygenase (decycling) 1
-9.21 -4.4 NM_001264 CDSN K Corneodesmosin
-16.31 -10.1 NM_018661 DEFB103 H Defensin, beta 103
A
RnRel Factor GenBank Gene Class Gene Name
9.10 6.3 NM_002963 S100A7 K S100 calcium binding protein A7 (psoriasin 1)
5.29 2.4 NM_000213 ITGB4 A Integrin, beta 4
4.99 3.0 NM_003855 IL18R1 S Interleukin 18 receptor 1
4.21 3.0 NM_000892 KLKB1 P Kallikrein B, plasma (Fletcher factor) 1
-4.11 -2.1 NM_000210 ITGA6 A Integrin, alpha 6
-4.16 -2.5 NM_005729 PPIF M Peptidylprolyl isomerase F (cyclophilin F)
-4.40 -3.0 NM_002750 MAPK8 S Mitogen-activated protein kinase 8
-4.47 -2.2 NM_000359 TGM1 K Transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase)
-5.42 -2.6 NM_001444 FABP5 K Fatty acid binding protein 5 (psoriasis-associated)
-5.62 -3.0 NM_002185 IL7R S Interleukin 7 receptor
-6.58 -4.1 NM_002133 HMOX1 S Heme oxygenase (decycling) 1
-7.11 -4.1 NM_021571 ICEBERG S Caspase-1 inhibitor 
-7.28 -3.8 NM_001185 AZGP1 P Alpha-2-glycoprotein 1, zinc
-12.72 -8.5 NM_018661 DEFB103 H Defensin, beta 103
B
The factor given reflects the fold up- or downregulation of the transcript. Corresponding Genbank accession 
number, gene symbol, classification, and gene name are indicated by respectively Genbank, Symbol, Class, 
and Gene name. One-letter classification codes represent the following:
P = proteinase, proteinase inhibitor S = (stress) signalling, inflammation
H = host defence G = growth, proliferation
A = adhesion, extracellular matrix M = metabolism, protein synthesis
K = keratin, differentiation related protein O = other
Table 1: Most prominent differentially expressed transcripts (-4 > RnRel > +4) in normal human 
keratinocytes, 48 h after addition of 10-6 M all-trans retinoic acid to confluent cultures upon a medium 
switch from KGM to KGM/FCS. Panel (A) and (B) represent duplicate experiments.
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   =    log
2
   (as derived from lowess fit)
        
Figure 1 shows the lowess normalisation curve in which the gene codes are indicated 
of the transcripts with the six highest and six lowest RnRel values, located among 
the total of data points of the ATRA-treated culture system mimicking the psoriatic 
phenotype. The borderline for discriminating differential expression was set 
arbitrarily to be 4-fold (+/-) with respect to RnRel. All cDNAs matching this criterion 
are listed in Table 1A in combination with their corresponding gene code, gene 
name, and GenBank accession number. Likewise, data are presented for a duplicate 
A B
C
Figure 2: Phenogram-like rooted trees of differentially expressed transcripts in normal human keratinocytes, 
48 h after addition of 10-6 M all-trans retinoic acid to confluent cultures upon a medium switch from KGM 
to (A) KGM/-gf, (B) KGM/FCS, and (C) KGM/FCS-duplo. Rooted trees are based on associated keywords 
derived from the Swiss-Prot Protein Knowledgebase and the Protein Information Resource (PIR), and 
result as output of PHYLIP software[405].
+: upregulated; ─ : downregulated
(signal)
(reference)
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hybridisation experiment of the KGM/FCS-model (Table 1B), and for a hybridisation 
experiment of the KGM/-gf-model (Table 2).
As stated above, a duplicate experiment was performed for the ATRA-treated culture 
system mimicking the psoriatic phenotype.  Sample material derived from a duplicate 
culture was purified and labelled separately from the sample material used in the 
initial hybridisation. In order to express similarity of the duplicate experiments, data 
were analysed by Spearman Rank Order Correlation. Data points delimited by –1 < 
RnRel < +1, represent a large number of genes, that differ only slightly in value for 
RnRel. Genes located within this window are either not differentially expressed at all 
or their levels of differential expression may be too subtly distinct for detection due to 
noise that is introduced by the many ATRA-independent variables. As a consequence, 
the rank number of a single gene located in this window might differ considerable 
from the rank number in the duplicate experiment. Therefore, to compare replicate 
arrays we included the 176 cases that are delimited by –1 > RnRel > +1. The square 
rank order correlation factor r
s
2 was 0.76 (p< 0.001) (data not shown). In conclusion, 
this indicates that gene expression profiles were highly similar for an independently 
performed duplicate hybridisation experiment using the SKINarray.
A convenient way to visualise relations between large numbers of genes that encode 
proteins is to create a rooted tree diagram based on associated keywords derived from 
the Swiss-Prot Protein Knowledgebase and the Protein Information Resource (PIR). 
We applied PHYLIP software (freely available at http://evolution.genetics.washing
ton.edu/ phylip.html)[405] to data sets of differentially expressed genes for all three 
hybridisations performed, in order to create phenogram-like rooted trees as depicted 
in Figure 2. Prominent clusters of these rooted trees were used, partly in combination 
with classical literature search, as a guide to identify several classes of functional 
molecules. One-letter classification codes are indicated in Table 1 and Table 2, and 
represent the following:
P = proteinase / proteinase inhibitor S = (stress) signalling / inflammation
H = host defence G = growth / proliferation
A = adhesion / extracellular matrix M = metabolism / protein synthesis
K = keratin / differentiation-related protein O = other
In the following two paragraphs members of each of these classes will be discussed 
with respect to their previously (un)noted in vitro/in vivo expression and/or regulation 
by ATRA in keratinocytes. 
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RnRel Factor GenBank Symbol Class Gene name
19.07 12.8 NM_002963 S100A7 K S100 calcium binding protein A7 (psoriasin 1)
17.48 4.5 NM_005547 IVL K Involucrin
12.44 2.7 NM_001769 CD9 A CD9 antigen (p24)
11.85 4.0 NM_001908 CTSB P Cathepsin B
11.21 3.6 NM_000576 IL1B S Interleukin 1, beta
11.03 3.8 NM_000213 ITGB4 A Integrin, beta 4
10.59 6.5 NM_003914 CCNA1 G Cyclin A1
10.15 5.0 NM_000892 KLKB1 P Kallikrein B, plasma (Fletcher factor) 1
10.05 3.1 NM_013230 CD24 O CD24 antigen (small cell lung carcinoma cluster 4 antigen)
10.01 3.7 NM_002203 ITGA2 A Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
8.28 3.6 NM_001085 SERPINA3 P Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
7.07 3.7 NM_000362 TIMP3 P Tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)
6.44 1.9 NM_001323 CST6 P Cystatin E/M
6.41 2.5 NM_003855 IL18R1 S Interleukin 18 receptor 1
6.27 2.2 NM_001898 CST1 P Cystatin SN
6.13 2.2 NM_000577 IL1RN S Interleukin 1 receptor antagonist
6.01 2.5 NM_001251 CD68 O CD68 antigen
5.92 2.1 NM_001557 IL8RB S Interleukin 8 receptor beta
5.75 1.9 NM_003110 SP2 M Sp2 transcription factor
5.59 1.9 NM_000610 CD44 A CD44 antigen (homing function and Indian blood group system)
5.51 1.8 NM_002638 PI3 P Protease inhibitor 3, skin-derived (SKALP)
5.48 2.0 NM_000611 CD59 A CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)
5.34 1.7 NM_000526 KRT14 K Keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner)
5.33 2.2 NM_005218 DEFB1 H Defensin, beta 1
5.32 1.7 NM_003264 TLR2 H Toll-like receptor 2
5.26 2.1 NM_000648 CCR2 S Chemokine (C-C motif) receptor 2
5.15 2.2 NM_004345 CAMP H Cathelicidin antimicrobial peptide
5.03 2.1 NM_002450 MT1L S Metallothionein 1L
4.99 2.7 NM_005949 MT1F S Metallothionein 1F (functional)
4.87 2.3 NM_005947 MT1B S Metallothionein 1B (functional)
4.79 1.8 NM_001909 CTSD P Cathepsin D (lysosomal aspartyl protease)
4.77 1.8 NM_003254 TIMP1 P Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)
4.72 1.8 NM_006919 SERPINB3 P Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3
4.62 1.7 NM_001675 ATF4 M Activating transcription factor 4 (tax-responsive enhancer element B67)
4.58 1.7 NM_145869 ANXA11 S Annexin A11
4.55 1.9 NM_001911 CTSG P Cathepsin G
4.37 1.9 NM_006090 CEPT1 M Choline/ethanolaminephosphotransferase
4.34 1.9 NM_003238 TGFB2 G Transforming growth factor, beta 2
4.24 1.8 NM_004139 LBP H Lipopolysaccharide binding protein
4.19 1.8 NM_002770 PRSS2 P Protease, serine, 2 (trypsin 2)
4.15 2.3 NM_005953 MT2A S Metallothionein 2A
-4.15 -2.0 NM_001775 CD38 A CD38 antigen (p45)
-4.19 -1.7 NM_000494 COL17A1 A Collagen, type XVII, alpha 1
-4.51 -1.8 NM_000142 FGFR3 G Fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism)
-4.62 -1.9 NM_005555 KRT6B K Keratin 6B
-5.35 -1.8 NM_005213 CSTA P Cystatin A (stefin A)
-5.35 -1.9 NM_000094 COL7A1 A Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)
-5.44 -1.9 NM_000299 PKP1 A Plakophilin 1 (ectodermal dysplasia/skin fragility syndrome)
-5.76 -2.0 NM_033641 COL4A6 A Collagen, type IV, alpha 6
-5.81 -2.0 NM_000210 ITGA6 A Integrin, alpha 6
-5.96 -2.0 NM_020548 DBI M Diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding protein)
-6.04 -2.0 NM_000424 KRT5 K Keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types)
-6.84 -2.7 NM_001918 DBT M Dihydrolipoamide branched chain transacylase 
-13.75 -7.1 NM_000421 KRT10 K Keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris)
The factor given reflects the fold up- or downregulation of the transcript. Corresponding Genbank accession 
number, gene symbol, classification, and gene name are indicated by respectively Genbank, Symbol, Class, 
and Gene name. One-letter classification codes represent the following:
P = proteinase, proteinase inhibitor S = (stress) signalling, inflammation
H = host defence G = growth, proliferation
A = adhesion, extracellular matrix M = metabolism, protein synthesis
K = keratin, differentiation related protein O = other
Table 2: Most prominent differentially expressed transcripts (-4 > RnRel > +4) in normal human 
keratinocytes, 48 h after addition of 10-6 M all-trans retinoic acid to confluent cultures upon a medium 
switch from KGM to KGM/-gf .
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EFFECT OF ATRA ON NHK IN A MODEL FOR NORMAL 
EPIDERMAL DIFFERENTIATION (KGM/-GF)
Class P: proteinases / proteinase inhibitors 
Proteinases (endopeptidases) are considered to be the key enzymes in degradative 
processes, because the protein components of most matrices (collagens, proteoglycans, 
elastin, fibronectin, and laminins) are the predominant determinants of tissue structure 
and function. Intracellularly, proteinases are involved in diverse processes such as 
turnover, activation and antigen processing. The four major classes of proteinases 
are: matrix metalloproteinases, serine proteases, cysteine proteinases, and aspartic 
proteinases. Five upregulated gene transcripts were identified that are members of 
three of these classes of proteinases. The aspartic proteinase cathepsin D (CTSD) 
and the cysteine proteinase cathepsin B (CTSB) are involved in the intracellular 
digestion (lysosomal) of phagocytosed material. The serine proteinase cathepsin G 
(CTSG) has a specificity similar to that of chymotrypsin C. It is known that during 
the process of skin inflammation human neutrophils release cathepsin G within the 
epidermis. Electron-microscopy of cathepsin G-treated full thickness human skin, 
showed widening of the extracellular space followed by complete separation of 
keratinocytes without intradesmosomal cleavage[406]. Expression of cathepsin G in 
NHK has thus far not been described. The role of cathepsin G in keratinocytes upon 
induction by ATRA is unclear at present. Two additional serine proteases that showed 
upregulated gene transcripts are serine protease-2 (PRSS2) and plasma prekallikrein 
(KLKB1). The latter is a precursor of plasma kallikrein, member of the trypsin family 
of serine proteases that acts on kininogens to generate bradykinin. In addition, plasma 
kallikrein activates procollagenases 1 and 2 and prostromelysin 1, all proenzymes 
involved in the process of matrix protein degradation. 
In order to efficiently regulate the degradative events of proteinases, a large 
abundance and diversity of proteinase inhibitors are present in the cell or in 
connective tissue. We found the induction of proteinases in the presence of ATRA to 
be accompanied by the upregulation of several protease inhibitors. Two inhibitors of 
matrix metalloproteinases were identified: TIMP1 and TIMP3. TIMP1 is produced 
by many cell types, including keratinocytes[407,408], and has been described to be 
upregulated by retinoids in human bronchoalveolar lavage cells[409] and capillary 
endothelial cells[410]. In addition, two cysteine proteinase inhibitors were upregulated: 
cystatin 1 (CST1) and 6 (CST6), that belong to the type 2 cystatins. Remarkably, the 
cysteine proteinase inhibitor cystatin A (CSTA), which belongs to the type I cystatins 
(stefins), was downregulated. This cystatin is synthesised without a signal sequence 
and is confined to the cell, although the protein has been found in extracellular fluids 
as well[411]. Cystatin A forms tight complexes with papain and the cathepsins B, H, and 
L. Besides, cystatin A also functions as one of the precursor proteins of the cornified 
cell envelope in keratinocytes. Since ATRA is well-known to inhibit the process of 
terminal differentiation it might be that cystatin A is regulated in this pathway and 
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therefore behaves distinctly from the other cystatins.
Inhibitors of serine proteases were represented by two members of the serpin 
superfamily (SERPINA3 and SERPINB3), and by skin-derived anti-leukoproteinase 
(SKALP), which is an alias of the protein product of protease inhibitor 3 (PI3). 
Protein levels of SERPINA3 were elevated in vitro when human hepatoma cells were 
cultured in presence of ATRA[412]. No reports are present on the effect of ATRA on 
SKALP regulation in keratinocytes cultured in growth factor-depleted medium. It is 
well-documented, however, that growth factor depletion leads to nearly undetectable 
levels of SKALP both at mRNA and protein level, which is in contrast to the relative 
high levels that result from serum-stimulation[59,78]. In the latter case, ATRA results in 
a marked down-regulation of SKALP[220,317]. 
Class H: host defence
The epidermis of human skin constitutes a major barrier to the environment and 
provides the first line of defence against invading microbes. Among the participants 
of the innate immune system of human skin that are involved in this process of host 
defence are antimicrobial peptides and specific surface receptors. As a result of 
the addition of ATRA to the culture system, 4 transcripts of genes involved in host 
defence were upregulated. These included messenger for two human antimicrobial 
peptides: beta defensin 1 (DEFB1) and LL-37, the latter being encoded for by the 
gene called cathelicidin antimicrobial peptide (CAMP). Toll-like receptor 2 (TLR2), 
which presence on human epidermal keratinocytes has recently been discovered[117], 
is a surface receptor that can recognise microbial-derived molecules and is thereby 
an important mediator of the innate immune response in human epidermis. 
Lipopolysaccharide (LPS) binding protein (LBP) is involved in acute-phase response 
and xenobiotic metabolism and response to pathogenic bacteria. 
Class A: adhesion molecules / extracellular matrix constituents
It has been shown that keratinocyte adhesion of cells cultured in growth factor-
deficient medium in the presence of ATRA is markedly inhibited, as measured by 
the resistance to trypsin-mediated release from the substrate and attachment to the 
substrate[145]. In the data presented here, we found a number of adhesion molecules to 
be differentially regulated by ATRA. Integrins are heterodimeric integral membrane 
proteins, composed of an alpha chain and a beta chain, which are known to participate 
in cell-cell and cell-matrix adhesion, as well as cell-surface mediated signalling. The 
observed upregulation of integrin beta 4 (ITGB4) and integrin alpha 6 (ITGA2) 
mRNA confirms earlier observations where ATRA exerted similar in vitro effects in 
respectively NHK[413] and HaCaT[414]. We found integrin alpha 6 (ITGA6) mRNA 
to be downregulated under growth factor depleted culture conditions in presence of 
ATRA. Similarly, ITGA6 is downregulated by ATRA at the mRNA level in cultures 
of NHK grown in serum-free medium supplemented with EGF[413]. This implies that, 
at least in vitro, the expression of ITGB4 and ITGA6 is differentially regulated by 
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ATRA.
Three genes encoding collagens that are molecular components of the dermal-
epidermal junction were downregulated. COL4A6 encodes one of the six subunits of 
type IV collagen, the major structural component of the basement membrane (lamina 
densa), which provides a basic three-dimensional scaffold through association 
with several ligands, including COL7A1. The latter collagen is the main structural 
component of the anchoring fibrils, which often enmesh dermal collagen fibrils, thus 
ensuring the connection between the anchoring complex and the dermal extracellular 
matrix. Retinoid-mediated inhibition of type VII collagen mRNA expression has 
been described for NHK growing in serum-free keratinocyte growth medium[415]. 
COL17A1 encodes the alpha chain of type XVII collagen, a transmembrane 
protein and a structural component of hemidesmosomes. These are multiprotein 
complexes at the dermal-epidermal basement membrane zone that mediate adhesion 
of keratinocytes to the underlying membrane. With respect to this, it should be noted 
that those mutations in COL17A1 that lead to the absence of the protein from skin, 
cause generalized atrophic benign epidermolysis bullosa (GABEB), a skin disease 
characterised by blistering, slight skin atrophy and temporal alopecia[416-420]. However, 
effects of oral administration of retinoids on uninvolved skin in psoriatic patients 
are merely associated with skin fragility without epidermal blistering. It therefore 
remains to be elucidated in what way and to what extent the observed downregulation 
of the above-mentioned collagens in vitro parallels the (side-)effect of ATRA in 
human skin.
Desmosomes are adhesive intercellular junctions that link adjacent cells and provide 
anchoring points for the keratin filament cytoskeleton, thereby contributing to the 
cohesion of epidermal keratinocytes. One of the desmosomal structural components 
is plakophilin 1 (PKP1). Total ablation of plakophilin 1 causes clinical features 
of the affected individuals as skin fragility and ectodermal dysplasia with loss of 
hair, reduced sweating and nail dystrophy[421]. Notably, an undesirable side-effect 
of retinoid treatment is skin fragility. In a study where ATRA was applied to normal 
skin, immunohistochemical analysis revealed that several desmosomal constituents, 
including plakophilin 1, were significantly reduced[422]. Our data of reduced mRNA 
levels for PKP1 are in accordance with the observations described above.     
A number of CD-antigens were identified as being differentially regulated: CD9, 
CD44, CD59, CD68 mRNA levels increased, while messenger for CD38 decreased 
with respect to untreated controls. The current knowledge on specific functions of 
most of these CD antigens in keratinocyte biology is limited. CD9 and CD44 have 
been detected in immunoprecipitates together with the cell-surface heparan sulfate 
proteoglycan syndecan, a major collagen receptor. 
CD44 is a transmembrane glycoprotein and the major cell surface receptor for the 
extracellular matrix component, hyaluronan (HA). Synthesis of all CD44 variants is 
strongly downregulated when cultured keratinocytes become confluent or when they 
normally differentiate[423]. When skin organ culture of human epidermis are treated 
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with retinoic acid, normal differentiation is disturbed, and levels of HA are 70% 
elevated with respect to untreated controls[424]. The observed upregulation of CD44 in 
our study seems in accordance with these earlier observations. Moreover, binding of 
growth factors to proteoglycans via glycosaminoglycans (GAGs) has been proposed 
to provide a mechanism for growth factor recruitment at the cell surface, presentation 
to specific receptors, regulation of their action on target cells at short range, and 
establishment of a growth factor gradient within tissues[425-427]. A role of CD44 
and TGF-β (also upregulated in this model) has been described in a physiological 
mechanism of tissue remodelling involving the matrix metalloproteinases-9. MMP-9 
localization to the surface of NHK is dependent on CD44, where it proteolytically 
cleaves latent TGF-β, providing a novel and potentially important mechanism for 
TGF-β activation. 
 
Class K: keratins, differentiation related proteins
Keratins are the major intermediate filamentous proteins of epithelial cells, and occur 
at their greatest density and complexity in the keratinocytes of the epidermis. The 
expression pattern of keratins changes with the state of differentiation. ATRA is well-
known for its potent modulation of keratinocyte differentiation. Human keratinocytes 
cultured in presence of RA have shown diminished expression of epidermal keratins 
CK1, CK10[133,283]; CK6, CK16[134]; and CK5, CK14[134,135]. Our data confirm the 
inhibition observed for keratins 5 (KRT5), 6 (KRT6B), and 10 (KRT10). However, 
the observed upregulation of KRT14 was not in accordance with a literature report by 
Kunchala et al., who showed that levels of KRT14 were decreased upon addition of 
ATRA to cultures of NHK[428].
Involucrin (IVL) is a major component of the cornified envelope and a marker for 
terminal differentiation in keratinocytes. While ATRA stimulates the in vivo expression 
of involucrin[429], conflicting outcome has resulted from in vitro experiments so 
far[283,430]. Here, data indicate that ATRA is capable to markedly induce mRNA levels 
of involucrin in an experimental setting of autocrine cell culture comparable to the 
one used by Poumay et al.[283] 
Psoriasin (S100A7) is a transglutaminase substrate[431], and a member of the S100 
family of proteins, that is involved with cell cycle progression and differentiation. 
Besides, a role has been implicated in the inflammatory response, where it can serve as 
a potent and selective chemotactic inflammatory protein for CD4+ T lymphocytes and 
neutrophils[432]. The protein was originally found to be highly expressed in psoriatic 
skin[84], and later also in the involved skin of patients with other hyperproliferative 
and inflammatory skin diseases, like atopic dermatitis, mycosis fungoides, Darier’s 
disease and inflammatory lichen sclerosus et atrophicus[433]. We identified S100A7 as 
the highest upregulated gene with a 12.8-fold induction at the mRNA level. At present, 
there is limited information on the regulation of S100A7 by ATRA. However, mRNA 
levels of RIS-1, which is identical to psoriasin, were shown to be highly inducible by 
ATRA, both in normal human skin and in cultured human keratinocytes[434].
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Class S: (stress) signalling, inflammation
The addition of ATRA resulted in an induction of 9 transcripts that were related to 
signalling and inflammation. Notably, 4 out of 9 are isoforms of two metallothionein 
subfamilies (MT1L, MT1F, MT1B, MT2A). Metallothioneins are proteins with 
heavy-metal binding activity that can be active in metal homeostasis and protect 
against heavy-metal toxicity.  Besides, metallothionein-1 and –2 are readily inducible 
in most tissues by exposure to some of the acute phase cytokines (e.g. interleukin 
(IL)-1, IL-6)[435]. Metallothionein can be released to the extracellular environment 
via unknown mechanisms, where it can interact with cells of both innate and 
adaptive immune response[436-438]. More recently, metallothionein-1 and –2 showed 
to reduce the proinflammatory mediators tumour necrosis factor alpha (TNF-α) and 
cyclooxygenase-2 (Cox-2) in a murine experimental model of rheumatoid arthritis[439]. 
The mechanism by which MT1 and MT2 exert their effects is currently unknown.
In addition, keratinocytes responded to ATRA by upregulation of various inflammation-
related molecules. One of these was IL-1β (IL1B), a member of the IL-1 cytokine 
family. This cytokine is an important mediator of the inflammatory response, and is 
involved in a variety of cellular activities, including cell proliferation, differentiation, 
and apoptosis. In human epidermis, basal keratinocytes are the main source of IL-1, 
and IL-1α is the predominant form, whereas IL-1β appears to exist predominantly 
in cultured keratinocytes. ATRA induced mRNA levels of IL-1β when NHK were 
cultured in low calcium serum-free medium[440]. Besides IL-1β, the IL-1 receptor 
antagonist (IL1RN) was also upregulated in our experimental set-up. This protein 
competitively inhibits the activity of IL-1(α/β) by binding to its receptors thereby 
attenuating the response of the inflammatory mediator[441]. Alternatively, Bernard et 
al. have suggested that epidermal keratinocytes generate IL-1 receptor antagonist in 
order to protect themselves from the IL-1 they produce. This might also indicate that 
the IL-1 message is not dedicated to keratinocytes themselves, but to other underlying 
responsive cells, such as the dermal fibroblasts or cells of the immune system[442].
Moreover, two transcripts encoding receptors for interleukins were upregulated as 
well. The observed increase of IL-18 receptor (IL18R1) by ATRA was not reported 
earlier in literature. IL-18 is related to IL-1β more than any other cytokine, based on 
the resemblance in structure, and in biological and postreceptor properties[443]. Il-18 
is constitutively expressed in human keratinocytes[444] and  the receptor for IL-18 
has been detected in the cell periphery in living keratinocyte cell layers of human 
epidermis[445]. Besides its firstly discovered activity of induction of interferon-gamma 
(IFN-γ) production, IL-18 has wider effects in the regulation of immune responses 
(e.g. stimulation of Th1 responses, activation of NK cells). However, the precise role 
of IL-18 and its receptor in keratinocyte biology are not yet understood.  
Transcription levels of the IL-8 receptor beta (IL8RB) were also increased by ATRA. 
This receptor binds to IL-8 with high affinity, but can also bind to growth-related 
oncogene alpha (MGSA/GRO-α). It has been demonstrated that MGSA/GRO-α 
and IL-8 receptor beta are expressed during wound healing by keratinocytes and 
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endothelial cells at areas where epithelialisation and neovascularisation occur. 
Interestingly, IL8RB-knockout mice show delayed wound healing. Moreover, in 
vitro wounding experiments with cultures of keratinocytes established from -/- and 
+/+ mice revealed a retardation in wound closure in IL8RB -/- keratinocytes[446]. 
These above mentioned observations are interesting in light of the fact that it has 
been consistently observed both in animal models[447] and clinical settings[448-450] that 
treatment of the skin with retinoids prior to wounding improves re-epithelialisation. 
Taken together, one possible explanation for this phenomenon is that, due to ATRA 
pre-treatment, levels of IL-8, MGSA/GRO-α, and IL-8 receptor beta are elevated, 
thereby enhancing keratinocyte proliferation and migration. Data from several studies 
are consistent with this theoretical model. Namely, ATRA initiates proliferation in 
keratinocytes that are growth-suppressed due to growth factor deficient medium[145], 
suggesting that this retinoid may in vivo stimulate quiescent epidermal keratinocytes 
and thus accelerate keratinocyte proliferation at around the time of wound healing. 
Moreover, ATRA increased the expression and release of IL-8 in both normal human 
epidermis and in a human skin equivalent[451]. Furthermore, addition of MGSA/
GRO-α and IL-8 to organotypic raft culture, which resembles in vivo skin in several 
respects, resulted in a markedly enhanced keratinocyte growth[452]. 
CCR2 encodes two isoforms of a receptor for monocyte chemoattractant protein-1 
(MCP-1), a chemokine that specifically mediates monocyte chemotaxis. Surprisingly, 
expression of CCRs is not confined to monocytic cells alone. Several CC chemokine 
receptors (-1, -3, and -5) have also been detected on the surface of (cultured) human 
keratinocytes[453-455]. The increased CCR2 expression that we observed in response to 
ATRA has not been reported previously.
Annexins are highly conserved proteins that are characterised by their ability to 
interact with phospholipids in a calcium-dependent manner. Although diverse 
functions have been ascribed to annexins based on in vitro analyses, their in vivo 
functions still remain unclear. Annexin A11 (ANXA11) is one of 12 vertebrate 
subfamilies in the annexin superfamily of calcium/phospholipid binding proteins, 
distinguishable by long, non-homologous N-termini rich in proline, glycine and 
tyrosine. To the best of our knowledge, expression of ANXA11 in keratinocytes has 
not been earlier reported.  
Class G: growth, proliferation
Three genes involved with growth and proliferation were identified. The upregulated 
CCNA1-messenger encodes for cyclin A1, a protein that belongs to the highly 
conserved cyclin family, whose members are characterised by a dramatic periodicity 
in protein abundance through the cell cycle. To date, reports on CCNA1 have been 
limited to its description in testis and brain[456].
Levels of transforming growth factor-beta 2 (TGFB2) mRNA were also increased. 
Functions of this growth factor are pleiotropic since TGF-β
2
 is involved with cell 
growth and proliferation, cell-cell signalling, regulation of cell cycle, and signal 
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transduction. Effects of TGF-βs in relation with retinoids have predominantly been 
associated with growth regulation and differentiation modification. Induction of 
TGF-β
2
 by ATRA has been described for mouse keratinocytes both in vitro and in 
vivo. In mouse keratinocytes, ATRA concentrations of 10-6 M are sufficient to inhibit 
proliferation, and TGF-β seemed to mediate these antiproliferative effects[457]. ATRA 
also increased the secreted levels of latent TGF-β
1
 and TGF-β
2
 in culture medium 
of NHK. It has been suggested that both factors, after activation at the cell surface, 
could inhibit cellular proliferation in an autocrine and/or paracrine manner[458]. In a 
skin raft culture where most morphological and biochemical features of epidermis 
in vivo are retained, TGF-β
2
 inhibited normal keratinisation in suprabasal cells and 
promoted the type of differentiation commonly associated with wound-healing and 
epidermal hyperproliferation[459]. In contrast, Fisher et al. observed a 50% induction 
of TGF-β
1
 protein, but no detectable change in TGF-β
2
 as cultured NHK were treated 
with retinoic acid[460].
The transcript of fibroblast growth factor receptor 3 (FGFR3) was downregulated. 
The extracellular portion of this type of receptor interacts with fibroblast growth 
factors, setting in motion a cascade of downstream signals, ultimately influencing 
mitogenesis and differentiation. Expression of FGFR3 in human keratinocytes has 
been described by Pilcher et al.[461]. Downregulation of the FGF3-receptor has to date 
only been observed during retinoic acid-induced differentiation of Tera-2 human 
embryonal carcinoma cells. Differentiation led to loss of FGFR-4 mRNA expression, 
where mRNA levels for FGFR-2 and FGFR-3 were considerably downregulated, and 
mRNA levels for FGFR-1 remained unaltered[462].
Class M: metabolism, protein synthesis
Genes classified here are generally expressed in almost all cell types. Little is 
known with respect to their regulation by ATRA and their specific role in human 
keratinocytes (or even in epidermis). By necessity, we therefore limit this section to a 
brief description of the genes.
Messenger RNA-levels of two transcription factors were increased. Sp2 (SP2) 
contains a highly conserved DNA-binding domain composed of three zinc fingers 
and serine/threonine- and glutamine-rich domains. Sp2 should not be considered a 
member of the Sp family, that consists of Sp1, Sp3, and Sp4, because it has more 
similarity to non-Sp transcription factors[463]. ATF4 encodes a transcription factor 
widely expressed in human tissues, suggesting that it may be involved in regulating 
transcription in a wide variety of cells. ATF4 is activated by translation initiation 
factor eIF2α, which gets activated by a single-event phosphorylation resulting from 
of multiple intracellular stress pathways[464]. 
Two genes involved in lipid metabolism were found to be downregulated. Human 
diazepam binding inhibitor (DBI) is expressed in human skin. The physiological 
role in skin remains unknown to date but it has been proposed that its activity could 
be related to the regulation of lipid and cholesterol synthesis in keratinocytes[465]. 
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Dihydrolipoamide branched chain transacylase (DBT), the so-called E2 component 
of branched chain keto acid dehydrogenase complex, is a protein harbouring 
acyltransferase activity. Its expression in keratinocytes has not earlier been reported.
In contrast, another gene with a role in lipid metabolism showed a decreased level of 
transcription. The CEPT1-gene codes for choline/ethanolaminephosphotransferase, 
whose function is related to phospholipid biosynthesis. The protein can synthesise 
either choline- or ethanolamine-containing phospholipids.
EFFECT OF ATRA ON NHK IN A MODEL FOR PSORIATIC 
DIFFERENTIATION (KGM/FCS)
In this paragraph we will refrain from repetition of the basic explanatory text parts on 
gene names that were already clarified under “Effect of ATRA on NHK in a model for 
normal epidermal differentiation (KGM/-gf)”. Gene codes of these specific transcripts 
are underlined to indicate that information can be found in the section above.
Class P: proteinases / proteinase inhibitors
The serine protease plasma prekallikrein (KLKB1), also upregulated in the growth 
factor- depleted model system, showed a near identical increase in mRNA transcript 
level in the serum stimulated-model. Of the four serine proteinase inhibitors that 
were differentially regulated, SERPINA3 was the only upregulated transcript, while 
SERPINB3, PI3, and the secretory leukocyte inhibitor (SLPI) were all downregulated 
by ATRA. Remarkably, PI3 (SKALP) was found to be upregulated by ATRA in the 
growth factor-depleted model. In a previous study we have found that systemic 
administration of retinoids to psoriatic patients can induce SKALP expression in 
uninvolved skin, whereas SKALP expression in lesional skin is suppressed[321]. This 
again demonstrates that retinoids have profoundly distinct effects on uninvolved and 
involved epidermis, which is reflected in the effect on the two model systems.
SLPI is a proteinase inhibitor that besides its expression in several glandular 
epithelia, is also expressed at low level in normal human skin[306]. We previously 
showed that SLPI is markedly upregulated in psoriatic skin and in healing wounds, 
while expression can be highly upregulated in cultured keratinocytes by addition 
of FCS[306]. SLPI inhibits leukocyte-derived proteinases[466,467], has anti-HIV-1[468], 
antibacterial[306,469], and anti-inflammatory properties, and interferes with the induction 
of synthesis of proinflammatory mediators in monocytes and macrophages[470,471]. 
In a study with normal human tracheobronchial epithelial cells ATRA showed to 
decrease levels of SLPI both at the mRNA level and at the protein level[472,473]. The 
downregulation of SLPI mRNA that resulted from addition of ATRA to our serum-
supplemented model system harmonises with these earlier reports.
AZGP1, zinc-α2-glycoprotein 1, was originally isolated from the upper granular layer 
and the stratum corneum of human epidermis, and named desquamin for its believed 
major role in desquamation[474]. Later, it was discovered that AZGP1 also harboured 
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trypsin-like serine proteinase activity[475], and ribonuclease activity[476]. Messenger for 
AZGP1 was induced in NHK, but decreased in keratinocytes from psoriatic lesion, 
upon culturing in presence of high calcium, serum, and induction by IFN-γ[477]. Due 
to the pleiotropic functions of AZGP1, and the absence of ample quantity of related 
literature, there is no unambiguous conclusion to be drawn from the downregulation 
of AZGP1 observed in our model system. 
Class H: host defence
DEFB103 is the gene code for the anti-microbial peptide human beta defensin-3. The 
mRNA level of DEFB103 was, by far, the most profoundly downregulated among 
all transcripts, with an approximately 10-fold decrease in expression level. This anti-
microbial peptide was originally isolated from human lesional psoriatic scales and 
cloned from keratinocytes. Investigation of different tissues revealed skin and tonsils 
to be the major expressing tissues of DEFB103 mRNA[478]. There have been no reports 
on the downregulation of human beta defensin-3 by ATRA. 
Class A: adhesion molecules / extracellular matrix constituents
Several transcripts of this class (ITGA6, ITGB4, CD44), that all possess functions 
related to adhesion, were identically up- or downregulated in our two model systems. 
Although ATRA induces in general profoundly distinct effects on uninvolved and 
involved epidermis, these in vitro observations indicate that there is no differential 
effect of ATRA on regulation of these adhesion-related transcripts.
COL5A2 encodes a subunit of collagen type V, which is a relatively minor component 
of the extracellular matrix but shares a close structural relationship with the major 
fibrillar collagen (types I-III). It has been implicated in regulating the diameter of 
types I and II collagen fibrils. This was a surprising finding since expression of 
COL5A2 has to date only been described in fibroblasts.
DSPG3 is the third member of the small dermatan sulfate proteoglycan family 
along with biglycan (PG-I) and decorin (PG-II). The protein contains three potential 
glycosaminoglycan attachment sites, two N-glycosylation sites, a poly- glutamic acid 
stretch, and six cysteines. By Northern analysis, it was demonstrated that DSPG3 is 
expressed in cartilage, as well as ligament and placental tissues[479]. Dermatan sulfate, 
the predominant glycosaminoglycan in human skin, is the principle cofactor for FGF-
7 (alias KGF)[480], a polypeptide mitogen that is induced after injury and promotes the 
proliferation of keratinocytes[481-484]. Ultrastructural analysis has shown that increased 
levels of dermatan sulphate exist in psoriatic epidermis as compared to normal 
epidermis[485]. However, the here-described downregulation of DSPG3 by ATRA is 
the first reported observation with regard to regulation in keratinocytes.
Class K: keratins, differentiation related proteins
Psoriasin (S100A7) was identified as being the transcript with the highest level of 
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induction in both models. The upregulation observed in the serum-supplemented 
model was an unexpected result. After all, S100A7 mRNA is highly expressed in 
keratinocytes of psoriatic skin while it is nearly absent in normal skin[84,433], suggesting 
it to be a marker molecule for psoriasis. As successful treatment of psoriatic skin with 
ATRA is associated with normalisation of the epidermal phenotype, we anticipated 
S100A7 mRNA levels to be decreased in our serum-supplemented model in the 
presence of ATRA. The possibility exists that the increased levels of S100A7 are 
merely associated with an irritative effect of ATRA.
Corneodesmosin (CDSN) is a late differentiation epidermal glycoprotein 
putatively involved in keratinocyte adhesion, and located in the extracellular part 
of the desmosomes. It is a preferred substrate of two serine proteases involved in 
desquamation, the stratum corneum tryptic and chymotryptic enzymes[486]. In lesional 
poriasis, a significant increase in CDSN expression has been observed, as compared to 
the expression in nonlesional and normal epidermis[487]. Although effects of ATRA on 
CDSN regulation have not been reported, the downregulation of CDSN in our model 
correlates with the well-known property of ATRA to inhibit the process of terminal 
differentiation.
Assembly of the insoluble cornified cell envelope (CE) is a hallmark of terminally 
differentiated keratinocytes. The enveloped structure contributes to the structural 
stability and barrier function of the epidermis. Transglutaminase type 1 (TGase1), 
or keratinocyte transglutaminase (TGaseK), plays a major role in the process of 
protein cross-linking associated with the assemblage of the CE[49,488]. Defects in the 
transglutaminase type I (TGM1) gene interfere with normal CE formation, resulting in 
the severe skin disorder lamellar ichthyosis (LI)[489]. Homozygous TGM1 -/- knockout 
mice are born with an abnormal epidermis symptomatic of the human disease, and die 
soon after birth[490]. The TGase1 enzyme is limited to the upper layers of stratifying 
epithelium in vivo, while the mRNA is generally present throughout the epidermis, 
suggesting the possibility of posttranscriptional regulation[491]. Immunohistochemical 
analysis of retinoid-treated psoriatic epidermis showed decreased levels of 
TGase[321,492]. Moreover, TGM1 mRNA is also expressed in cultured keratinocytes[491], 
where ATRA showed to effectively reduce both mRNA[493,494] and protein[495] levels 
of TGase1. The downregulation of TGM1 transcript as detected in our model is in 
accordance with these earlier reports. 
Class S: (stress) signalling, inflammation
Two transcripts of this class were also upregulated in the growth factor-depleted 
model: IL-1 beta (IL1B) and the receptor for IL-18 (IL18R1). The induction of IL-
1β mRNA in this FCS-stimulated culture model does not correspond with the earlier 
observation that during systemic retinoid-therapy the amount of both IL-1 species 
decreased in lesional psoriatic skin[496]. Regarding IL18R1, there is no literature report 
on regulation of its expression by ATRA.
The transcript for the receptor of IL-7 (IL7R), which belongs to the IL-2 subfamily[497], 
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was downregulated. Presence of this receptor on keratinocytes has not been reported 
to date. Keratinocytes have been shown to produce IL-7, but the physiological or 
pathological relevance of this cytokine with respect to skin biology is presently 
unknown.  
Heat shock proteins have been recognised as molecules that maintain cellular 
homeostasis during changes in the environment. However, besides its commonly 
accepted function in stress response, HSP90 (HSPCA) may also be associated with 
certain aspects of cellular differentiation. For example, the cellular differentiation 
of human embryonal carcinoma cells, induced by ATRA, resulted in a decrease of 
HSP90[498]. Since there are no additional reports in literature that relate to this topic, 
it can only be speculated that the reduced level of HSPCA mRNA as detected in our 
model, also refers to modulation of differentiation in keratinocytes. 
Besides reduction of a member of the heat shock protein family, another transcript 
encoding a protein involved in stress signalling was found downregulated by ATRA in 
the serum-induced model. MAPK8 encodes the mitogen-activated protein kinase 8, 
more commonly referred to as JNK1 (c-Jun N-terminal Kinase 1). JNKs are activated 
by exposure of cells to environmental stress (ionising radiation, heat shock, oxidative 
stress, osmotic shock) or by treatment with pro-inflammatory cytokines. Targets of 
the JNKs include the transcription factors c-jun[499], Elk-1[500], and ATF-2[501]. The 
transcription factors c-jun and ATF-2 both belong to a group of proteins that can form 
AP1 complexes as homo- or heterodimers with other proteins. The JNKs are therefore 
the major regulatory factor in the formation of active AP1 complexes in mammalian 
cells in response to cellular stress. 
Two types of IL-1 receptor can be expressed by human epidermal keratinocytes both 
in vitro and in vivo. Firstly, the type I IL-1R, which is active in signal transduction. 
The other, which was downregulated in our model, is the less well-characterised type 
II IL-1R (IL1R2). The latter is incapable of transducing a signal and is thought to 
function as a decoy receptor[502].  It has been proposed by Eller et al. that one function 
of epidermal IL-1 is to promote keratinocyte differentiation and that a change in 
the IL-1 receptor profile of these cells initiates this Il-1 response through a relative 
enhanced expression of functional IL-1 receptors. This suggestion is based on the 
IL-1 induced mRNA expression of two molecules that are associated with normal 
epidermal differentiation: cellular retinoic acid binding protein type II (CRABPII) 
and small, proline rich protein 1 (SPRR1). The ability of IL-1 to induce these 
transcripts correlated directly with expression of IL-1 R1, while expression of IL-1 
R2 was decreased[503]. However, literature provides no information on the effects of 
ATRA on the regulation of the type II IL-1 receptor.
HMOX1, which was downregulated in our model, encodes one of two existing 
isoenzymes of heme oxygenase (HO), originally identified as the rate-limiting enzyme 
in the degradation of heme to biliverdin, carbon monoxide, and free iron[504,505]. 
In addition to its obvious role in iron metabolism, a series of findings indicate an 
important role for HO in cellular protection against oxidative stress. For instance, 
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cells from mice lacking functional HMOX1 showed profound decreased stress 
defence, as measured by markedly higher free radical production as compared to 
control cells, upon oxidative challenge. Furthermore, young adult HMOX1 (-/-) mice 
were vulnerable to mortality and hepatic necrosis when challenged with endotoxin[506]. 
Protection against oxidative stress might be of particular importance during wound 
healing and also in inflammatory disease. With respect to this it is of interest that the 
level of HMOX1 mRNA was strongly overexpressed in the skin of psoriatic patients. 
In vitro studies with cultured keratinocytes revealed a potential role for reactive 
oxygen species (ROS), but not for growth factors and pro-inflammatory cytokines, as 
inducers of HMOX1 expression in inflamed skin[507]. No studies have been performed 
to date with regard to a possible effect of ATRA on HMOX1 regulation. 
Decreased levels of mRNA were also detected for ICEBERG, a gene encoding an 
inhibitor of caspase-1. Caspase-1 proteolytically processes the proinflammatory 
cytokine proIL-1beta. ICEBERG is induced by proinflammatory stimuli, suggesting 
that it may be part of a negative feedback loop[508]. Furthermore, the protein can 
interact physically with caspase-1 and blocks, in a monocytic cell line, the IFN-γ 
and LPS-induced secretion of IL-1β which is a well-known consequence of caspase-
1 activation[509]. Downregulation of ICEBERG could therefore lead to absence of 
negative feedback, resulting in an increased production of IL-1β. We indeed observed 
an increased transcription of the IL1B gene in our model system.  
Class G: growth, proliferation
Insulin-like growth factor binding protein-1 (IGFBP1) is likely to play a role in 
transport and targeting of insulin-like growth factor-1 (IGF-1), a mitogen for epidermal 
keratinocytes, which is primarily derived from dermal fibroblasts. The mitogenic 
effect of IGF-1 was described to be enhanced when recombinant IGFBP-1 was 
added to cultures of NHK[510]. Although IGFBP1 mRNA was not localised in normal 
differentiated human skin by in situ hybridisation[511], Northern analysis following 
culture of NHK in complete serum-containing medium revealed IGFBP1 mRNA, at 
early passage[512]. We found ATRA to markedly reduce IGFBP1 mRNA in our serum-
complemented model, in which keratinocytes show a sustained hyperproliferation[265]. 
Downregulation of IGFBP1 gene expression in this model might indicate the ablation 
of hyperproliferation and the concurrent onset of a phenotype characterised by a low 
proliferative rate, which parallels the therapeutic effect that ATRA exerts on psoriatic 
epidermis[513,514].
Transitions between the different phases of the cell division cycle are triggered and 
coordinated by cyclin-dependent kinases (CDKs). CDK7, ubiquitously expressed  in 
human tissues[515], is an essential component of the transcription factor TFIIH, which 
is involved in transcription initiation and DNA repair[516]. CDK7 is therefore thought 
to serve as a direct link between the regulation of transcription and the cell cycle. 
There have been no reports on the expression of CDK7 in keratinocytes to date. 
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The peptidyl-prolyl cis-trans isomerase (PPIF), previously known as cyclophilin 3, 
is a protein that is part of the mitochondrial permeability transition pore. Activation 
of this transition pore is involved in the induction of necrotic and apoptotic cell death. 
Although not distinguished as specific family members, there was no significantly 
difference reported for cyclophilin mRNA levels between normal and involved 
psoriatic epidermis[517]. Current literature provides no additional information that 
could elucidate the diminished PPIF mRNA levels that we observed in our ATRA-
treated culture system.
FABP5 encodes psoriasis-associated fatty-acid binding protein (PA-FABP), a lipid 
transport molecule expressed in the stratum granulosum of normal epidermis, and 
throughout the suprabasal layers of psoriatic epidermis. FABP5 mRNA is highly 
upregulated in psoriatic unfractionated noncultured keratinocytes compared to normal 
control samples[79]. Larsen et al. reported FABP5 mRNA to be inducible in cultured 
NHK upon the addition of foetal calf serum (FCS) to the medium[518]. In comparison, 
Northern blot analysis showed messenger for PA-FABP to be weakly present in our 
culture model mimicking the psoriatic differentiation phenotype[59]. Application of 
ATRA to normal skin induced levels of FABP5 mRNA[518], while immunohistochemical 
analysis showed that the expression of PA-FABP was only minimally decreased in 
psoriatic skin after treatment with acitretin, a trimethyl methoxyphenol analog of 
ATRA[321]. Our current data, that show a 2-fold downregulation of FABP5 mRNA 
levels upon treatment with ATRA, correspond with the latter in vivo observation.
In summary, application of the SKINarray in the experimental setting described 
here, largely confirms the known effects of ATRA on human epidermis and cultured 
keratinocytes, but has also uncovered genes not previously known to be expressed and/
or controlled by this retinoid in human keratinocytes. Results from the culture model 
originally developed to mimic the normal epidermal phenotype, parallel the generally 
known irritative effects of retinoids on normal human skin in vivo. Furthermore, 
data derived from the culture model that mimics the psoriatic phenotype were to a 
great extent compatible with the known effects of retinoid therapy as reflected by 
the decrease of PI3, SLPI, TGM1, IGFBP1, and MAPK8. We intend to verify the 
most prominent microarray results in the near future by means of alternative methods 
of analysis (e.g. quantitative RT-PCR). In addition, we plan to perform comparable 
studies with other established antipsoriatics in order to identify regulatory genes/
pathways that are likely to provide leads for causal events involved in psoriasis.
We reach the conclusion that the combined use of our cell culture models and the 
microarray methodology promises to be a useful tool to examine relative high-density 
patterns of gene expression that reflect effects of keratinocyte-targeted compounds. 
Ultimately, application of the SKINarray may lead to improved pharmaco-therapy 
for psoriasis.
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The general aim of this thesis was to develop and validate human keratinocyte cell 
culture systems that are useful in large-scale pharmacological screening. Although 
not every specific aim as defined in the introduction was achieved, the present 
thesis provides data that demonstrate the feasibility of drug screening in a 96-well 
keratinocyte culture format. Our data indicate the limitations of the model system 
used. Furthermore, our data delivers new insight into the transcriptional regulation of 
SKALP, a gene that can be used as a paradigm for the specific differentiation program 
of activated epidermal keratinocytes.
Large-scale pharmacological screening demands time-reduced analysis of read-out 
parameters in order to be practical and functional. This implies that it is advantageous 
to limit the number of parameters in a first screen, and additionally establish robust 
and fast analysis for the selected variables. In a number of studies described in 
this thesis, both the proteinase inhibitor and anti-microbial protein SKALP and the 
structural protein CK10 have been used as surrogate markers for a defined phenotype. 
Obviously, one should be very careful to reduce the complex characteristics of an 
epidermal phenotype to the expression of a single gene. However, several studies 
have shown that expression of CK10 and SKALP is very tightly associated with the 
onset and maintenance of respectively normal[41,519] and abnormal[520-522] epidermal 
differentiation. Because of this very tight association we assume that elucidation of 
mechanisms and/or factors that are involved in the regulation of expression of these 
genes should be informative on the regulation of at least a part of the accompanying 
phenotype. It is however indisputable that other characteristics of each individual 
phenotype need to be analysed before extrapolating the results found for a single 
marker gene to conclusions concerning the total clinical phenotype. With respect 
to this, extensive characterisation of the applied cell culture models, that mimic the 
normal and the psoriatic phenotype, has demonstrated that both CK10 and SKALP are 
valid markers as they are expressed in a context of differentiation-related molecules 
that corresponds to the  in vivo situations[59]. 
Inflamed epidermis as present in psoriasis, wound healing, and UV-irradiated skin, is 
characterised by the existence of keratinocytes that are hyperproliferative and display 
an abnormal differentiation program. Effective antipsoriatics might function through 
the keratinocyte by affecting either one or both of these hallmarks. Chapter 2 describes 
the development of a system applicable to screen drugs that are pharmacologically 
active in keratinocyte growth inhibition, using a highly sensitive, inexpensive 
fluorescent dye to monitor cell proliferation in a 96-well format. Incorporation of [3H]-
thymidine is at present still a generally used method for measurement of cell growth. 
However, it should be realised that this technique may lead to underestimations of 
true keratinocyte proliferations rates since human keratinocytes are able to catabolise 
[3H]-thymidine and nucleoside analogues of thymidine. Therefore, utilisation of 
the dsDNA-binding dye Picogreen may reflect cell proliferation more accurately. 
A number of known antipsoriatic compounds were used to validate the system. We 
found a strong concentration-dependent growth inhibition by dithranol, a compound 
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that is presumed to target the epidermal compartment. Anti-psoriatics that presumably 
act on the immune system (CsA) or on keratinocyte differentiation (ATRA) did not 
suppress growth at therapeutically relevant levels. 
In order to improve the quantitative measurement of SKALP levels, monoclonal 
antibodies were developed and applied for an enzyme-linked immunosorbent assay 
of SKALP (chapter 3). The monoclonal antibodies were superior to the existing 
polyclonal sera with respect to specificity and affinity in the detection of ‘full-length 
SKALP’, that is, the molecule comprised of a first domain with transglutaminase 
substrate motifs and a second domain with proteinase-inhibiting properties. Isolation 
of SKALP from keratinocyte cell culture supernatant yields predominantly this full-
length molecule [77]. Due to the high sensitivity of the monoclonal-based ELISA only 
1-2% of culture supernatant is required as input volume for the assay, leaving the 
possibility to measure additional parameters in the remainder of the supernatant if 
desired.      
In chapter 4 we describe a screening model to detect pharmacologically active drugs 
in two keratinocyte-based, 96-well culture models that use expression of CK10 and 
SKALP as markers for respectively normal and psoriatic differentiation. This model 
was also validated by testing several known antipsoriatics. The finding that CsA, 
when tested at  physiological concentrations, did not have any effect on markers 
of both normal and psoriasis-like differentiation, is in accordance with the view 
that the specific immunosuppressive features of CsA contribute to its antipsoriatic 
efficacy. As expected ATRA displayed a strong inhibitory effect on SKALP 
expression. Interestingly, the observed reduction of CK10 was in accordance with 
reports mentioning reduction of early and late markers of normal differentiation (e.g. 
CK1/CK10 and loricrin). Dithranol displayed a strong inhibitory effect on SKALP 
expression which together with the outcome of the proliferation assay implies that 
the antipsoriatic mode of action through the keratinocyte might be twofold: reduction 
of both hyperproliferation and aberrant differentiation. Calcipotriol, a vitamin D
3
 
derivative, strongly reduced levels of CK10, an observation which is in conflict with 
reports describing vitamin D
3
 to induce normal differentiation. Although further study 
is required, this finding apparently limits our model system with respect to the use as 
a screening assay for vitamin D
3
 derivatives.   
Though SKALP expression is regarded to be a useful marker for psoriatic 
differentiation, the time-consuming SKALP ELISA limits its practical use in 
high-throughput drug screens. To circumvent this drawback we generated a stably 
transfected keratinocyte cell line that expresses EGFP, under the control of a 0.8 kb-
fragment derived from the promoter of the SKALP gene (Chapter 5). Induction of 
the SKALP promoter by TNF-α, resulted in increased fluorescence levels of secreted 
SKALP-EGFP. Unfortunately, the transgene achieved only 0.5% of the expression 
level of the endogenous SKALP gene, thereby limiting the dynamic range of the 
system. Several factors can contribute to this low expression. For example, random 
insertion might put the gene of interest out of its natural genomic context and/or 
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the promoter fragment used contains insufficient information. However, use of a 
considerable larger SKALP promoter region (4 kb) did not result in a higher mRNA 
expression of the transgene (chapter 6). This might indicate that the additional 3.2 kb 
promoter region upstream of the 0.8 kb promoter region contains no information that 
contributes to increased gene expression. Although this conclusion might be justified, 
it should be realised that these data were derived from two random insertion events. 
This implies that there is a discrepancy in genomic context of the two transgenes 
compared to the endogenous gene that contributes to the low expression levels 
observed, while the intrinsic expression capacities of the two promoter sizes might 
differ. In view of future experiments, we speculate that homologous recombination 
is a valid approach to construct the desired cell line harbouring an EGFP reporter 
gene. Homologous recombination will place the reporter gene in the correct genomic 
environment, which allows expression to be driven by the correct promoter and 
flanking sequences.
We hypothesised that knowledge on the molecular regulation of SKALP expression 
could provide information on the molecular regulation of the phenotype associated 
with activated epidermis and its characteristic program of gene expression. Chapter 
6 describes the regulation of SKALP gene expression in human keratinocytes, which 
was studied at the molecular level. The transcription start site of the SKALP gene was 
determined and it was found that the SKALP mRNA possesses an unusually short 
5’-untranslated region. Furthermore, by using transient transfection of luciferase 
constructs of the SKALP promoter we mapped a 440 bp region upstream of the 
translation start site that induces high levels of expression. Moreover, the specified 
promoter region conferred high-level expression only in keratinocytes, but not 
in glioblastoma (U138-MG) cells, epithelial A431 cells, and primary human skin 
fibroblasts. Our transfection experiments with SKALP promoter constructs in human 
keratinocytes showed a discrepancy between the expression of these clones and the 
endogenous gene. The promoter constructs used were constitutively active under 
all culture conditions in contrast to the endogenous SKALP gene promoter. We 
therefore presumed that the reporter constructs consisting of naked plasmid DNA 
were not suitable to examine SKALP gene regulation in further detail. When SKALP 
promoter/reporter constructs were stably transfected in the HaCaT keratinocyte cell 
line, TNF-α-dependent inducible expression of both the endogenous SKALP gene 
and the transgene was observed. Having established that chromosomal integration 
was necessary for proper regulation, we investigated whether these cell lines could 
be used to study the effect of pharmacological manipulation of SKALP expression. 
Unfortunately, we found that the expression of the stably transfected reporter 
constructs carrying a 0.8 kb or a 4 kb SKALP promoter fragment are not subjected 
to ATRA-induced suppression as is the case for the endogenous gene. This indicates 
that additional cis-acting sequences or a correct genomic environment is required 
for proper regulation. Further studies are needed to unravel the complex regulation 
of a gene that can be used as a paradigm for the specific differentiation program of 
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activated epidermal keratinocytes.
The identification of new targets for therapeutic intervention in psoriasis is lagging the 
rapid increase in our knowledge of the human genome and transcriptome. Recently, 
however, new technologies have emerged which, combined with the proliferation/
differentiation assay, can form a powerful platform for the discovery of novel drug 
targets in psoriasis. Screening of large compound libraries in cellular assays based 
upon the read-out of a small number of parameters (e.g. proliferation, SKALP, CK10) 
will yield potentially novel drugs. Together with known antipsoriatic drugs that are 
active in these model systems, these compounds can be analysed to uncover the 
specific mode of action. Microarray expression profiling is a powerful method that 
can be employed to reveal (clusters of) genes that are differentially expressed in drug 
treated and untreated cell culture models. In chapter 7 we describe the application 
of a customized microarray system (SKINarray) containing 750 cDNAs that are 
relevant for skin biology and inflammation. The SKINarray was used to analyse the 
effect of ATRA on the gene expression profiles of submerged keratinocyte cultures 
that can mimic the normal or the psoriatic phenotype of human epidermis. The 
experimental data largely confirmed the known effects of ATRA on human epidermis 
and cultured keratinocytes, and additionally uncovered genes not previously known to 
be expressed and/or controlled by this retinoid in human keratinocytes. We anticipate 
the combined use of our cell culture models and the microarray methodology to be 
a powerful tool for evaluation of gene expression profiles induced by keratinocyte-
targeted compounds. We intend to perform comparable studies with other established 
antipsoriatics in order to reveal regulatory genes/pathways that may provide leads for 
causal events involved in psoriasis. Identification of these pathways is also important 
to uncover other ‘drugable’ genes such as G protein-coupled receptors (GPCRs), ion 
channels, proteinases, and kinases. This will in the end lead to development of new 
low molecular weight compounds or protein-based ‘biologicals’. Another example of 
a new technology that adds to the drug discovery platform is expression screening. 
Libraries for large-scale application can be produced either of plasmid, retroviral, 
or adenoviral origin. An example is the arrayed adenoviral expression library from 
human placenta with a size of 120,000 viruses described by Michiels et al [523]. This 
PhenoSelect™ library contains human cDNAs in a replication-defective adenoviral 
vector that allows efficient transduction of diverse cell types. Successful transduction 
of such an arrayed format in our cell culture models would allow rapid screening of 
this library in a search for genes that, by overexpression, induce/repress a psoriatic 
phenotype. In addition, ‘small interfering RNA’ (siRNA) technology in combination 
with the existing cell culture models will make up a complementary constituent of 
the platform. Specific degradation of target mRNA allows to study the consequence 
that reduction of the expression level of a specific gene has on the phenotype of 
keratinocytes. Preferably, large-scale application of siRNA technology will be 
performed in an arrayed setting as well. The constructs could thereto be arranged 
in a knockdown library based on retroviral[524] or plasmid [525] delivery tools whose 
146  Chapter 8 Summary, discussion and future prospects Chapter 8 Summary, discussion and future prospects  147
functionality as delivery tools has been described by others.
In conclusion, this thesis describes the feasibilities and limitations of keratinocyte-
based culture systems that are applicable for conventional drug screening procedures. 
In addition, we propose that these screens can be useful in expression-based drug 
discovery platforms for the development of new antipsoriatics.
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De menselijke huid bestaat uit het bindweefsel van de dermis (lederhuid), waarover 
het gelaagde weefsel van de epidermis (opperhuid) ligt. De epidermis is een 
dynamisch weefsel, dat voornamelijk bestaat uit keratinocyten die deelnemen aan 
een sterk gecoördineerd proces welke bepalend is voor de vorming van een barrière 
tussen het externe milieu en het menselijk lichaam. Tijdens dit proces vindt er een 
overgang plaats van delende keratinocyten vanuit de binnenste, basale cellaag van 
de epidermis naar terminaal gedifferentieerde keratinocyten welke de dode, stevige, 
buitenste laag van de huid vormen. In normale huid ligt een complexe regulatie van 
genexpressie ten grondslag aan de precieze balans welke bestaat tussen celdeling 
en celdifferentiatie. Bij de huidziekte psoriasis is deze balans afwezig, hetgeen 
gekenmerkt wordt door de afwezigheid van de normale gelaagde structuur, de 
aanwezigheid van overmatig delende (hyperproliferatieve) keratinocyten in de 
zieke huid, alsmede een infiltraat van immuuncellen. Wat betreft de behandeling van 
deze huidziekte ligt het aangrijpingspunt van gangbare antipsoriatica op het gebied 
van ontsteking, hyperproliferatie, abnormale differentiatie of een combinatie van 
deze pathologische verschijnselen. De exacte werkingsmechanismen van de meest 
gangbare antipsoriatica zijn echter veelal nog onbekend. Door toepassing van o.a. 
proefdier- en celkweekgerelateerde modelsystemen, waarin aspecten van psoriasis 
bestudeerd kunnen worden, wordt getracht het precieze werkingsmechanisme 
van farmaca te ontrafelen ten einde de specificiteit ervan te verhogen en/of de 
bijwerkingen te reduceren. 
Hoewel er in de afgelopen decennia een sterke kennistoename heeft plaatsgehad met 
betrekking tot de pathogenese van psoriasis, is de exacte etiologie nog onvolledig 
bekend, alsook de rol welke de diverse epidermale celpopulaties er mogelijk in 
hebben. In dit proefschrift dient de keratinocyt als uitgangspunt voor verdere 
kennisverwerving op dit gebied. De grondslag van de hoofdstukken 2, 4, en 5, 
wordt gevormd door de aanname dat het grootschalig gebruik van farmacologische 
testprogramma’s kan leiden tot de versnelde identificatie van potentiële kandidaten 
voor de behandeling van psoriasis. Hoofdstuk 2 beschrijft een methode die het 
mogelijk maakt om in 96-wells formaat farmaca te beoordelen op het vermogen de 
proliferatie van humane keratinocyten te beïnvloeden. Een panel bestaande uit stoffen 
met bewezen antipsoriatisch effect, alsmede enkele experimentele antipsoriatica, 
werd getest in een kweeksysteem waarbij celproliferatie gemeten werd door middel 
van een gevoelige fluorescentie-uitlezing gebaseerd op een DNA-bindende kleurstof 
(PicoGreen). Dithranol, een stof waarvan verondersteld wordt dat die rechtstreeks 
effect uitoefent op de epidermis, bleek een sterke remming op de groei uit te oefenen. 
Anti-psoriatica die waarschijnlijk via het immuunsysteem werken (cyclosporine A, 
CsA) of via differentiatie van de keratinocyt (all-trans-retinoïnezuur, ATRA) bleken 
de groei niet te remmen bij therapeutisch relevante concentraties. Validatie van het 
modelsysteem wordt bemoeilijkt door het feit dat zelfs voor de meest gangbare 
antipsoriatica geen sterk experimenteel bewijs bestaat, of consensus bereikt is, 
aangaande het exacte werkingsmechanisme in de patiënt. 
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Fenotypische verschillen tussen normale en psoriatische epidermis, met betrekking 
tot differentiatie, worden ondermeer gekarakteriseerd door de specifieke expressie 
van een aantal eiwitten. Binnen onze afdeling zijn voorheen reeds celkweekmodellen 
ontwikkeld, waarmee het normale fenotype en het psoriatische fenotype van humane 
epidermis nagebootst kan worden. In deze modellen kan expressie van cytokeratine 
10 (CK10) en ‘skin-derived antileukoproteinase’ (SKALP) dienen als marker 
voor respectievelijk het normale en het psoriatische fenotype van keratinocyt-
differentiatie. Hoofdstuk 3 geeft een beschrijving van de ontwikkeling van SKALP-
specifieke monoklonale antilichamen en de toepassing ervan in een enzyme-linked 
immunosorbent assay (ELISA). De monoklonale antilichamen overtroffen de 
bestaande polyklonale antilichamen wat betreft specificiteit en affiniteit. In opvolgend 
onderzoek werd deze ELISA toegepast in de kwantitatieve bepaling van concentraties 
gesecreteerd SKALP in het medium van gekweekte keratinocyten. 
In hoofdstuk 4 wordt een screeningsmodel beschreven om farmacologisch actieve 
stoffen te detecteren in twee 96-wells kweeksystemen,  waarin expressie van CK10 
en SKALP gebruikt wordt als markers voor normale en psoriatische differentiatie van 
keratinocyten. In deze kweekmodellen werden zowel stoffen getest met een bewezen 
antipsoriatisch effect, alsmede enkele experimentele antipsoriatica. De bevinding dat 
fysiologische concentraties CsA geen effect hebben op beide differentiatiemarkers is in 
overeenstemming met de opvatting dat de specifieke immuunsuppressieve kenmerken 
van CsA bijdragen aan zijn antipsoriatisch effect. ATRA gaf naar verwachting een 
sterke remming van SKALP-expressie te zien. Het was daarbij opvallend dat de 
waargenomen daling van CK10 overeenkomt met literatuurgegevens die beschrijven 
dat ATRA de expressie van verschillende vroege en late markers die kenmerkend zijn 
voor de normale differentiatie (bijv. CK1, CK10, loricrine) kan verlagen. Dithranol 
veroorzaakte een sterke verlaging van SKALP-expressie. In combinatie met het 
hierboven beschreven effect op proliferatie impliceert dit een tweeledig effect van 
dithranol op de keratinocyt: vermindering van zowel hyperproliferatie als van 
afwijkende differentiatie. Het vitamine D
3
 derivaat calcipotriol veroorzaakte een 
sterke vermindering van CK10 , hetgeen tegenstrijdig is met eerdere beschrijvingen 
waarin vitamine D
3
 normale differentiatie juist bevorderd. Hoewel aanvullend 
onderzoek naar deze discrepantie benodigd is, lijkt het hier beschreven model niet 
toepasbaar te zijn voor het screenen van vitamine D
3
 derivaten.
Hoewel de expressie van SKALP een uiterst bruikbare marker is voor psoriatische 
differentiatie, wordt de bruikbaarheid ervan in grootschalige farmacologische 
testmodellen beperkt door de bewerkelijke, tijdrovende ELISA die nodig is voor de 
kwantificering van het gesecreteerde eiwit. Dit gegeven vormde de aanleiding om 
een methode te ontwikkelen waarbij de activiteit van de SKALP-promoter bepaald 
kon worden aan de hand van een praktischer uitlezing in de vorm van fluorescentie. 
In hoofdstuk 5 is weergegeven hoe een stabiel getransfecteerde keratinocyT cellijn 
gecreëerd is, die een fluorescerend eiwit (Enhanced Green Fluorescent Protein, 
EGFP) tot expressie brengt, dat onder controle staat van een 0.8-kb fragment van de 
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endogene SKALP-promoter. De beweegreden om deze promoterlengte te gebruiken 
was gebaseerd op transiente transfectiestudies in normale humane keratinocyten 
waarin gevonden werd dat 800 bp gelegen voor de transcriptiestartplaats de volledige 
promoteractiviteit deden behouden (zie hoofdstuk 6). Inductie van de promoter met 
tumor necrosis factor alpha (TNF-α) resulteerde in verhoogde expressieniveaus 
van het gesecreteerde SKALP-EGFP fusie-eiwit, hetgeen aangetoond werd met 
directe uitlezing van fluorescentie en fluorescentie polarisatie in 96-wells platen. De 
combinatie van een relatief hoge intrinsieke fluorescentie van het medium en een 
laag expressieniveau van het transgen, resulteerden in een klein dynamisch bereik. 
Desondanks werd aangetoond dat een gesecreteerd EGFP-fusie-eiwit onder controle 
van een fysiologisch relevante endogene promoter, conceptueel bruikbaar is om op 
basis van fluorescentie een testsysteem te ontwikkelen waarin stoffen beoordeeld 
kunnen worden op hun effect ten aanzien van keratinocyt-gerelateerde differentiatie 
en ontsteking. Tot besluit van dit hoofdstuk wordt de suggestie voor toekomstig 
onderzoek gedaan, dat verbetering van het dynamisch bereik mogelijk bewerkstelligd 
kan worden door het EGFP-gen middels homologe recombinatie in de correcte 
genomische omgeving te plaatsen, zodat expressie gestuurd wordt door de correcte 
promoter en flankerende sequenties. 
We veronderstelden dat kennis aangaande de regulatie van SKALP op moleculair 
niveau informatief kon zijn met betrekking tot de moleculaire regulatie van het 
fenotype dat geassocieerd is met psoriatische epidermis en het daarbij behorende 
karakteristieke profiel van genexpressie. In hoofdstuk 6 wordt een studie beschreven 
die gericht is op de opheldering van de regulatie van SKALP-genexpressie in humane 
keratinocyten. Allereerst werd de startplaats van de transcriptie van het gen bepaald. 
Met twee verschillende technieken werd aangetoond dat het SKALP mRNA een 
zeer ongebruikelijk korte 5’-‘untranslated region (5’-UTR) bezit. Verder wordt de 
constructie beschreven van een set promoter/reportergen plasmiden die vervolgens 
in transiente transfectie-experimenten werd gebruikt. Het bleek dat een gebied ter 
grootte van 440 bp, dat voor de transcriptie startplaats gelegen is, nog resulteert in 
hoge expressie van het construct in humane keratinocyten. Opvallend was dat de 
promoterconstructen niet onderhevig waren aan dezelfde regulatie als het endogene 
SKALP-gen. De constructen waren in hoge mate actief onder kweekomstandigheden 
die het psoriatisch fenotype van keratinocyten induceren alsook onder 
kweekomstandigheden die het normale fenotype induceren. Om meer inzicht te 
verkrijgen in het regulatoire mechanisme dat aan deze discrepantie ten grondslag 
ligt, werden SKALP-promoter constructen stabiel getransfecteerd in de HaCaT-
keratinocytcellijn. Zowel het endogene gen als het transgen konden geïnduceerd 
worden door TNF-α, hetgeen suggereert dat genregulatie van SKALP afhankelijk is 
van chromatinestructuren.  Toepassing van deze stabiel getransfecteerde klonen om 
effecten van farmacologische manipulatie op SKALP-expressie te bestuderen, bleek 
onmogelijk omdat het 4 kb SKALP-promoterfragment van een kloon, in tegenstelling 
tot de endogene SKALP-promoter, niet gevoelig bleek voor de negatieve regulatie 
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door retinoïnezuur. Dit suggereert dat er additionele sequenties benodigd zijn voor de 
correcte regulatie van het SKALP-gen.
Het is wenselijk om het exacte werkingsmechanisme van een geneesmiddel te kennen 
omdat dit kan bijdragen tot een meer efficiënte therapie en een vermindering van 
ongewenste neveneffecten. Hiertoe kunnen DNA microarrays toegepast worden 
omdat hiermee (clusters van) genen onthuld worden die differentieel tot expressie 
komen waaruit informatie verkregen kan worden omtrent regulatoire mechanismen en 
biochemische paden binnen een cel. In hoofdstuk 7 wordt de toepassing beschreven 
van een cDNA-microarray (SKINarray) die is samengesteld uit 750 cDNAs die 
geacht worden relevant te zijn voor biologische processen van de huid of die een rol 
spelen in het proces van ontsteking. De SKINarray is gebruikt om de effecten van all-
trans retinoïnezuur te bestuderen op de genexpressieprofielen van keratinocyten in de 
kweekmodellen voor het normale en psoriatische fenotype. De effecten van all-trans 
retinoïnezuur op epidermale groei en differentiatie zijn reeds uitgebreid bestudeerd, 
zowel in humane huid alsook in kweekmodellen. De beschikbare literatuurgegevens 
konden daarom tot op zekere hoogte dienen om de uitkomst van dit experiment te 
voorspellen en te valideren. De resultaten bevestigden het merendeel van de bekende 
effecten die ATRA heeft op humane epidermis en gekweekte keratinocyten. Daarnaast 
werd echter ook de regulatie van genen aangetoond waarvan nog niet bekend was 
dat ze onder controle staan van dit retinoid. In de nabije toekomst zal verificatie 
van de meest prominente resultaten plaatsvinden met behulp van alternatieve 
analysetechnieken (zoals kwantitatieve RT-PCR). Daarnaast zullen vergelijkbare 
studies uitgevoerd worden met andere bekende antipsoriatica waarmee beoogd wordt 
regulerende genen en paden te identificeren die bijdragen aan de pathogenese van 
psoriasis.
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En dan is hier ruimte gereserveerd om al die mensen te bedanken zonder wie dit 
dankwoord niet had kunnen bestaan. Een groot aantal mensen heeft op uiteenlopende 
wijze bijgedragen aan de totstandkoming van dit proefschrift, sommigen misschien 
zonder te beseffen in welke mate. Enkele dienen speciaal vermeld te worden (maar 
onvermeld maakt niet onbemind).
Allereerst mijn copromotor Joost Schalkwijk. Joost, ik kan me gelukkig prijzen 
dat ik jou al deze jaren als steun en toeverlaat naast me heb gehad. In goede en in 
mindere perioden (GFP…door de plee!) heb je altijd oprechte betrokkenheid getoond, 
enthousiasme behouden en bewezen gespeend te zijn van een dosis humor. Je open 
werkkamerdeur creëert een lage drempel voor binnenlopen zodat we meestal alles 
al besproken hadden voor ons, om uiteenlopende redenen steevast geannuleerde, 
werkoverleg. Woensdagmiddag 15.30 uur zal voor mij nooit meer hetzelfde zijn!
Dan mijn tweede copromotor Rolph Pfundt. Rolph, voor heel veel en nog een beetje. 
Vanaf het moment dat ik je leerde kennen heb je bewezen een talent te hebben voor het 
combineren van zinvol werk met je welhaast manische drang tot het uitoefenen van 
‘practical jokes’. Je hebt me op de voor jou karakteristiek ongedwongen wijze veel 
bijgebracht op het gebied van microarrays. Ondanks je overstap naar Antropogenetica 
zorgen werkbesprekingen en lunches ervoor dat we elkaar gelukkig nog veelvuldig 
spreken over alles wat zich maar aandient.
Omdat de feitelijke grondslag voor dit proefschrift gelegd werd door mijn promotor, 
Peter van de Kerkhof, wil ik deze bedanken voor de geboden mogelijkheid om op de 
afdeling dermatologie het promotieonderzoek uit te voeren. 
Tijdens mijn stageperiode had ik al kunnen voorvoelen eens terug te keren naar de 
apenrots, oftewel lab21. In zijn glorietijd gingen de alledaagse researchwerkzaamheden 
hier gepaard met een hevige strijd voor het vaststellen van de positie van zilverrug. De 
hierbij gesproken en gepraktiseerde humor, welke zich het beste laat omschrijven als 
‘onder de gordel’ alsook ‘over de schreef’, heeft een onuitwisbaar prettige indruk bij 
mij achtergelaten. Alle primaten die de rots in de voorbije jaren zijn naam eer hebben 
aangedaan (Fred, Miriam, Gys, Bas, Patrick, Rolph, Ivonne, Diana) wil ik hiervoor 
hartelijk danken.
Gys ‘Google’ de Jongh, voor het beantwoorden van ontelbare vragen. Gelukkig weet 
je geen snars van topografie (personal communication) anders leek je nog slim ook. De 
manier waarop je wetenschappelijk onderzoek verricht, is behoorlijk uniek temidden 
van die van de lichting jonge enthousiaste wetenschappers en het stelt uiterst gerust 
dat er nog één iemand weet waarom A bij B wordt gepipetteerd. Daarnaast, voor je 
vele onnavolgbare en soms onvolgbare grappen. En dat we nog maar veel prelimanary 
data mogen produceren samen…..het liefst gisteren.
Patrick, voor je niet aflatende bereidwilligheid even iets uit te leggen of in dat juweel 
van een labjournaal na te zoeken…..en wel meteen. En voor het ettelijke malen 
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uitlenen van je strontkleurige fiets (hou jij nou maar vol dat het goudkleurig is). Ook 
bedankt voor al je extroverte chagrijnige buien (“ja, zo kan ik toch niet werken!”) die 
mijn gemoed op een of andere manier altijd weer een enorme lift gaven.
Mieke, voor al het kweekwerk en ELISAs. Aan de datalawine die daaruit voortkwam 
heb ik nog een comfortabele anti-RSI-bureaustoel overgehouden. Leon, voor alle 
uitgevoerde secretariële taken die komen met het kamergenootschap en voor de 
belangeloos verstrekte dropvarianten. David, voor je ruwbolsterige uitlatingen op 
het lab en je blankpitterige kindvriendelijkheid op LEGO-dag. Manon Z., voor 
het gezamenlijk trotseren van “de hel van Dell”. Bovendien samen met de andere 
hardcore kwekers, Rolph, Mieke, Manon F. en Michelle, voor de gezelligheid, de 
vertrouwelijke gesprekken, en de roddel en achterklap op die paar vierkante meter 
begrensd door muren die net dik genoeg zijn. Piet, voor je toeschietelijkheid bij 
vragen op velerlei gebied, maar vooral toch weer dat ene. Volgens mij is het antwoord 
op de vraag of het nu een vloek of een zegen is om veel van computers te weten: het 
ligt eraan of er een “z” in de dag zit! 
De vele labgenoten en medewerkers van de afdeling die een oneindige reeks 
herinneringen tot stand hebben gebracht, welke hun oorsprong hadden in de 
koffiekamer, op een congres, tijdens borrels of op het lab: ik had er niks van willen 
missen (soms)!    
Diny, Els, Richarda en Ans, voor jullie onmisbare hulp bij alle vragen van “waar 
liggen de..”, “zijn er nog..” en nog veel meer. 
Ex-kamergenoten Jürgen en Milan: bedankt voor de gezellige tijd op kamer 28. 
Ondanks het feit dat de stethoscopen in de meerderheid waren, en dat jullie regelmatig 
je verbale veldslagen betreffende pokke-pc’s op mijn trommelvlies uitvochten, denk 
ik met plezier terug aan de tijd dat we de zuurstof (en andere gassen) deelden. Milan, 
daarnaast ook nog dank voor de prachtige lay-out en het geduld bij het doorvoeren 
van al mijn wijzigingen. Je verraste me telkens met de snelheid waarmee je weer een 
nieuwe versie gereed had. 
Jan, voor je spontane bereidheid om telkens even tussendoor een paar foto’s voor de 
cover te schieten wat steevast uitmondde in minstens twee uur werk en een Niagara 
Falls aan zweetdruppels (‘t was me een zomertje, hè!). 
Jet, voor je creativi-tijd en kunde die geleid hebben tot een prachtig omslag. 
Volleyvrienden, jullie verkeerden menige dinsdag en donderdag in de gelukkige dan 
wel noodlottige positie om getuige te zijn van mijn introvert-extrovert persoonlijk-
heidswisseling. Wellicht beseffen jullie het niet maar de ontspanning die de vele uren 
van een balletje slaan en het participeren in slappe borrelpraat en haarscherpe analyses 
(zoek de verschillen) mij bezorgd hebben, zijn van grote waarde geweest voor het 
verschijnen van dit ‘stageverslag’.
Sander en Chris, naast het hoogste goed, vriendschap, voor het één na hoogste goed, 
paranimf te willen zijn!
Familie en vrienden, het is een geruststellende gedachte om je omringd te weten 
met mensen waarmee je al zoveel gedeeld hebt, dat je je onvoorwaardelijk door hen 
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geaccepteerd en gesteund weet. Er was geen 5 jaar voor nodig om dit te leren, wel om 
het allemaal bevestigd te zien.
Klaas en Maartje, jullie heerlijke eenvoud, het niet druk maken om verleden en 
toekomst en het genieten van het moment dat zich aandient, heeft me veel bijgebracht 
de laatste jaren. Jullie dagelijkse spel en onuitputtelijke fantasie benadrukt alles wat 
er echt toe doet in het leven en relativeert de rest.
En dan Jacqueline. Lieve Jacq, als sleutel tot het succes behoort jou het slot toe. Jouw 
optimisme, flexibiliteit en nuchtere kijk op zaken zijn mij tot grote steun geweest: 
jij maakt het verschil. Bedankt dat je er altijd voor me bent in ons ‘simpel mooi 
bestaan’!
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Arno Pol werd op 6 mei 1970 geboren te Apeldoorn. In juni 1988 
behaalde hij het VWO-diploma aan het plaatselijke Christelijk Lyceum. 
In datzelfde jaar begon hij aan de Hogeschool Enschede (sector Techniek) 
de opleiding Chemische Technologie, welke succesvol afgerond werd in 
juni 1992. Enige maanden later volgde een verhuizing naar Nijmegen en 
werd aangevangen met het HBO-doorstroomprogramma Scheikunde aan 
de Katholieke Universiteit Nijmegen, met biochemie als hoofdrichting. 
Zijn stageperiode in het kader van de nevenrichting Dermatologie, 
betekende een eerste kennismaking met die afdeling. In augustus 1995 
werd het getuigschrift behorende bij het doctoraal examen Scheikunde 
in ontvangst genomen. In de maand november van datzelfde jaar 
verhuisde hij naar New York alwaar hij gedurende twee jaar als 
‘research associate’ werkzaam was; de eerste maanden onder 
leiding van dr. Sanjay Tyagi op de afdeling Molecular 
Genetics van het Public Health Research Institute te 
New York, later onder leiding van dr. John Chan 
op de afdeling Microbiology & Immunology van 
het Albert Einstein College of Medicine te New 
York. Na terugkeer in Nederland begon hij op 1 mei 
1998 als assistent in opleiding (AIO) op de afdeling 
Dermatologie van het Universitair Medisch Centrum 
St. Radboud aan het promotieonderzoek dat heeft 
geresulteerd in dit proefschrift. Sinds 1 oktober 2002 is 
hij bij diezelfde afdeling werkzaam als onderzoeker binnen 
een project gericht op bestudering van differentiële genexpressie 
van keratinocyten met behulp van DNA-microarraytechnologie.  
Enkele hier te noemen niet werkgerelateerde mijlpalen betreffen zijn 
huwelijk met Jacqueline Vet op 11 december 1998,  alsmede de geboorte 
van zoon Klaas op 10 april 1999 en die van dochter Maartje op 5 oktober 
2000.
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